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ABSTRACT

Vitiligo is an autoimmune disease characterized by destruction of

melanocytes, leaving 0.5% of the population with progressive depigmentation.

Current treatments offer limited efficacy. Observations that heat shock proteins
(HSPs) can serve as adjuvants in antitumor vaccines first suggested to us a link
between HSPs and stress-induced vitiligo. Such proteins are marvelously well

conserved throughout evolution, which has placed them in the spotlight for helping
to understand the intriguing relationship between infection and immunity.

Intracellularly, inducible heat shock protein 70 (HSP70i) is upregulated by stress

and helps protect cells from undergoing apoptosis. In times of stress, melanocytes
will secrete antigen bound HSP70i to act as an alarm signal in activating dendritic
cells (DCs), invoking a targeted response towards melanocytes. Thus HSPs are

candidate molecules mediating the transition between causative stress and the

autoimmune response to follow. We hypothesized that HSP70i is important for
inducing an autoimmune response in vitiligo through presentation of

melanocyte antigens and activation of dendritic cells and , and that blocking
its dendritic cell activating region will halt depigmentation. Data in this

dissertation reveal 1) Vitiliginous melanocytes (e.g., melanocytes harvested from
vitiligo patient nonlesional skin) secrete higher levels of HSP70i, 2) HSP70i

colocalizes with melanocyte antigens, 3) HSP70i is required to induce vitiligo, 4) The
xiv

sequence QPGVLIQVYEG located in the C-terminus is required for immune activity

leading to depigmentation, 5) Vaccination with mutant HSP70iQ435A prevents and

treats vitiligo by altering antigen presenting cell and T cell profiles. Together these
findings suggest that the autoimmune response is funneled through HSP70i, and

provide compelling experimental evidence that exposure to inducible heat shock
protein 70 (HSP70i) carrying a single amino acid modification offers potent
prophylactic and therapeutic opportunities in vitiligo.

xv

CHAPTER I

STATEMENT OF THE PROBLEM

Vitiligo skin lesions are milky-white patches changing in shape and size over

time (Ortonne et al., 1983). Once lost, melanocytes are difficult to replace and

treatment opportunities are limited, tedious, and largely unsuccessful (Shaffrali and
Gawkrodger, 2000). Local, generic immunosuppression by light treatment or

corticosteroids are among the most commonly applied remedies. However, the

success is limited and involves long lag periods (Grimes, 2004). Several groups have
implicated local production of reactive oxygen species (ROS) in vitiligo as well as

other autoimmune disorders (Namazi, 2007). To prevent melanocyte death, it has

been proposed to increase catalase activity in skin to protect melanocytes; however,
this will similarly support longevity of infiltrating T cells (Hultqvist et al., 2007). In

particular among dark skinned individuals, the emotional effects can include severe
social anxiety, reinforcing the impact of vitiligo on a patient’s quality of life (Mattoo
et al., 2002; Sampogna et al., 2004). Thus there is a dire need for treatment
measures that can truly inhibit and preferentially reverse depigmentation.

Several theories have been put forth for the cause of vitiligo including: 1) that

it is due to a biochemical pathway in which free radicals are formed during melanin
production, 2) that it is a disease of neurological origin, or 3) that it is an
1

2
autoimmune disorder (Ortonne et al., 1983). The general consensus agrees with the
latter hypothesis as there is increasing evidence for autoimmunity as supported by

genetic predisposition to candidate genes including MHC class I and II, PTPN22 and
IL2RA which are involved with the signaling events in response to antigen; thus,

patients with vitiligo have genetic predispositions to other autoimmune disorders
(Jin et al., 2010). In addition, skin from vitiligo patients contains increased CTL

infiltrates, and patients with vitiligo can frequently develop other autoimmune

disorders, in particular thyroid disease (Le Poole et al., 1996; Laberge et al., 2005).

Stress attributed to mechanical trauma or exposure to bleaching phenols has

been shown to initiate or intensify skin lesions (Das et al., 2001; Boissy and Manga,
2004; Lerner, 1959). Psychological stress may also contribute to vitiligo etiology
(Picardi et al., 2003). Such precipitating factors translate into an autoimmune

response specifically targeting melanocytes through unknown mechanisms. Here,

we propose a role for heat shock proteins (HSPs) in mediating this response. HSPs
are cytoplasmic chaperones upregulated under stress, and are involved in

maintaining cellular integrity, and preventing apoptosis (Lindquist and Craig, 1988;
Mehlen et al., 1996). Extracellular HSPs in turn function as alarm signals to the

immune system by supporting uptake, processing and presentation of antigens in

the context of MHC class I and II, and invoking both innate and adaptive responses
(Javid et al., 2007; Srivastava, 2002). Dendritic cell (DC) activation then allows for
recruitment of CD8+ T cells from draining lymph nodes (Srivastava, 2002).
A potentially unique role of inducible HSP70 (HSP70i) in initiating

autoimmunity is better understood considering that HSP70i is actively secreted by

living cells of neuronal origin (Mambula et al., 2007). In fact, melanocytes

3

established from non-lesional vitiligo skin treated with skin bleaching 4-tertiary
butyl phenol (4-TBP) show increased secretion of HSP70i; the same stress also

confers sensitivity to DC mediated cytotoxicity (Kroll et al., 2005). In addition to

active secretion through exosomal release, HSP70i can enter the circulation through
non-secretion pathways, such as necrosis (Gallucci et al., 1999; Johnson and

Fleshner, 2006). We postulate that under stress, secreted inducible HSP70 serves as
an adjuvant in vitiligo, binding melanocytic antigens to be processed by DCs,

followed by the breaking of tolerance. HSP70i may activate DCs through specific

receptor binding, leading to the production of various cytokines such as IL-12 and
IFN-γ, and subsequent activation and recruitment of effector cells from draining

lymph nodes (Nicchitta, 2003). Thus, the identification of a peptide within HSP70i
crucial to eliciting autoimmunity will be significant as it will open doors to

preventing the causative chain of events leading to depigmentation in vitiligo, and

autoimmunity in general. This dissertation aims to firmly establish a role for HSP70i
in autoimmune vitiligo, identify a targetable peptide within the molecule and

importantly, reveal the potentially unique treatment avenue of blocking the effects of
HSP70i in activating the immune system.

CHAPTER II: INTRODUCTION

A central role for inducible Heat Shock Protein 70 in autoimmune Vitiligo
(Mosenson et al., Exp. Dermatol., 2013)

Vitiligo is an organ-specific autoimmune disease of the skin.
Vitiligo is a skin disorder presenting with progressive depigmentation and

affecting 0.5% of the world population (Krüger and Schallreuter, 2012).

Depigmentation is due to the loss of melanocytes from the epidermis (Le Poole et al.,
1993). Genetic studies support the involvement of abnormalities affecting immune
function in vitiligo (Jin et al., 2010). T cell infiltrates are observed in perilesional

skin of patients with active vitiligo (Le Poole et al., 1996). Melanocyte-reactive T
cells are relatively abundant among peripheral T cells from patients with active

disease (Ogg et al., 1998). T cells isolated from vitiligo skin are cytotoxic towards
melanocytes (Wankowicz-Kalinska et al., 2003; van den Boorn et al., 2009). Thus
vitiligo is primarily T cell mediated, although humoral responses may also
contribute to disease development (Kemp et al., 2011).

Intrinsic abnormalities were found in vitiligo melanocytes, including dilated

ER profiles, mitochondrial abnormalities and abnormal melanosome

compartmentalization (Boissy et al., 1991), possibly rendering the cells increasingly
sensitive to stress (Le Poole et al., 1999). Patients consider stress a precipitating
4

factor for their disease (Cedercreutz et al., 2010) and known stressors, including

5

bleaching phenols, UV irradiation and mechanical injury invoke a Koebner

phenomenon in about half of patients (van Geel et al., 2012). In terms of emotional
stress, obsession and phobia has been correlated with autoimmune markers in

vitiligo (Moretti et al., 2012). In ‘occupational vitiligo’ individuals develop disease in
response to bleaching phenols in the workplace (Boissy and Manga, 2004). These
can cause oxidative stress in the skin. Several lines of evidence support an

association between oxidative stress and vitiligo (Laddha et al., 2013). This has

culminated in the development of pseudocatalase (PC-KUS) treatment for vitiligo,
which has unfortunately shown limited efficacy in the clinic (Schallreuter et al.,

2008; Bakis-Petsoglou et al., 2009). Gene expression analysis revealed upregulated
IL-6 and IL-8 expression by melanocytes in response to bleaching agents (Toosi et

al., 2012). Thus stress can cause micro-inflammation and support recruitment of an
immune infiltrate to the skin, reflecting the connection between stress and

autoimmunity. In summary, vitiligo is a T cell mediated autoimmune disease
precipitating under stress.

The immune response presents a mirror image of that found in melanoma.
Antigens recognized by T cells infiltrating vitiligo skin were known targets

for T cells infiltrating melanoma tumors (Das et al., 2001). These antigens are

predominantly expressed in melanosomes which bear functional resemblance to
lysosomes (Raposo and Marks, 2007). Adding a melanosomal trafficking signal

enhances immunogenicity of non-melanosomal proteins (Wang et al., 1999; Robila

et al., 2008). Thus, localization likely contributes to the immunogenicity of

6

melanosomal proteins. A resemblance between immune reactivity in vitiligo and
melanoma is supported by leukoderma in melanoma patients with detectable

immune responses to their tumor. In fact, depigmentation is a positive prognostic
factor in melanoma (Quaglino et al., 2010). Unfortunately the immune response

rarely clears tumors, whereas robust immunity directed towards the same antigens

is a hallmark of vitiligo. A lack of regulatory T cells infiltrating vitiligo skin compared
to their abundance in melanoma contributes to such differences (Turk et al., 2004;
Klarquist et al., 2010). In fact, autoimmune destruction of melanocytes following

Treg depletion in tumor challenged mice is required for generating effective antitumor responses (Byrne et al., 2011).

Treatments under development to boost anti-tumor immunity in melanoma

include vaccines based on heat shock protein 70 (HSP70) fusion proteins (Qu et al,
2010). HSP70 is included in vaccines as a chaperone protein, immunogenic in its
own right (Faure et al., 2007; Stangl et al., 2011) and functioning as an immune
adjuvant as described below.

Inducible HSP70 can mediate immune responses.
Cells under stress halt mainstream protein synthesis in favor of heat shock

protein and/or glucose regulated protein synthesis (Welch, 1993; Määttänen et al.,

2012). In the ER this can activate the unfolded protein response (UPR), upregulating
heat shock proteins (Gardner et al., 2013). The UPR has been implicated in many

diseases including vitiligo (Toosi et al., 2012). This finding is congruent with dilated

7
ER profiles reported for vitiligo melanocytes, potentially regulated by VIT1/FBXO11
(Le Poole et al., 2001; Guan et al., 2010). Within the cell, stress proteins bind

preexisting proteins, promoting autophagy to avert cellular apoptosis (Benbrook
and Long, 2012). This function can have implications for vitiligo (Elassiuty et al.,
2011). Cell derived stress protein fractions can also ignite immune responses

specific to the proteins and peptides they chaperone and thus, to the originating

host cells (Calderwood et al., 2012). Among larger heat shock proteins, inducible

HSP70 is unique for its secretion from live cells as a chaperokine (e.g., having both

chaperone and cytokine activity) (Vega et al., 2008). Other stress proteins likely gain
access to the extracellular milieu only after necrotic cell death (Strbo and Podack,

2008). The unique secretory property of HSP70i may be ascribed at least in part to
its cellular location, associated in part with melanosomes (Chi et al., 2006). HSP70i
is exported by live cells through the endo-lysosomal pathway (Mambula and

Calderwood, 2006). A rise in intracellular calcium serves as a signal for exocytosis

for several cell types (Johnson and Fleshner, 2006). In this setting DCs are provided
with antigenic peptides from live cells for processing and presentation to T cells

(Nicchitta, 2003). HSP70i can also stimulate proliferation and cytotoxicity of natural
killer (NK) cells (Nicchitta, 2003), and enhance leukotriene secretion by mast cells
(Multhoff, 2009; Mortaz et al., 2007). Moreover, HSP70i induces maturation and

type-1 polarizing cytokine production by dendritic cells (DCs) and stimulates cross
priming of T cells (Krammerer et al., 2012), and importantly, breaks tolerance and
induces autoimmune tissue destruction in mice (Millar et al., 2003).

A causative role of HSP70 in autoimmune disease remains controversial

8

(Denman et al., 2008; Wachstein et al., 2012). Most studies identify the C-terminal,

substrate binding region of the HSP70 protein as the region dictating immune

reactivity, which may in turn be modulated by bound antigen (Wheeler et al., 2011;
Spiering et al., 2012). The C-terminus of stress proteins is thus likely important for
stimulating DCs (Zhang and Huang, 2006). Subtle sequence differences may define

immune activation versus tolerization, as microbial HSP70 was shown to suppress
inflammation in several studies (Motta et al., 2007; Borges et al., 2012). The

outcome of immune responses was not reported to depend upon the maturation

stage of recipient antigen presenting cells. However, the separate identification of
immune stimulatory and immune suppressive regions within the C-terminus of
HSP70 (Wang et al., 2005) suggests that receptor binding affects the prevailing
consequences of HSP70 exposure.

Several surface receptors were implicated in mediating the effects of

extracellular HSP70, including CD91, TLR-2, CD14/TLR4, CCR5, and scavenger

receptors (Thėriault et al., 2006; Aneja et al., 2006; Floto et al., 2006; Qazi et al.,

2007; Fischer et al., 2010). Interestingly, elevated surface expression of HSP70 on
circulating lymphocytes was reported for vitiligo patients (Frediani et al., 2005).

HSP70-induced inflammatory killing of melanocytes confers immunological memory
against tumor cells, and may thus enhance autoimmune responses to melanocytes
as well (Sanchez-Perez et al., 2006). The ability of HSP70 to chaperone antigenic

moieties and to activate a specific, T cell-mediated immune response is exploited in

anti-tumor vaccines (Fletchner et al., 2006; Abkin et al., 2012). Thus HSP70 is a
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likely contributor to autoimmune reactivity.

HSP70 is involved in trafficking and degradation of lysosomal proteins.
The constitutive form of HSP70, HSPA8, reroutes cytosolic proteins

otherwise destined for proteasomal degradation to the lysosome (Terlecky, 1994).
Proteins rerouted for lysosomal degradation are linearized by a lysosomal

membrane complex involving HSP70, then transferred to LAMP-2a molecules

forming a pore in the lysosomal membrane (Agarraberas and Dice, 2001). Once

inside the lysosome, proteins again encounter HSP70 (lyHSP70) (Agarraberas et al.,
1997), to safeguard entering resident lysosomal proteins from inadvertent

degradation. In rheumatoid arthritis, autoimmune reactivity was assigned in part to
the process whereby HSP70 chaperones proteins into lysosomes (Auger and

Roudier, 2005). HSP70 safeguards lysosomal integrity, protecting against conditions
of oxidative stress (Nylandsted et al., 2004). When misfolded proteins are no longer
remedied by autophagy, loss of lysosomal integrity contributes to programmed

necrosis (Yamashima, 2012). Disrupted autophagy may also occur in vitiligo (van
den Boorn et al., 2001). Consequently, HSP70 and its co-chaperones (particularly
CHIP) appear as gatekeepers defining the proportion of proteins undergoing

proteasomal degradation and MHC class I antigen presentation, or lysosomal
degradation (Shin et al., 2005). In cells expressing MHC class II molecules,

lysosomes are a source of peptides to be presented in the context of such MHC class
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II molecules, thus HSP70 helps segregate class I and class II destinations (Zhou et al.,
2005; Nedelkovska and Robert, 2013).

Besides professional antigen presenting cells, resident tissue cells can

express MHC class II molecules under exceptional circumstances. For melanocytes,
these circumstances are met in melanoma, vitiligo and Vogt-Kayanagi-Harada

syndrome (Le Poole and Luiten, 2008; Damico et al., 2009). Melanosomes engage in
melanosome-endosome fusion and antigen processing (Marks et al., 2003).
Mutations in constitutive HSP70 have been implicated in disruption of the
endosomal/lysosomal compartment (Chang et al., 2002). Interestingly,

overexpression of HSP70i in melanoma cells inhibited melanin production (Hoshino
et al., 2010). Overall the presence of HSP70 in melanosomes, potentially involved in
trafficking of melanosomal proteins, has not been thoroughly investigated. Yet the
exceptional immunogenicity of melanosomes can likely be ascribed in part to

melanocyte specific melanosomal proteins presented in the context of MHC class II
molecules by melanocytes and melanoma cells (Robila, et al, 2008).

The HSP70’s are a complex family of proteins with specific household tasks.
The HSP70 family is composed of at least 17 highly related genes on

chromosomes 1, 5, 6, 9, 11, 14 and 21 in humans, encoding constitutively expressed
and inducible proteins (Brocchieri et al., 2008). The common denominator is

expression induced by elevated temperatures (heat shock) of proteins with an

approximate molecular weight of 70 kDa (66-78 kDa) (Tavaria et al., 1996). Three
functional domains have been assigned: an N-terminal ATPase domain of

11
approximately 44 kD (~350 aa), an 18 kD substrate binding domain (~150 aa) and
a 10 kD C terminal domain (~100 aa) responsible for binding chaperone cofactors
(Lehner et al., 2004). Family members serve as chaperones, guiding intracellular

proteins to respective organelle targets (Kriebaumer et al., 2012). In this function
HSP70 facilitates folding, binding and translocation of proteins (Gething and

Sambrook, 1992). Loci encoding the HSP70 family were named HSPA1 through
HSPA14 (Brocchieri et al., 2008). Canonical HSP70 isoforms are functionally

redundant, with the main differences found in their spatio-temporal expression

(Kabani et al., 2008). The localization of individual gene products will vary from
nuclear/cytoplasmic (A1/HSP72/Hsp70i, and A8/ HSP73/HSC70) to ER

(5/BiP/GRP78) and mitochondrial (9/GRP75/PBP74) (Tavaria et al., 1996). HSP70
will bind to CD40 by means of its upstream ATPase domain, coinciding with the
binding site of chaperone cofactor Hip, stabilizing the ADP state of HSP70 to

facilitate peptide binding (Mayer and Bukau, 2005). Substrate specificity may be
defined by J protein cofactor binding (Kampinga and Craig, 2010).

A chaperokine function was assigned mainly to inducible HSPA1A (Mambula

and Calderwood, 2006). The constitutively expressed isoforms are considered

important for cellular housekeeping, whereas inducible isoforms offer protection
from stress (Brocchieri et al., 2008; Daugaard et al., 2007). Enhanced secretion of
HSP70i by live cells was observed in response to IFN-γ (Bausero et al., 2005),

important for vitiligo development (Harris et al., 2012). Gene products protecting

cells from the consequences of heat shock are well conserved, and homologues are
found across species (Petitjean et al., 2012).

12
HSP70 is a star player in anti-tumor vaccines and treatment of autoimmune disease.
The chaperone function of HSP70, supporting uptake and processing of

antigens by DCs renders the molecule an ideal adjuvant in anti-tumor vaccines

(Farzanehpour et al., 2013). DNA encoding HSP70i-antigen fusion proteins was

included in vaccines to melanoma (Choi et al., 2011). Such applications frequently
use mycobacterial HSP70 (Liu et al., 2009). For anti-cancer vaccines, the use of
xenogeneic stress proteins has the added advantage that nucleotide variations

render the resulting protein increasingly immunogenic (mycobacterial and mouse
HSP70 are approximately 50% homologous), whereas either version can bind

peptides and proteins. Meanwhile murine cell lines will bind human HSP70 and vice
versa (MacAry et al., 2004).

An intriguing relationship exists between anti-tumor immunity and

autoimmunity in melanoma versus vitiligo (Teulings et al., 2013). This ultimately

prompted our studies into the involvement of heat shock proteins in vitiligo after
HSPs were implicated in anti-tumor immunity (Srivastava and Udono, 1994).

Whereas vaccines supporting the role of HSP70 in anti-tumor immunity will benefit
melanoma patients, blocking HSP70 from perpetuating autoimmune responses can

benefit vitiligo patients. Stress proteins are suited to serve as the ‘molecular funnel’
channeling environmental stress into an autoimmune response targeting

melanocytes these events. Initial studies supporting this hypothesis involved

studying differential expression of heat shock proteins among non-lesional and
lesional vitiligo skin samples (Le Poole and Luiten, 2008). Subsequently, it was

shown that heat shock proteins induced DCs to assume a cytotoxic profile, attacking

cells expressing TGF receptor family molecules, including stressed melanocytes
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(Kroll et al., 2005). Heat shock protein overexpressing melanocytes can support
immune response to differentiation antigens (Sanchez-Perez et al., 2006).

Overexpression of HSP70i likewise led to accelerated and progressive vitiligo

(Denman et al., 2008). As other stress proteins can activate DCs, these may likewise
supports vitiligo development.
SUMMARY

Vitiligo is an autoimmune disorder caused by melanocyte-reactive T cells.

Importantly, vitiligo is known to initiate and accelerate under stress, thus HSPs are
likely candidates in mediating this response. HSP70i plays a pivotal role in the

development of autoimmune disorders and activating the immune response in
general. Part of this immune activation is thought to occur by DC activating

sequences within HSP70i. There is evidence that HSP70i chaperones melancocyte
antigens, and may be secreted in response to stress. This peptide chaperoning

function may contribute to melanocyte-antigen specific targeting resulting in vitiligo
pathology as shown in Figure 1. Taken together, targeting HSP70i offers a novel
approach for treating vitiligo.
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Figure 1. Translating stress to the skin into an autoimmune response to
melanocytes. [1] Melanocytes, when exposed to stressors [2] compromise their
physiology and lead to generation of ROS. [3] Melanocytes secrete/release HSP70
(in part chaperoning melanocyte-specific antigens) which [4] activates dendritic cell
DC that migrate to skin-draining lymph nodes to [5] recruit CD4 and, particularly,
CD8 T cells, which [6] kill remaining melanocytes by the perforin/granzyme
pathway.

HYPOTHESIS AND AIMS
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A unique feature of HSP70i is that it is actively secreted by living cells. Upon

secretion, HSP70 induces immune response by chaperoning antigen, or activating

dendritic cells (DC) directly. It is unknown which region(s) of HSP70i activates DCs,

whereas multiple HSP70i DC receptors have been identified. Thus identifying the DC
stimulatory epitope(s) within HSP70i in itself is novel. I hypothesize that HSP70i is

important for inducing an autoimmune response in vitiligo through presentation of

melanocyte antigens and activation of dendritic cells, and that blocking its dendritic
cell activating region will halt depigmentation. The findings outlined in this

dissertation firmly establish a role for HSP70i in vitiligo, identify a targetable peptide
within the molecule and importantly, reveal the potentially unique treatment avenue
of blocking the effects of HSP70i in activating the immune system.
The following aims were designed to test this hypothesis:
Aim 1: To characterize HSP70i localization and secretion in vitiligo
melanocytes
Hypothesis: HSP70i is differentially expressed and secreted in melanocytes harvested
from vitiligo skin

Genetic profiling suggests inherent differences in melanocytes between

vitiligo and healthy patients (Stromberg et al., 2008). The co-occurrence of stress
and vitiligo suggests a role for a molecular pathway to link both processes. Heat

shock proteins are prime candidates to initiate disease as they are upregulated in

response to cellular stress, including the inducible isoform of HSP70 (HSP70i)
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(Morimoto, 1998). These proteins can prevent apoptosis in stressed cells by

chaperoning proteins to prevent misfolding (Lindquist and Craig, 1988; Mehlen et
al., 1996). The presence of HSP70 on or in melanosomes, potentially involved in
trafficking of melanosomal proteins has not been investigated to date. Yet the

exceptional immunogenicity of melanosomes can likely be ascribed, at least in part,
to melanocyte specific melanosomal proteins presented to the immune system in
the context of MHC class II molecules by vitiliginous melanocytes (Wang et al.,

1999). Also, the HSP70 associated with melanosomes may be externalized during
melanosome transfer, potentially affecting antigen uptake, processing and

presentation by DC. In this regard, secretion of HSP70 by live cells appears to be
mediated by secretory-like granules (Evdonin et al., 2006). Identifying the
localization of HSP70i within melanocytes may reveal an association with

melanocyte antigens. Because HSP70i is unique in that it is secreted by live cells and
has chaperone activity (Asea, 2007), dendritic cells may be activated after uptaking
the peptide bound HSP70i initiating the chain of events leading to an autoimmune
response. To date, it is unknown whether HSP70i is differentially expressed or

secreted in vitiligo melanocytes. The following sub-aims addressed this question.

a) Compare cell viability of vitiligo and control melanocytes in response to
stress

b) Identify subcellular localization of HSP70i within melanocytes
c) Compare HSP70i secretion in vitiligo and control melanocytes

Overall, data from this aim suggests that vitiligo melanocytes are more
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sensitive to stress (in the form of exposure to bleaching agents) by secreting higher
levels of HSP70i. This was shown by performing an HSP70i ELISA on cultured

melanocytes from vitiligo and healthy patients. However, these cells are not more

prone to cell death as determined by an MTT assay. It was also found that HSP70i is
located in the melanosome where it comes into close proximity to melanocyte

antigens. This was determined by both confocal and electron microscopy, as well as
western blot analysis.

Aim 2: To assess the requirement of HSP70i for inducing depigmentation in
vivo
Hypothesis: HSP70i is important for inducing an autoimmune response towards
melanocytes via dendritic cell activation and cytotoxic T lymphocyte (CTL) mediated
cytotoxicity

A link between HSP70i and depigmentation was first suggested when

inducible murine hsp70 coexpressed with an artificial antigen in mouse

melanocytes and melanoma cells resulted in enhanced melanocyte killing (SanchezPerez et al., 2006). A direct role for HSP70 in CTL-mediated autoimmunity was then

solidified by vaccinating mice with DNA encoding tyrosinase-related protein 2 (TRP2) in the presence and absence of HSP70i (Denman et al., 2008). These studies

demonstrate the importance of inducible HSP70 in breaking CD8+ T cell tolerance

towards melanocytes. However, there may be redundancy amongst other HSPs (e.g.

gp96, or HSPs 60, 90, and 100). The following sub-aims addressed the question
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whether the role of HSP70i is unique and non-redundant, and whether HSP70i is

necessary and sufficient to induce vitiligo in order to identify HSP70i as a potential
treatment target.

a) Demonstrate whether HSP70i knockout mice are resistant to developing
vitiligo

b) Measuring relative DC activation and T cell reactivity to melanocytes

c) Determine if HSP70i is enough to activate autoimmunity in disease-prone
mice

From this aim it was determined that HSP70i knockout mice are resistant to

developing vitiligo. This was tested by vaccinated C57BL/6 and HSP70i knockout

mice with melanocyte antigens. Moreover, it was determined that vaccination with
HSP70i alone accelerates depigmentation in vitiligo-prone mice which carry a

melanocyte-reactive T-cell receptor transgene expressed by the majority of

circulating T cells. Our results showed that vaccination with wild-type HSP70i
drives an inflammatory response mediated by activated DCs, and CD8 T cells.
Depigmentation was mediated by a CTL response as determined by

immunohistochemistry and in vivo CTL assays. Finally we showed that HSP70i

activates and drives an inflammatory DC/ T cell response by FACS analysis of mouse
splenocytes.

Aim 3: To assess HSP70i blocking agents in preventing an autoimmune
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response
Hypothesis: HSP70i-derivative peptides provide superior immune activation over full
length protein and the depigmentation response will be prevented by blocking the
putative DC binding region of HSP70i

It is well known that HSP70i activates DCs (Basu et al., 2000; Kuppner et al.,

2001); however, no one has identified the stimulatory sequence within mammalian
HSP70i. HSP70i may activate DCs through specific receptor binding, leading to the
activation and recruitment of effector cells from draining lymph nodes. Thus, the
identification of a peptide within HSP70 crucial to eliciting autoimmunity will be

significant as it will open doors to preventing the causative chain of events leading to
depigmentation in vitiligo, and autoimmunity in general. The amino acid sequence
QPSVQIQVYQGEREIAAHNK within the C-terminus of the microbial HSP70

homologue DnaK was previously shown to bind and activate DCs in response to

infection (Wang et al., 2005). We thus focused on this sequence to narrow down the
region important for inducing an immune response in human HSP70i. Using
alignment software, a similar sequence was identified within the sequence

QPGVLIQVYEGERAMTKDNN, rendering the peptide with the greatest homology as
QPGVLIQVYEGER (amino acids 435-447) as a relevant candidate involved in DC
activation. It was predicted that both the microbial and mammalian sequences

would show similar folding patterns based on the evolutionary conservation of the
molecule. In this aim, the QPGVLIQVYEGER epitope as well as other regions of
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HSP70i were rigorously tested for DC binding and immune stimulatory capabilities.
We predicted that targeting this region can abrogate this effect in the following subaims.

a) Identify the HSP70i region most relevant to autoimmunity

b) Demonstrate involvement of the 13-mer peptide in immune activation

c) Demonstrate whether blocking HSP70i via commercially available
antibodies prevents DC activation in vitro

d) Test effects of mutant HSP70i in preventing depigmentation and immune
responses in vivo

Overall, it was determined that the immune activating portion of HSP70i

required for vitiligo resides in the C-terminus. Specifically, the DC activating

sequence (QPGVLIQVYEG) of HSP70i is required for depigmentation. We showed
that mutating the DC activating sequence prevents HSP70i from inducing

depigmentation in vaccinated animals, but does not affect overall binding to DCs. To
block DC activation by HSP70i, we tested the commercially available HSP70i

antibody (SPA-810). It was determined that SPA-810 recognizes a peptide including

the sequence PGVLIQVYEG which prevented DC activation in vitro, but was unstable
in vivo. In addition, we discovered that vaccinating vitiligo-prone mice with mutant

HSP70iQ435A prevents and treats vitiligo. It was shown that vaccination with

HSP70iQ435 drives an anti-inflammatory response mediated by decreased (and

inhibited) DCs, and the upregulation of anti-inflammatory macrophages. Using

immunohistology we showed that wild-type and HSP70iQ435 increase and decrease

skin infiltrating CTLs respectively. The mechanism of HSP70iQ435 was mediated by
driving quiescent versus T cells as determined by expression of the T cell

transcription factors Eomes and T-bet, and through inhibition of DC activation.
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CHAPTER III

PREFERENTIAL SECRETION OF INDUCIBLE HSP70
BY VITILIGO MELANOCYTES UNDER STRESS

INTRODUCTION

Vitiligo is a skin disorder characterized by progressive depigmentation. Over

0.5% of the world population is affected by vitiligo, with a 25% increased incidence
among women (Cedercreutz et al., 2010). Depigmentation will progress by 1% of

body surface area a year on average (Cedercreutz et al., 2010). Expanding lesions
are frequently infiltrated by T cells reactive with melanocytes thus supporting an
etiologic involvement of cell mediated autoimmunity (van den Wijngaard et al.,

2000). Genetic evidence likewise supports a process involving a break in tolerance

(Jin et al., 2012), leading to activated T cells trafficking to the skin. However, there is
limited concordance between monozygotic twins, suggesting a role for

environmental factors in disease precipitation (Spritz, 2010). Indeed, patients

appear to develop vitiligo under stressful circumstances (Cedercreutz et al., 2010;
Picardi et al., 2003). Stress associated with psychological as well as

mechanical/chemical insults can initiate or accelerate vitiligo (Picardi et al., 2003).
Several chemicals induce vitiligo, some of which are used in bleaching creams
(Boissy and Manga, 2004). These agents may induce oxidative stress, lending
22

credibility to the observation that antioxidant enzymes such as superoxide
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dismutase and catechol-O-methyltransferase are overexpressed in vitiligo skin (Le
Poole et al., 1994; Sravani et al., 2009). Differential gene expression data further

suggest that melanocytes from vitiligo patients may be inherently sensitive to stress
(Stromberg et al., 2008).

To understand why stress would translate into an immune response

specifically targeting melanocytes, it may be important to take note of the natural
target antigens that have been uncovered, which predominantly reside in

melanosomes. These organelles are uniquely immunogenic (Sakai et al., 1997), and

carry lysosome-like properties (Orlow, 1995; Le Poole, 1993a; Raposo et al., 2002).
Moreover, the process of melanogenesis within these organelles is associated with

generating hydrogen peroxide and free radicals during melanogenesis, providing a
direct link to stress-induced disease (Mastore et al., 2005). Thus stress can be a
consequence of the very organelles that form a source of melanocyte antigens.

Taken together with morphologic abnormalities reported for vitiligo melanocytes
also affecting melanosomes (Li et al., 2009; Boissy et al., 1991) it has long been

postulated that patient cells selectively succumb to oxidative stress within vitiligo
skin.

Meanwhile, heat shock proteins (HSPs) are prime candidates to mediate the

process that translates environmental factors and oxidative stress into an

autoimmune disease. Including the inducible isoform of HSP70 (HSP70i), heat shock
proteins are upregulated in response to cellular stress, preventing apoptosis by

chaperoning proteins to prevent misfolding (Beere and Green, 2001). When found

in the extracellular milieu, stress proteins serve as an alarm signal to the immune
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system by activating local antigen presenting cells (APCs) (Kammerer et al., 2002).

HSP70i is unique in this regard, as it is reportedly secreted by live cells (Asea, 2007).
Several lines of evidence have since solidified a role for HSP70i in

precipitating vitiligo, including the observation that wild-type and vitiligo-prone
mice develop accelerated disease in response to HSP70i (Mosenson et al., 2012;

Mosenson et al., 2013). It was also determined that mice lacking the HSP70i gene do
not depigment, attesting to a requirement for the HSP in disease development

(Mosenson et al., 2012). The importance of HSP70i in initiating vitiligo may be

attributed to its potent adjuvant and chaperone properties (Zhang et al., 2006). This
is supported by prior studies which have shown that HSP70i can chaperone

immunogenic peptides derived from melanocyte differentiation antigens (Noessner
et al., 2002).

Here we address the hypothesis that disease precipitation in vitiligo follows a

process whereby HSP70i is in contact with immunogenic melanosomal peptides and
preferentially exported from vitiligo melanocytes under stress. We thus exposed
primary melanocytes to phenolic agents modeling factors that can precipitate

disease, comparing the sensitivity of cells from vitiligo and healthy origin in viability
assays. Colocalization of HSP70i and melanosomal proteins was tested by Western
blotting of fractionated cells, accompanied by electron microscopic analysis of

concentrated fractions. Differential melanosome trafficking of HSP70i in vitiligo
melanocytes after treatment with phenolic agents was followed by confocal

microscopy using software plugins, while stress protein secretion was measured by

ELISA. Taken together, the experiments can help to understand the interplay
between melanocytes and the environment to precipitate disease.

25

RESULTS
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HSP70i is aberrantly expressed in vitiligo skin
Vitiligo is frequently associated with stress which may be accompanied by

expression of HSP70i. We thus probed nonlesional, perilesional and lesional skin
sections from four vitiligo patients with the HSP70i specific antibody SPA-811

(Figure 2A). HSP70i expression was observed mainly in the epidermis, with highest
expression in the lesional sections. Lesional skin contained intense

immunoperoxidase staining of all cells and extracellular matrix, whereas

nonlesional skin was mostly devoid of HSP70i expression (Figure 2A). Due to these
staining patterns, HSP70i expression was evaluated by blinded subjective

quantification of immunoperoxidase intensity. It was determined that HSP70i

expression is significantly higher in lesional (P = 0.0044) and perislesional (P =

0.0480) versus nonlesional skin (Figure 2B). These data support previous findings
that HSP70 is overexpressed in vitiligo skin, specifically the inducible isoform.
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Figure 2. HSP70i overexpression in vitiligo skin. (A) Representative
immunoperoxidase staining of HSP70i in vitiligo skin displaying expression
predominantly located in the epidermis, with minimal cellular expression observed
in nonlesional (left), and moderate to strong expression in perilesional (middle) and
lesional (right) skin. (B) Subjective, blinded quantification of HSP70i expression in
tissue sections. Immunoperoxidase intensity: 1=low, 2=medium, 3=high. Data are
presented as mean ± SEM. Student’s one-tailed t-test. *P< 0.05, **P<0.01, n=7
subjects.

Vitiligo and control melanocytes are equally sensitive to stress induced by phenolic
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agents
The above data suggested that the overexpression of HSP70i in vitiligo skin

may play a protective role in response to stress. Thus, we measured the viability of
primary melanocytes harvested from nonlesional vitiligo and control skin in

response to the phenolic agents 4-tertiary butyl phenol (4-TBP) and monobenzyl
ether of hydroquinone (MBEH). The melanocytes were exposed to 125, 250, and

500 μM of 4-TBP or MBEH for 72 hours, and viability was determined by MTT assay
(Figure 3). All samples were compared relative to vehicle (20% dimethyl sulfoxide
diluted in 70% EtOH, and diluted to 1:1000 in melanocyte media) treated control

cells. Treatment with 4-TBP reduced viability by approximately 4, 24, and 69% in

response to 125, 250, and 500 μM concentrations of 4-TBP respectively (Figure 3).
Treatment with MBEH reduced viability by approximately 19, 32, and 62% in

response to 125, 250, and 500 μM concentrations of MBEH respectively (Figure 3).
Our results indicate that melanocyte viability decreases as the concentration of 4-

TBP and MBEH increases; however, there were no differences between control and
vitiligo melanocytes in response to any of the treatments (Figure 3). These data

were performed in duplicate with similar results, and demonstrate that vitiliginous
melanocytes are not more resistant or susceptible to direct killing by bleaching
agents.
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Figure 3. Cell viability of vitiliginous melanocytes. Primary melanocytes from
control and vitiligo patients were plated at 10,000 cells per well in triplicate, and
exposed to 125, 250, or 500 μM concentration of 4-tertiary butyl phenol (4-TBP) or
monobenzyl ether of hydroquinone (MBEH) for 72 hours. Percentage viability was
quantified in MTT assays, and compared relative to vehicle (20% dimethyl sulfoxide
diluted in 70% EtOH, and diluted to 1:1000 in melanocyte media) treated controls.
Cell viability decreased as 4-TBP and MBEH dosage increased; however, no
differences were observed between control and vitiligo melanocytes for any
treatment. Data provided from two independent experiments with triplicate values
for each experiment, with similar results. Healthy control (n =8 subjects), vitiligo (n
=5 individual cultures). Data are presented as mean ± SEM. Student’s one-tailed ttest.
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Vitiligo melanocytes specifically increase HSP70i colocalizing within the melanosome
fractions in response to stress
To assess HSP70i and melanosomal antigen colocalization, melanocyte

homogenates were fractionated by density gradient centrifugation (Figure 4A), and
proteins within individual fractions were further separated by SDS-PAGE (Figure
4B). Blotted proteins were probed with the pAb SPA-820 which binds both the

constitutive and inducible HSP70 isoforms. Intense immunoperoxidase detection
(40.56% mean band intensity) of HSP70 by SPA-820 was observed in the

melanosomal fractions (19-24) whereas weak or no HSP70 expression was detected
(6.33% mean band intensity) in the non-melanosomal fractions (1-18) (Figure 4C).

Fractions 7-9 and 20-22 were pooled, concentrated and processed for transmission

electron microscopy (Figure 4B). Electron micrographs of fractions 20-22 support a
high concentration of late melanosomes, coinciding with high content of HSP70. In

order to delineate the presence of inducible HSP70 amongst these fractions, blotted
proteins were probed with the HSP70i specific mAb SPA-810. Again, detection of

HSP70i was limited to the melanosomal fractions (19-24; Figure 4D). In addition,
the presence of the melanosomal antigen gp100 (Ab HMB45) was detected

selectively amongst these fractions (Figure 4D). These data indicate that HSP70i is
in close proximity to melanocyte antigens.
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Figure 4. HSP70i colocalizes with melanosomal fractions. (A) Adult melanocytes
(HM162P7) were dounced and underloaded on an iodixanol gradient for
ultracentrifugation. Dense bands containing melanin were observed in the
melanosomal (20/21 and 23) fractions. (B, upper image) Collected fractions (nonmelanosomal 7-9, and melanosomal 20-22) were fixed and analyzed by electron
microscopy (EM). (B, lower image) Collected fractions were run on a Western Blot.
SPA-820 antibody (which binds both constitutive and inducible HSP70 isoforms)
reacted with the melanosomal (19-24) but not non-melanosomal fractions (1-15).
(C) Quantification of western blot band intensities shown in EM. Mean luminosities
indicate stronger antibody reactivity in fractions 19-24 versus 1-18. Student’s onetailed t-test, * P<0.05. (D) Western blot analysis of non-melanosomal (1, 2 and 18)
and melanosomal (19-23) fractions probed with the antibody SPA-810 which only
detects inducible HSP70 (70 kD), and HMB45 to the melanocyte antigen gp100
(HMB45 detects a 45 kD product of gp100). Only the melanosomal fractions (19-23)
react with both HSP70i and gp100 antibodies. Purified HSP70i protein was probed
as a control. Together these data indicate that HSP70i is expressed within the
melanosome containing fractions.

Intracellular HSP70i colocalizes in part with melanosomal proteins
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To further examine the location of HSP70i within melanocytes at rest,

fluorescently labeled antibodies to HSP70i (GFP) and TRP-1 (PE/Cy7) were

detected by confocal microscopy (Figure 5). Images of 1.0 μm serial Z-slices

indicated that both HSP70i and TRP-1 are ubiquitously expressed throughout the

cytoplasm, but not in the nucleus (Figure 5A). HSP70i appears to have a punctate

pattern directly outside the nucleus, whereas TRP-1 is mainly detected within the

dendrites (Figure 5A). Next, primary vitiligo and control melanocytes were exposed
to sub-lethal doses (125 μm) of 4-TBP or MBEH for 72 hours. We analyzed HSP70i

(GFP) and the melanocyte antigen gp100 (PE/Cy7). The gp100 reactive antibody

HMB45 was selected as it was previously shown to bind a 35 kD fragment of gp100

located predominantly in the melanosome (Harper et al., 2008). The confocal images
displayed colocalization of HSP70i and gp100 as shown by Z-slices and merged

images (Figure 5B). Interestingly, punctate staining of HSP70i was detected outside
the melanocytes suggestive of secretion (Figure 5B). Extracellular gp100 staining

was also visible to a lesser extent, possibly due to degradation or loss of the HMB45
binding epitope (Figure 5B). No extracellular staining was observed in the control
slides where no primary antibody was added (Figure 6). Colocalization of HSP70i
and gp100 was quantified using the ImageJ colocalization plug-in JACoP (Just

Another Co-localization Plugin; Bolte and Cordelières, 2006), which calculates the

distance between fluorescent pixels (green and red), and also assigns a pseudocolor
representing gradation of colocalization (Figure 5B). The number of HSP70i/gp100
colocalized pixels was compared relative to the total number of HSP70i labeled
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pixels within the cell. The data indicate no difference in the amount of HSP70i and
gp100 colocalization in vitiligo and healthy melanocytes treated with vehicle

(Figure 5C). When treated with bleaching phenols, however, the amount of HSP70i
and gp100 colocalization differed between vitiligo and healthy melanocytes.

Importantly, vitiligo melanocytes treated with MBEH demonstrated the greatest

colocalization (7.5%) as compared to any treatment (Figure 5C; P = 0.0001). Vitiligo
melanocytes treated with 4-TBP displayed ~2-fold increased HSP70i/gp100
colocalization as compared to healthy melanocytes (Figure 5C; P = 0.0439).

However, less colocalization was detected in melanocytes after treatment with 4TBP compared to vehicle (Figure 5C). This prompted us to further assess HSP70i

expression in response to 4-TBP. Healthy melanocytes were exposed to 125 um 4TBP for four hours, followed by immunostaining with gold particle-conjugated

HSP70i antibodies. Detection was performed by transmission electron microscopy
(Figure 7). The images display HSP70i (gold particles) throughout the cytoplasm,
which are more abundant in the 4-TBP treated melanocytes (Figure 7). Labeling

was quantitated as described in Materials & Methods. The expression of HSP70i in
control and 4-TBP treated melanocytes was 10.1 (+ 4 SD) and 25.2 (+ 3 SD) gold
particles/50x10-6 nm2, respectively (P=0.0002). HSP70i justapositioned to

melanosomes could be observed under higher magnification (Figure 7, insets).

Together with the confocal images, these data demonstrate that HSP70i traffics to
the melanosome which can be significantly enhanced in vitiligo melanocytes
exposed to MBEH.

A

C

B
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Figure 5. HSP70i is overexpressed in vitiliginous melanosomes after stress. (A)
Representative serial 1.0 μM Z-sliced images of neonatal melanocytes (Mf0627P11)
indicate cytoplasmic expression of HSP70i (SPA-811 Ab detected by FITC) and the
melanocyte antigen TRP-1 (Ta99 Ab detected by PE/Cy7) throughout the cell, but
not present in the nucleus (DAPI counterstained). (B) Representative 0.5 μM Z-slice
images of neonatal melanocytes (Mf0627P11) probed with antibodies to HSP70i
(SPA-811) and gp100 (HMB45). Individual channels for HSP70i (GFP), gp100
(PE/Cy7) and merged images are shown. Note extracellular detection of
HSP70i/gp100. An image pseudocolored by the ImageJ plug-in JACoP indicates
levels of HSP70i/gp100 colocalization as low (blue), middle (yellow) and high (red).
Perinuclear red mapping indicates over-lapping between the two labels, suggestive
of colocalization. (C) Vitiligo and neonatal melanocytes were treated with 250 μM
bleaching agents (4-TBP and MBEH) for 24 hours followed by confocal microscopy.
Five z-slices from representative treated melanocytes were analyzed for
HSP70i/gp100 colocalization using JACoP, with an nMDP cutoff of 1 used in the
calculations. Data is presented as HSP70i/gp100 colocalization relative to total
HSP70i staining. Graphed is the normalized mean deviation production (nMDP) for
5, 1μm Z-slices for each sample. Healthy control (n =3 individual cultures), vitiligo
(n =3 individual cultures). Data are presented as mean ± SEM. Student’s one-tailed ttest.* P<0.05, ***P< 0.001
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Figure 6. Minimal background in confocal no primary images. Representative
0.5 μM Z-slice control images of a neonatal melanocyte (Mf0627P11) probed with
anti-rabbit FITC and anti-mouse PE/Cy7 antibodies, excluding primary antibodies. A
brightfield image displays the location of the melanocyte, with its nucleus visible in
the DAPI channel. Minimal background fluorescence is observed in the FITC and
PE/CY7 channels, demonstrating the secreted HSP70i/gp100 (Figure 5) is not an
artifact.
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Figure 7. Transmission electron microscope detection of HSP70i in 4-TBP
treated melanocytes. Healthy melanocytes (Mf06321P2) were treated with 125
μM 4-TBP for 4 hours followed by immunostaining with gold particle-conjugated
antibodies to HSP70i. The melanocytes were next fixed and scanned by transmission
electron microscopy. Gold particles (red arrows) are observed in sections probed
with anti-HSP70i which are more abundant (P < 0.0002, n=8 micrographs) in 4-TBP
treated melanocytes. HSP70i is seen throughout the cytoplasm in line with data
shown in Figure 5, and occasionally justapositioned to melanosomes (insets). Bar
equals 500 nm. (inset bars equal 40nm). Student’s one-tailed t-test.

Primary vitiligo melanocytes secrete more HSP70i in response to MBEH treatment
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The above data support that HSP70i is in close proximity to melanocyte

antigens in cells under stress. Extracellular HSP70i is known to have adjuvant
properties, thus we next compared HSP70i secretion of vitiligo and control

melanocytes in response to chemical stress. It was previously published that

immortalized vitiligo PIG3V cells secrete more HSP70i in response to the bleaching
agent 4-TBP versus immortalized control PIG1 cells (Kroll et al., 2005). The above
confocal data suggested that MBEH greatly upregulates HSP70i trafficking to

melanosomes, therefore we investigated its effects on HSP70i secretion. Here, we
exposed the same immortalized PIG1 and PIG3V cultures, representing control

versus vitiligo melanocytes respectively, to MBEH. The PIG1 and PIG3V cells, as well

as primary melanocytes from healthy and vitiligo patients were treated with 125 um
of MBEH for 24 hours. Images indicate that exposure to a low dose of MBEH does
not induce significant cell death in either the immortalized or primary cell lines

(Figure 8A and B), similar to the results in Figure 2. The supernatants were then

analyzed for HSP70i by high sensitivity ELISA, and measurements were compared

relative to untreated samples. The results confirm that PIG1 and PIG3V cells secrete
~ 3-fold increased levels of HSP70i after MBEH treatment, comparable to reported

findings using 4-TBP (Kroll et al., 2005). Importantly, PIG3V cells secrete

significantly higher levels of HSP70i as compared to PIG1 cells with vehicle (P =

0.0145) and MBEH (P = 0.0053) treatment (Figure 8A). In addition, it was revealed

that primary vitiligo melanocytes secrete ~7-fold increased amounts of HSP70i after
MBEH versus vehicle treatment, whereas no detectable levels of HSP70i were

observed with healthy melanocytes (Figure 8B). HSP70i secretion was similar
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between vitiligo and healthy melanocytes after vehicle treatment (Figure 8B). Most
importantly, MBEH induced significantly greater HSP70i secretion in vitiligo

melanocytes (P = 0.0031; Figure 8B). In total, these data indicate that vitiligo

melanocytes respond to stress by secreting higher levels of HSP70i after phenol
exposure.

A

B
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Figure 8. Vitiligo melanocytes secrete more HSP70i in response to MBEH. (A)
The immortalized melanocyte lines (vitiligo PIG3VP54 and control PIG1P96; n=3
measurements) and (B) primary healthy and vitiligo melanocytes were treated with
125 um MBEH for 24 hours. Supernatants from treated and untreated cultures were
assessed for HSP70i content by high-sensitivity ELISA. The percent increase in
HSP70i of MBEH and vehicle treated compared to untreated samples is indicated.
Images of cell cultures (A and B) show no differences in cell density or death after
MBEH treatment. A significant increase in HSP70i secretion was observed in vitiligo,
but not control melanocytes after MBEH treatment. These data indicate that
melanocytes obtained from vitiligo skin secrete more HSP70i in response to stress
than healthy cells. Control (n =4 individual cultures), vitiligo (n =3 individual
cultures). Data are presented as mean ± SEM. Student’s one-tailed t-test. **P< 0.01,
***P< 0.001.

DISCUSSION
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Controversies remain regarding the etiology of vitiligo. There is support for

an overproduction of free radicals in stressed vitiligo melanocytes, as well as for an
autoimmune response wherein T cells specifically target melanocytic antigens. The
data presented in this manuscript suggest that the above may not represent

mutually exclusive mechanisms, but rather aspects of disease that complement each
other, joining forces to initiate and perpetuate vitiligo development. This supports
the convergence and melanocytorrhagy theories which state that autoimmunity,
impaired redox status, and genetic predisposition all contribute to vitiligo
development (Le Poole et al., 1993b; Kumar and Parsad, 2012).

Melanocytes obtained from vitiligo patients express intrinsic abnormalities

including dilated endoplasmic reticulum profiles and abnormal melanosome

compartmentalization (Li et al., 2009; Boissy et al., 1991). Moreover, others have
reported that melanocytes from vitiligo patients have reduced calcium uptake,

which is important for inhibiting redox activity (Schallreuter-Wood et al., 1996).

Such observations suggest that vitiligo melanocytes are more sensitive to stress, and
generate hydrogen peroxide and other free radicals, especially during

melanogenesis. Increased production of H2O2 may increase the susceptibility of

melanocytes to apoptosis/necrosis (Zhang et al., 2013). Although a preliminary
study suggested that vitiligo melanocytes may be more sensitive to 4-TBP than
control cells, the most important data from that study is the restoration of cell

viability in presence of catalase (Manga et al., 2006). Meanwhile, the sensitivity of

cells to bleaching phenols is greatly affected by donor pigmentation, donor age and
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culture conditions, and a comparison among multiple cultures is required to identify
overall differences in viability upon exposure. In our current study, the data indicate
that cell viability of vitiligo melanocytes is not different from that of healthy

melanocytes in response to bleaching agents. Thus, the loss of melanocytes from

vitiligo skin likely involves a different pathway. This prompted us to identify a factor
that translates stress into melanocyte death observed in vitiligo.

Patient surveys indicate that vitiligo is initiated and accelerated after stress,

with ~50% of patients reporting a Koebner phenomenon (Cedercreutz et al., 2010).
Heat shock proteins are produced in response to stress, and function to re-fold

damaged proteins to prevent cell death (Beere and Greene, 2001). Recently, it was
shown that HSP70 is overexpressed in lesional and perilesional vitiligo skin;

however, it was unclear which isoform(s) of HSP70 is affected as antibody W27
used in this study was directed to both the constitutive and inducible isoforms

(Abdou et al., 2013). As inducible form of HSP70 (HSP70i) is the primary instigator
of immune responses (Mosenson et al., 2021), this prompted us to focus on the

inducible form of HSP70 (HSP70i) as a mediator of vitiligo. Here we determined that
inducible HSP70 specifically is overexpressed in vitiligo lesional tissue. This

corresponds with our recently published data that HSP70i is a critical component in
vitiligo development (Denman et al., 2008; Mosenson et al., 2012). Besides

activating dendritic cells (DCs) to become lytic towards tumor necrosis factor-

related apoptosis-inducing ligand (TRAIL) receptor expressing melanocytes, it was

shown that HSP70i overexpression can enhance vitiligo development in mice (Kroll
et al., 2005; Mosenson et al., 2012). Moreover, a central role for HSP70i was

determined by demonstrating that Hsp70-1 knockout mice are resistant to
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depigmentation after vaccination with melanocyte antigens (Mosenson et al., 2012).

We previously reported that vitiliginous melanocytes overproduce HSP70i in

response to 4-TBP induced stress (Kroll et al., 2005). This appears counterintuitive

since HSPs protect cells from apoptosis under stress. However, extracellular HSP70i
serves as an “alarm signal” to activate immune responses (Kammerer et al., 2002).

This illustrates the importance of HSP70i in immune activation as it is the only HSP
secreted by live cells (Asea, 2007). This suggests that immune targeting follows

stress to melanocytes as a factor in vitiligo mediated by HSP70i secretion. Here, we

predicted that HSP70i would be differentially secreted by MBEH treated control and
vitiliginous melanocytes. Using a high sensitivity ELISA we demonstrated that
immortalized PIG3V vitiligo melanocytes show relatively increased HSP70i

secretion compared to PIG1 immortalized normal melanocytes upon MBEH

exposure, similar to data previously using 4-TBP (Kroll et al., 2005). Importantly, we
also established that HSP70i is more abundantly secreted by primary vitiliginous

melanocytes. These data suggest that vitiliginous melanocytes respond to stress by
overproduction/secretion of HSP70i rather than by direct cell death. We propose
that the increased HSP70i secretion by vitiligo melanocytes is subsequently

followed by selective immune activation and recruitment of melanocyte-reactive
cytotoxic T lymphocytes (CTLs), which ultimately contribute to vitiligo
development.

HSP70i binds proteins/peptides to serve many functions including protein

folding, trafficking, and potentially MHCI/II loading (Srivastava, 2002). Within
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melanocytes, melanosomal proteins such as TRP-1 and gp100 are transported from
endosomes to lysosomes by HSP70i to be transferred to LAMP-2a proteins for
internalization (Terlecky, 1994; Agarraberes and Dice, 2001). Intriguingly,

vitiliginous melanocytes express MHCII which is normally reserved to APCs (Le

Poole et al., 1993c). Thus, melanocytes under stress may upregulate expression of

HSP70i which cross-presents melanocyte-antigens to MHCII as has been observed in
other cell types (Srivastava, 2002).

Besides these intracellular immune functions, HSP70i residing in

melanosomes may also be externalized during melanosome transfer, potentially

affecting antigen uptake, processing and presentation by DCs. Secretion of HSP70i
by live cells has been recently suggested to involve lysosomal contents, and the
formation of exosomes, and appears to be mediated by secretory-like granules

(Evdonin et al., 2006). In melanoma, under minimal stress, low levels of HSP70i are

transported to the membrane via endosomes, whereas under stress, elevated levels
of expression lead to re-routing of HSP70i into lysosomes for subsequent secretion
(Juhasz et al., 2013). Extracellular HSP70i can induce DCs to more actively

phagocytize and cross present antigen, and activate responder T cells (Srivastava,

2002), thus the peptides bound to HSP70i may invoke a targeted immune response .
Because of these adjuvant properties, HSP70i has been useful in melanoma vaccines
(Zhang et al., 2006).

Stress proteins isolated from melanoma tumors will chaperone melanocyte-

specific peptides critical for directing a targeted response towards these antigens
(Noessner et al., 2002). This antigen-bound HSP70i can activate DCs leading to
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production and expansion of tumor reactive T cells. Not surprisingly, T cells isolated
from both melanoma and vitiligo patients recognize many shared melanocyte

antigens. Confocal microscopic analysis shows that a fraction of intracellular HSP70i
is associated with melanosomes. The same is shown by electron microscopic and
Western blot analysis of fractionated cells. This follows prior observations that
constitutive HSP70 is responsible for shuttling lysosomal content across the

organelle membrane (Agarraberes and Dice, 2001). Given the similarity in function
of melanosomes within melanocytes and lysosomes in other cells (Orlow, 1995; Le

Poole et al., 1993a; Raposo et al., 2002), a shuttle function for the other isoform may
explain the melanosomal association and its observed increase under stress.

HSP70i can bind melanocyte antigens (Noessner et al., 2002), and can be

found in close proximity to relevant target antigens. Interestingly, we showed that
HSP70i colocalizes with melanosomes to a greater extent after MBEH exposure.

Thus stress likely induces trafficking of HSP70i to the melanosome where it may

assist in protein folding, or antigen loading (Chi et al., 2006). This is coherent with
the observation that a melanosome transport signal enhances immunogenicity of
intracellular proteins (Wang et al., 1999). Greater colocalization occurred in

response to MBEH, whereas 4-TBP gave little to no effect, supporting the very

different responses of melanocytes to either form of stress (Hariharan et al., 2011).

This is also in line with evidence that MBEH and 4-TBP induce melanocyte cell death
by different mechanisms (Hariharan et al., 2011).

Overall, our data indicate that vitiliginous melanocytes are indirectly more

sensitive to MBEH-induced stress though increased secretion of HSP70i and

subsequent immune activation. MBEH and 4-TBP are known to induce reactive
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oxygen species (ROS) (van den Boorn et al., 2011; Manga et al., 2006), which will
contribute to HSP70i production (Kim et al., 2005). Once upregulated, HSP70i

traffics to the melanosome where it can bind antigenic peptides (Noessner et al.,

2002). Melanosomes contain MHCI/II in addition to several melanocyte antigens
which can be presented (Wang et al., 1999). Although the mechanism of HSP70i

secretion is not well understood, recent evidence supports an exosomal mechanism
(Lancaster and Febbraio, 2005) that involves melanosome occlusions (Ando et al.,
2012). Within the cell HSP70i may contribute to MHCI/II antigen loading and
membrane transport (DeNagel and Pierce, 1992; Castelli et al., 2001). Upon

secretion, the melanocyte-antigen bound HSP70i can activate DCs leading to

targeted killing of melanocytes. Our data provide a mechanism by which stress

differentially induces overexpression and melanosome localization of HSP70i within
vitiligo melanocytes, leading to enhanced secretion of HSP70i-antigen complexes,

subsequent DC activation and T cell recruitment. Thus stress may selectively initiate
an autoimmune response in vitiligo patients which leads to melanocyte cytotoxic T
lymphocyte killing.

CHAPTER IV

HSP70i is a critical component of the immune response leading to autoimmune
vitiligo (Mosenson et al., Pigment Cell Melanoma Res, 2012)

INTRODUCTION

Vitiligo is a T-cell mediated autoimmune disease of the skin. Patients present

with progressive depigmentation that advances at an average rate of 1% bodily
surface area a year (Cedercreutz et al., 2010). Genetic predisposition has been

assigned to candidate genes including MHC classes I and II, PTPN22 and IL2RA,

supporting the autoimmune etiology of the disease (Jin et al., 2010). Approximately

25% more women than men develop vitiligo (Cedercreutz et al., 2010). At this time,
there is no definitive evidence to support an association between vitiligo and a

particular ethnic background. However, the progressively depigmenting skin is
clearly more apparent for patients with a darker skin tone. Also, the social

implications of disease are particularly devastating in countries where leprosy is a

considerable health problem, as the appearance of skin lesions can bare similarities
among both patient groups, and patients with vitiligo are mistakenly identified as
individuals expressing a contagious disease (Millington and Levell, 2007).
Aside from a hereditary component, vitiligo pathogenesis involves

environmental factors that contribute to precipitating the disease. Among these
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exposure to skin bleaching phenols has been particularly well studied (Boissy and
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Manga, 2004). It is of great interest to identify the molecular connection between

environmental precipitating factors and the autoimmune response that follows, as
such studies can serve to identify candidate target molecules to develop novel and
effective treatment strategies for the disease. There is a lack of effective

therapeutics available for vitiligo, in part because halting disease progression and
re-establishing pigmentation are conceptually different phases of the disease that
may have to be addressed by separate means (Le Poole and Luiten, 2008).

Establishing pigmentation in patients with active disease is likewise

problematic. An important step forward in developing vitiligo therapeutics is thus to
recognize that progressive disease must first be effectively brought to a halt.

Understanding of mechanisms at work in progressive disease will be important. In
this respect, heat-shock and glucose-regulated proteins are prime candidates to

connect stress to the skin with the autoimmune response to follow. In particular,
gp96 and HSPs 60, 70, and 90 have been implicated in immune cell activation

(Multhoff, 2006). Stress proteins support immune reactivity by activating dendritic
cells to more efficiently phagocytize, process, and present antigens (Murshid et al.,
2008). This concept has been elaborately exploited in the design of anti-tumor

vaccines for melanoma, renal cell cancer, and less immunogenic tumor types (Tosti
et al., 2009).

Among heat-shock proteins, inducible HSP70 (HSP70i) stands out as it can be

secreted by live cells (Asea, 2007). Secretion of HSP70i by live cells would thus

indicate that even in the absence of cell death, an immune response can be triggered
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to proteins and peptides derived from the cells under stress, chaperoned by HSP70i.
This has guided an interest in defining the involvement of HSP70i in autoimmune
vitiligo. Interestingly, heat-shock proteins have been implicated in other

autoimmune diseases as well, including rheumatoid arthritis, and other skin
disorders such as psoriasis (Millar and Ohashi, 2007).

After observing consistent differential expression of HSP70i in non-lesional

and vitiligo skin from three patients (Le Poole and Luiten, 2008), the concept was
tested that the expression of inducible HSP70 is a major contributor to the

development of vitiligo in mice. Accelerated depigmentation was associated with
enhanced cytotoxic T-lymphocyte (CTL) responses to the vaccinated antigen,

supporting that depigmentation occurs in a T-cell mediated fashion in a vaccine-

based model of vitiligo (Denman et al., 2008). Also, melanocyte-directed

overexpression of HSP70 can enhance anti-tumor responses to melanoma (Sanchez-

Perez et al., 2006).

Whereas HSP70i can induce autoimmune depigmentation, given the shared

chaperone and immune-activating functions, the same is likely to hold true for other
stress proteins as well. The question then remains whether a single stress protein
can be held responsible for mediating progressive disease or whether there is

redundancy in this mechanism. The HSP70 family of proteins is extensive, with

estimates of up to 17 genes in human (Kabani and Martineau, 2008) and 3 in mouse

(Snoek et al., 1993). The canonical HSP70 isoforms are functionally redundant, with
the main differences found in their spatio-temporal expression (Kabani and

Martineau, 2008). The constitutively expressed isoforms are considered important

for cellular housekeeping, whereas the inducible isoforms protect the cell from
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stressful conditions (Daugaard et al., 2007; Kabani and Martineau, 2008).

What remains to be understood is whether HSP70i is critically important to

vitiligo development. If the stress protein is redundant, we expect that in the

absence of HSP70i another stress protein can mediate depigmentation. This issue

requires resolution before considering HSP70i depletion in the treatment of vitiligo.
Here, we addressed whether HSP70i is solely responsible for vitiligo pathogenesis

using different animal models. Initially, HSP70 knockout mice were vaccinated with
DNA encoding melanocyte-specific target antigens and assessed for progressive
depigmentation, melanocyte loss, T-cell infiltration, and CTL activity. These

experiments were performed in Hsp70-1 knockout animals lacking inducible HSP70

(Hunt et al., 2004) and repeated with Hsp70-2 knockout animals that lack a

constitutively expressed, tissue-specific isoform of the protein important for

spermatogenesis (Eddy, 1998). Next, a vitiligo-prone model was used to analyze
whether HSP70i alone is sufficient to support progressive depigmentation. This

model established by the group of N. Restifo at NIH carries a gp100-reactive T-cell

receptor transgene that is expressed by the majority of circulating T cells (Overwijk
et al., 2003). Untreated animals develop minor depigmentation by approximately 9

months of age. Finally, blocking of HSP70i-induced Dendritic cell (DC) activation by

antibodies was assessed using bone marrow-derived dendritic cells. Taken together,
these experiments provide a solid mean to identify HSP70i as a potential target for
immunotherapy of vitiligo.

RESULTS
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HSP70i is uniquely required for autoimmune depigmentation
To evaluate redundancy of the involvement of HSP70i in depigmentation,

wild-type C57BL/6 and inducible hsp70 knockout (Hsp70-1) mice were gene gun

vaccinated with antigenic mouse Tyrp1ee (optimized TRP-1)-encoding plasmid, an
antigen more potent than TRP-2, to ensure that even the most subtle

depigmentation responses may be detectable (Guevara-Patino et al., 2006). Gene

gun vaccinations involve coating gold particles with gene-encoding plasmids, which

are then rapidly fired into the skin via pressurized helium. Four weeks after the final
vaccination, we observed that depigmentation was virtually absent in the Hsp70-1

knockout mice (Figure 9A) and confirmed this using image analysis (Figure 9B). By
contrast, 16.9% depigmentation was detected in wild-type mice at the vaccination

site. Including the human HSP70i-encoding plasmid in the vaccine is insufficient to
restore the depigmentation process in Hsp70-1 knockout mice and resulted in

23.9% depigmentation in wild-type mice at the vaccination site (Figure 9A, B). We

also followed depigmentation in Hsp70-2 knockout mice gene gun vaccinated with

DNA encoding human TRP-2 (Figure 10A, B). The HSP70-2 mice lack tissue-specific

expression of a constitutive isoform of hsp70 involved in spermatogenesis. Here, we
observed no differences in depigmentation compared to wild-type C57BL/6 mice,
with both sets of animals displaying approximately 15% depigmentation at the
vaccination site after 4 weeks (Figure 10B). Taken together, the data indicate a

critical and non-redundant role for HSP70i in inducing a depigmentation response.
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Figure 9. Inducible Hsp70 knockout mice are resistant to depigmentation after
TRP-1 vaccination. (A) Wild-type (WT) and Hsp70-1 knockout (Hsp70-1 KO) mice
were gene gun vaccinated five times, every 6 days with DNA encoding either 6 μg of
optimized TRP-1 or 3 μg each of optimized TRP-1 and HSP70i and imaged 4 weeks
after the final vaccination. (B) Image analysis indicates that wild-type mice
depigment significantly more compared with the Hsp70-1 KO mice after either
vaccination (vacc), indicating that the expression of HSP70i is required for efficient
induction of autoimmunity. Data are presented as mean ± SEM, and were repeated
twice with similar results. Student’s unpaired 1-tailed t-test. (*P < 0.05; ***P <
0.001; n = 10 per group).
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Figure 10. Alternative HSP70 isoform Hsp70-2 is irrelevant for inducing
autoimmune responses. (A) Wild-type (WT) and constitutive Hsp70 knockout
(Hsp70-2 KO) mice were gene gun vaccinated five times every six days with 6 µg of
either TRP-2 or empty vector (EV; plasmid containing no gene insert) control DNA.
(B) No difference in depigmentation was observed between vaccinated (vacc) wildtype and Hsp70-2 KO mice. (C) No differences in cytotoxicity were observed in wildtype or Hsp70-2 KO mice towards TRP-2-pulsed splenocytes. Data are presented as
means ± SEM. Student’s unpaired 1-tailed t-test. (NS [no significance]; *P < 0.05; **P
< 0.01; n = 10 per group.)

HSP70i increases a cytotoxic response toward melanocyte antigens
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To determine whether HSP70i mediates the immune activation of CTLs, wild-

type C57BL/6 and Hsp70-1 knockout mice vaccinated with a combination of

optimized TRP-1- and HSP70i-encoding plasmids were boosted by two additional
vaccinations 3 days apart, and 6 days later were assessed for in vivo cytotoxicity

toward the encoded antigen as well as for reactivity toward human TRP-2 (Figure
11A). Gene gun-vaccinated wild-type mice displayed killing of 20.6% more

splenocytes pulsed with a peptide derived from optimized TRP-1 compared with

Hsp70-1 knockout mice (Figure 11B), indicating that CTL activation had taken place
primarily in mice capable of expressing HSP70i. The data also reveal cytotoxicity
toward approximately 25% of TRP-2 peptide-pulsed splenocytes, indicating that

significant epitope spreading had occurred (Figure 11B). By contrast, there were no
differences in cytotoxicity toward peptide-pulsed splenocytes from wild-type and

Hsp70-2 knockout mice vaccinated with the TRP-2-encoding plasmid (Figure 10C).
This is unlike the Hsp70-1 knockout mice, which displayed less killing toward the

antigen. It should be noted that mice vaccinated with optimized TRP-1 display two-

to threefold increased cytotoxicity toward the derivative peptide as compared with
TRP-2-vaccinated animals and in general achieve greater levels of depigmentation

as compared to mice vaccinated with TRP-2 (Figures 9 and 10). Together, these data

further demonstrate the unique requirement for inducible HSP70 expression in the
skin in precipitating autoimmune vitiligo.
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Figure 11. Cytotoxic T lymphocyte (CTL) killing towards melanocyte antigens
is reduced in Hsp70-1 knockout mice. (A) For in vivo cytotoxicity assays, mice
from Figure 9 were challenged with splenocytes pulsed with immunodominant
peptides from TRP-1 or TRP-2 or irrelevant control peptides plus differing
concentrations of carboxyfluorescein succimidyl ester. Spleens were harvested 18 h
after for analysis of CTL activity by fluorescence-activated cell sorter. Data from
individual wild-type (WT) and Hsp70-1 KO mice are shown. (B) 20.6% more
cytotoxicity was observed in wild-type mice (55.4%) toward TRP-1-pulsed
splenocytes than in Hsp70-1 KO mice (34.8%). Approximately 25% cytotoxicity
toward TRP-2-pulsed splenocytes is indicative of epitope spreading. Peptide-pulsed
splenocytes from control naïve mice are depicted as (C). Data are presented as mean
± SEM. Student’s unpaired 1-tailed t-test. (*P < 0.05; n = 10 per group).

HSP70i is associated with melanocyte loss and T-cell infiltration in actively
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depigmenting skin
To further support that depigmentation following HSP70i-induced skin

immune reactivity reflects a vitiligo phenotype, we evaluated local differences in

immune reactivity in response to HSP70i. We probed skin from wild-type C57BL/6
and Hsp70-1 knockout mice 1 week following booster gene gun vaccinations using

antibodies against the pan T-lymphocyte marker CD3 and evaluated the density and
location of the stained cells (Figure 12A). The vaccinated skin of wild-type mice

contained 58.1% more T cells than Hsp70-1 knockout mice (Figure 12B). Further
analysis revealed that the vast majority (>95%) of skin-infiltrating CD3+ cells coexpress CD8 in both wild-type and Hsp70-1 knockout mice (Figure 13). Although

rare, a few CD3+/CD4+ double-positive cells were detected. Most CD4 expression as
found primarily in the dermis could be assigned to a CD3-, non-T-cell population
(Figure 13). Consistent with the depigmentation data, immunodetection of the

melanocyte antigen TRP-1 revealed a 64% reduction in melanocyte-containing hair
follicles in wild-type mice compared with Hsp70-1 knockout mice (Figure 12C, D),
supporting the loss of melanocytes in the latter that was not observed in mice
lacking Hsp70i. Taken together, the immunohistology data establish the

development of vaccine-induced vitiligo in the skin of depigmenting wild-type
animals.

58

59

Figure 12. Immunohistology indicates that inducible HSP70 is necessary for
T-cell mediated loss of melanocytes. Treatment of mice engaged in this
experiment is described under Figure 9. (A) Image of skin near the dermoepidermal junction from mice 1 week after the final booster gene gun vaccination.
CD3+ T cells (arrows) are more abundant near hair follicles (*) of wild-type (WT)
than of Hsp70-1 KO mice. Gold particles can also be observed (open arrow). (B)
Quantification of T-cell infiltration. (C) Image of skin showing more melanocytecontaining hair follicles in vaccinated Hsp70-1 knockout mice compared to wildtype mice. TRP-1 expressing melanocytes (arrows) are shown within hair follicles
(*) in an Hsp70-1 KO mouse. (D) Quantification of melanocyte-containing follicles.
Depigmentation coincides with loss of melanocytes and T-cell infiltration only in
wild-type mice. Scale bar equals 50 μm. Data are presented as mean ± SEM.
Student’s unpaired 1-tailed t-test. (*P < 0.05; n = 10 per group).
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Figure 13. Immunohistology reveals a greater influx of CD8+ T cells in wildtype versus Hsp70-1 knockout mice. (A) Image of skin from a C57BL6 mouse
vaccinated with HSP70i + TRP-1 shown in Figure 9 reveal an abundant number of
CD3+ T cells (black arrows) in the dermo-epidermal junction. CD3-CD4+ non-T cells
(red arrows) were mainly localized to the dermis. A single CD3+CD4+ T cell is shown
in the epidermis (green arrow). (B) A serial section from the same tissue as (A)
indicates the vast majority of the T cells are CD8+ (black arrows). (C) Fluorescent
staining of skin from a C57BL6 mouse vaccinated with HSP70i + TRP-1 further
demonstrate the colocalization of CD3 (red) and CD8 (green) as indicated by yellow
(red arrows). CD3-CD4+ non-T cells were mainly confined to the dermis (white
arrow). A single CD3+CD4+ T cell is shown (green arrow). (D) Skin from an Hsp70-1
knockout mouse vaccinated with HSP70i + TRP-1 reveal less CD3+CD8+ T cell
infiltration (red arrow). CD3-CD4+ non-T cells were also present in the dermis
(white arrow). Scale equal 50 µm.
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HSP70i is sufficient to support depigmentation in a spontaneous model of autoimmune
vitiligo
We next tested whether HSP70i alone is sufficient to establish

depigmentation in animals predisposed to developing autoimmune depigmentation,
akin to human vitiligo. The T-cell-receptor (TCR) transgenic mouse strain Pmel-1

and C57BL/6 mice were gene gun vaccinated with either HSP70i-encoding plasmid
or empty vector control DNA. Six months after the final vaccination, Pmel-1 mice

approximately 9 months of age vaccinated with HSP70i-encoding DNA displayed
markedly increased depigmentation (3.7-fold ventral; 2.8-fold dorsal) compared

with mice vaccinated with control DNA (Figure 14A, B). Pmel-1 mice display subtle
depigmentation even after vaccinating with empty vector DNA alone, with 18 and

25% depigmentation ventral and dorsal, respectively (Figure 14A, B). This is similar
to depigmentation in animals of that age, which had not been vaccinated (Figure
15). As expected, no depigmentation was observed in wild-type mice gene gun

vaccinated with any plasmid (Figure 14A, B). This data set implies that elevated

HSP70i expression alone is sufficient to augment the depigmentation process in
animals prone to vitiligo development.
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Figure 14. HSP70i accelerates depigmentation in vitiligo-prone mice. (A) Wildtype (WT) and Pmel-1 mice were vaccinated three times every 7 days with 4 μg of
either HSP70i encoding or empty vector (EV) control DNA. Depicted are ventral and
dorsal images of representative vaccinated animals 6 months after the final gene
gun vaccination. Depigmentation in wild-type mice occurred within and distal to the
site of the gene gun vaccination (B) Upon quantification, Pmel-1 mice receiving
HSP70i-encoding DNA displayed significantly more depigmentation compared to
control vaccinations and vaccinations in wild-type mice, confirming that focal
overexpression of HSP70i is sufficient to induce vitiligo in disease-prone animals.
Data are presented as mean ± SEM and were repeated twice with similar results.
Student’s unpaired 1-tailed t-test. (***P < 0.001; n = 3 per group).
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Figure 15. Gene-gun vaccination alone does not accelerate depigmentation in
vitiligo-prone mice. This supplementary image of the Pmel-1 mice from Figure 14
demonstrates similar levels of depigmentation in empty vector vaccinated and
unvaccinated Pmel-1 mice. Ventral and dorsal views are shown.

HSP70i provides a durable shift of the dendritic cell population towards an
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inflammatory subset
We next tested whether HSP70i has lasting effects on monocyte-derivative

cell populations. Leukocyte phenotypic profiles were obtained from splenocytes of
9-month-old mice euthanized 6 months after the final vaccination. The mouse

splenocytes were stained for lymphocyte markers CD3, CD8, and Thy1.2 and the

non-lymphocyte markers CD11b, CD11c, and F4/80. No sustained differences in the
abundance of lymphocyte subpopulations were found; yet, we observed marked

differences in the abundance of monocyte-derived subpopulations discriminated
based on CD11b and CD11c expression levels, shown as R1 through R3 (Figure

16A). The R1 population is characterized by the expression of CD11bint/hiCD11clo,
typical for macrophages. Intriguingly, we show that the population R1 remained

markedly suppressed several months after vaccination with HSP70i (Figure 16B).
By contrast, the dendritic cell population R2 (CD11bintCD11cint), representative of
pro-inflammatory dendritic cells, showed an opposite trend (Figure 16B). These
data demonstrate that HSP70i can drive the relative abundance of dendritic cell

subpopulations with inflammatory versus immunosuppressive potential, associated
with autoimmune depigmentation.
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Figure 16. HSP70i has prolonged effects on peripheral leukocyte composition.
Splenocytes obtained from Pmel-1 mice 9 months after gene gun vaccination with
HSP70i or empty vector DNA was stained to discriminate leukocyte subpopulations,
and staining was quantified by flow cytometry. (A) Three distinct populations of
cells were observed after gating for CD11b and CD11c cells in the non-lymphocyte
population, with high (hi), low (lo), or intermediate (int) levels of expression.
Macrophages are observed in the R1 population as CD11bint/hiCD11clo cells, while
dendritic cells are among the R2 and R3 populations as CD11bintCD11cint and
CD11bloCD11chi cells, respectively. (B) Quantification of CD11b- and CD11cexpressing cells determined differential expression of these markers among
leukocytes after vaccination with HSP70i-encoding or empty vector plasmids. The
macrophage population (CD11bint/hiCD11clo) shown in R1 displays decreased
quantitative differences in response to HSP70i. By contrast, the inflammatory
dendritic cell population shown in R2 (CD11bintCD11cint) shows an opposite trend.
These results demonstrate the differential effects of HSP70i on monocyte derivative
leukocyte populations. Student’s unpaired 1-tailed t-test. *P < 0.05, n = 3.

Blocking HSP70i inhibits dendritic cell activation in vitro
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On the basis of the fluorescence-activated cell sorter (FACS) profiles

suggesting that HSP70i induced sustained changes in dendritic cell populations, we
assessed whether blocking the HSP70i protein could prevent dendritic cell

activation. Mouse bone marrow monocytes were magnetically sorted and driven to
a dendritic cell phenotype by the addition of granulocyte/macrophage colonystimulating factor (GM-CSF) and IL-4 cytokines. After 1 week, HSP70i with or

without blocking antibodies was added. To prevent the HSP70i antibody from
inducing Fc-receptor–mediated dendritic cell stimulation itself, Fc-receptor-

blocking antibodies were included. Lipopolysaccharide (LPS) and control media

were used as controls. Twenty-four hours later, the dendritic cells were stained for
activation markers CD11c, CD80, CD83, CD86, and MHCII and analyzed by flow

cytometry (Figures 17 and 18). Gating on the CD11c+ population, it was observed

that the entire population expressed CD80, CD86, and MHCII, with marked increases
in expression attributed to the addition of HSP70i or LPS (Figure 18A). By contrast,
the addition of antibodies to HSP70i markedly decreased activation (Figure 18A).

Staining for CD83 revealed expressing and non-expressing cells (Figure 18A), with
increases noted in the CD83+ population after the addition of LPS or HSP70i, and
decreased activation with HSP70i antibodies (Figure 18B). Together, these data

confirm that the HSP70i protein directly activates dendritic cells, while strongly
suggesting that antibodies to HSP70i may be useful in preventing dendritic cell
activation in vitiligo.
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Figure 17. Antibodies can block HSP70i induced dendritic cell activation in
vitro. This supplementary image displays the fluorocytometry histograms
representing activation marker expression by CD11c+, cultured mouse dendritic
cells as summarized in Figure 18. Whereas exposure to HSP70i increases expression
of CD80, CD83, CD86, and MHCII, in presence of antibodies to HSP70i, dendritic cell
activation is largely prevented.
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Figure 18. Antibodies to HSP70i interfere with dendritic cell activation in
vitro. Dendritic cells derived from mouse bone marrow monocytes were grown in
culture for 7 days followed by the addition of either 1 μg/ml of HSP70i or a
combination of HSP70i and Fc-receptor-blocking antibodies. LPS and control media
were used as controls. Twenty-four hours later, the cells were stained for the
dendritic cell maturation markers CD11c, CD80, CD83, CD86, or MHCII and analyzed
by fluorescence-activated cell sorter. Subsequent gating was performed on the
CD11c+ cells. (A) Mean fluorescent intensity (MFI) indicates higher expression levels
of CD80, CD86, and MHCII after the addition of HSP70i as compared to control
media, whereas the addition of blocking antibodies was able to reduce expression
levels close to baseline. (B) A higher percentage of dendritic cells expressing CD83+
were detected after the addition of HSP70i as compared to control media, whereas
blocking HSP70i reduced the cell number close to baseline. All data are represented
as % stimulation compared to LPS. These results demonstrate the stimulatory
effects of HSP70i on dendritic cells, which can be augmented by blocking antibodies.

DISCUSSION
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Our current data provide support to the notion that inducible HSP70 is a

critical component in mediating autoimmune reactivity to melanocytes in vitiligoprone animals. Previously, we have shown that overexpression of the heat-shock

protein, together with melanocyte-specific target antigen TRP-2 of human origin,
could serve to induce progressive depigmentation in mice (Denman et al., 2008).
Such depigmentation was originally restricted to the vaccination site but would

later diffusely spread to other sites as described (Denman et al., 2008). Melanocytes

were not detected in follicles giving rise to depigmented hair, which is similar to the
actual loss of melanocytes (rather than reduced melanization by existing

melanocytes) observed in human vitiligo skin (Le Poole et al., 1993). The vaccine

combining TRP-2 and HSP70i was effectively used to generate an inducible animal

model of the disease, useful to study immune effector responses involved in vitiligo.
At that time, we did not address the unique or redundant role of HSP70i versus

other stress proteins or discuss whether antigens other than TRP-2 can likewise
serve to direct immune responses toward melanocytes.

As emphasized by the current data, the role of TRP-2 as a target antigen is

not unique; we can replace this antigen by others expressed within the

melanosomal compartment to likewise introduce progressive, CTL-mediated

responses to melanocytes. This is in concordance with the literature where the

application of anti-melanoma vaccines targeting either tyrosinase or TRP-2 was
associated with depigmentation of the pelage (Chapman and Wolchok, 2002).
Depigmentation in response to DNA vaccines encoding human gp100 was
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mentioned previously as well (Chapman and Wolchok, 2002). There is, however, a
difference in the type and extent of immune activation elicited by individual

antigens. In fact, minimal humoral immunogenicity has been assigned to TRP-1,
whereas TRP-2 can drive CTL responses (Avogadri et al., 2010). To elicit robust

immune responses to vaccines, the immunogenicity of naturally occurring TRP-1
has been adjusted in its optimized version Tyrp-ee, generating peptides with

enhanced binding to MHC and neopeptides revealed by deglycosylation (GuevaraPatino et al., 2006). Indeed, in the current studies, optimized TRP-1 resulted in
greater levels of depigmentation, as well as a two- to threefold increase in

cytotoxicity as compared to vaccination with TRP-2 in C57BL/6 wild-type mice.

Also, following optimized TRP-1 vaccination, responses were observed to TRP-2

derivative peptide SVYDFFWL. This peptide shares homology to the TRP-1 protein
spanning the first eight amino acids. As vaccination with native TRP-1 does not

induce anti-TRP-2 responses, this phenomenon is most likely because of epitope

spreading, with T cells targeting heteroclytic epitopes killing melanocytes, which

subsequently results in response to TRP-2 as well. At this time however, we cannot
rule out that reactivity to TRP-2 is rather a consequence of cross-reactivity, where

optimized TRP-1 has altered its processing in such a way that the homologous TRP1 derivative peptide directly elicits a response to TRP-2.

The use of Tyrp-ee, eliciting optimal responses to melanocytes, was

important for the greatest possible odds of detecting vitiligo in vaccinated animals
in the absence of inducible HSP70. Even with this optimized antigen, however,
consistent depigmentation was not observed in animals lacking hsp70i, the

inducible form of hsp70. In contrast, depigmentation was uninhibited in mice
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lacking hsp70-2, a tissue-specific isoform of hsp70 constitutively expressed in
testes, even in response to vaccination with suboptimal antigen TRP-2. These

findings suggest that HSP70 isoforms expressed outside the skin are less important
to vitiligo development.

It is important to note that the progressive loss of melanocytes and T-cell

infiltration to the skin are considered hallmarks of vitiligo, and such hallmark events
were likewise observed in our depigmenting mice (Badri et al., 1993; Ongenae et al.,
2003). Enhanced T-cell infiltration was inversely related to the loss of melanocytes

within the wild-type mice, which can be attributed to increases in self-reactive CTLs.
Meanwhile, enhanced T-cell infiltration or reduced melanocyte numbers were not
observed in animals lacking expression of inducible HSP70. Removing isoform

Hsp70-2, however, still resulted in melanocyte death. Taken together, our data
demonstrate a critical role reserved for inducible HSP70 in supporting
depigmentation.

Regarding potential redundancy of HSP70i, anti-melanoma vaccines are

commonly applied in the absence of adjuvant heat-shock proteins. This led us to

consider that stress to the skin involved with the vaccine application process may be
sufficient to enhance heat-shock protein expression in the skin, serving as a natural
adjuvant to enhance autoimmunity. Stress-induced depigmentation is conclusively

supported by reports of depigmentation occurring at the site of injection in mice
previously vaccinated against melanocyte antigen TRP-2 (Lane et al., 2004). The

question addressed here was whether there is a unique role reserved for HSP70i in

autoimmune depigmentation in vitiligo. As other heat-shock proteins including
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HSP27 and HSP110 have likewise been implicated as adjuvants in anti-melanoma

vaccines, a non-redundant role of HSP70i would appear unusual (Srivastava, 2002).
Our preliminary data in fact showed that in contrast to HSP60, HSP27 was

differentially expressed in vitiligo lesional skin (not shown). This implies that

HSP27 may play a role similar to HSP70, where patchy expression of the heat-shock
protein was noted in lesional, but not in non-lesional skin (Le Poole and Luiten,

2008). Also, gp96 has been implicated in autoimmune disease (Han et al., 2010), and
it has been hypothesized that it is secreted in response to stress or cell death (Li et
al., 2002). Investigators have modified gp96 to allow it to be secreted; however,

there are no published data available supporting natural secretion of gp96, and this
finding remains exclusively reserved for HSP70i (Strbo and Podack, 2008). In

contrast to HSP70i, which is generally located in the cytoplasm or nucleus of the cell,
gp96 is expressed in the endoplasmic reticulum (Li et al., 2002). The difference in
subcellular location and function suggests that in the absence of HSP70i, gp96

cannot simply compensate for a loss of HSP70i. The current data indeed support
that compensation does not occur, which is best explained by different

circumstances that call for overexpression of either stress protein, as well as its
differential role in folding and chaperoning newly synthesized versus resident
cellular proteins (Srivastava, 2002).

The current data definitively support a non-redundant role of HSP70i in

progressive depigmentation, as we were unable to confer significant

depigmentation upon mice that lack expression of the inducible isoform of HSP70.

Although HSP70i was included in the vaccine, focal expression does not restore
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depigmentation, suggesting that systemic expression of HSP70i is required to drive
biologically relevant responses to melanocytes.

We next chose to determine whether HSP70i alone was sufficient to define

depigmentation in a model genetically prone to develop vitiligo. In this regard, the
recent development of relevant TCR transgenic mouse models now provides an

opportunity to study and modulate effector responses in vitiligo. T-cell receptor

transgenic animals with the majority of T cells reactive to a TRP-1-derived peptide

presented in the context of MHC class II were engaged in experiments to provide a

first line of evidence that a newly discovered subset of helper T cells, the Th17 cell,
provides a driving force behind immune reactivity to melanocyte differentiation
antigens in vitiligo (Muranski et al., 2008). This novel finding has yet to be

translated to the human setting, where an infiltrate of CD4 cells may likewise be

composed primarily of Th17 cells, as Th17 cells have now been implicated in several
autoimmune settings (Hu et al., 2011). The TRP-1 reactive, TCR transgenic model is

maintained in cappuccino mice, lacking any expression of the target antigen, as TRP1-reactive T cells are otherwise clonally deleted (Muranski et al., 2008).

Interestingly, clonal deletion does not occur in a setting of MHC class I restricted
TCRs. The FH, or ‘FMDGTMSQV specific, high affinity’ mouse expressing TCR

transgenic CD8 T cells reactive with mouse tyrosinase is therefore the first reported
spontaneous model of vitiligo, with depigmentation initiating by 4 weeks of age

(Gregg et al., 2010). This model has been pivotal to identify the central role of IFN-γ

in depigmentation (Gregg et al., 2010). Owing to the rapid development of vitiligo,

this model is, however, less amenable to prophylactic measures that may prevent
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depigmentation. On the other hand, the Pmel-1 mouse expresses a gp100-reactive

transgenic TCR on the majority of circulating CD8+ T cells, but mice are generally not

maintained to the point where spontaneous depigmentation is observed (Overwijk
et al., 2003). We found that by 9 months of age, minimal yet measurable

depigmentation will occur. Delayed depigmentation can possibly be explained by a
relatively lesser affinity of this TCR for its antigen, allowing T cell to circulate

without causing damage to melanocytes. It is also possible that the cognitive peptide

is less immunogenic or has reduced binding affinity to MHC. Whatever the cause, the
Pmel-1 mouse has provided us with the currently exploited opportunity to study
precipitating factors in vitiligo, as we were able to demonstrate that HSP70i is a
critical player in defining the depigmentation process.

Earlier, it was reported that CD11bintCD11cint dendritic cells induce IL-17-

producing T cells associated with autoimmunity, which fits with our observations

that this dendritic cell population (shown as R2 in Figure 16) remains increased at 6
months after vaccination with wild-type HSP70i (Denning et al., 2007). Further,

Denning et al. (2007) demonstrated that the CD11b+F4/80+CD11clo macrophage

population induced Foxp3+ regulatory T cells (Tregs). Although we recognize the
preliminary nature of our observations, we currently demonstrate that the same

subset of Treg-inducing macrophages is downregulated by HSP70i. Thus, HSP70i

may contribute to vitiligo through the inhibition of Tregs via reduced macrophage
activity and through supporting Th17-mediated autoimmunity by inflammatory

dendritic cells. It appears then that HSP70i may be acting on two fronts, by

activating CTLs via dendritic cell activation and simultaneously downregulating
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Treg activity.

Taken together, these data suggest that stress signals to the skin are funneled

through inducible HSP70 to activate dendritic cells in the immediate environment of
the stressful event. Thus, HSP70i may be regarded as a targetable entity, important
for the development of new treatment strategies in vitiligo. When considering this
opportunity, current knowledge about heat-shock protein-mediated dendritic cell

activation can be used for guidance (Basu et al., 2000; Kuppner et al., 2001). Under

stress, secreted inducible HSP70 serves as an adjuvant in vitiligo. Indeed, HSP70 has
been previously shown to break T-cell tolerance toward self-antigens as mediated

by dendritic cells (Millar et al., 2003). Thus, if dendritic cell activation is mediated
primarily by HSP70i, such activation may be prevented by preventing the stress
protein from binding dendritic cells.

Several stress protein receptors have been identified on the surface of

immature dendritic cells. Such receptors include TLR4, TLR2, CD14, CD91, and CD40

(Asea et al., 2000, 2002; Chen et al., 2009). Preventing binding of HSP70i by blocking
its receptors through antibodies is not likely to meet with success, as antibody
binding will have dendritic cell-activating consequences itself, and may have

cytolytic effects on cells other than the pivotal dendritic cell population. Thus, we
are currently focusing attention on HSP70i itself and attempting to prevent its
binding to dendritic cells. Here, we demonstrate that antibodies to HSP70i

prevented complete dendritic cell activation as measured by expression of CD80,

CD83, CD86, and MHC class II molecules. It is thus entirely possible that preventing

HSP70i from binding to dendritic cells will provide an effective prophylactic
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measure in vitiligo. In conclusion, the current data provide evidence of a unique and
pivotal role of HSP70i in progressive vitiligo, suggesting that targeting this heat-

shock protein can contribute to new treatment of the autoimmune depigmentation
process.

CHAPTER V

Mutant HSP70 reverses depigmentation in autoimmune vitiligo
(Mosenson et al., Sci Transl Med, 2013)

INTRODUCTION

Vitiligo is an autoimmune disease that affects about 0.5% of the world

population; patients with vitiligo present with progressive skin depigmentation
(Das et al,. 2001). About 25% more women than men develop the disease

(Cedercreutz et al., 2010). Current treatment modalities seldom induce lasting
repigmentation. Ablation of autoimmunity is the most commonly prescribed
approach, through the use of systemic or topical corticosteroids or topical
application of calcineurin inhibitors (tacrolimus, pimecrolimus), often

supplemented by ultraviolet (UV) phototherapy (Colucci et al., 2012). Treatment

responses are frequently inadequate, and complications from steroid therapy or

calcineurin inhibition can occur (Teraki et al., 2012). Melanocyte-protective

pseudocatalase treatment does not appear to offer superior efficacy over UV

treatment alone (Hossani-Madani and Halder, 2010). Transplantation can remedy
local depigmentation only in patients with already stable disease (Fongers et al.,

2009). Accordingly, a safe and effective approach that induces immune tolerance to

melanocyte differentiation antigens may offer a superior alternative. This prompted
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us to identify a molecular entity critically involved in depigmentation and design an
intervention method.

Expanding vitiligo lesions are consistently infiltrated with T cells in the areas

lining the lesional borders; these infiltrating T cells are composed primarily of CD8+

cytotoxic T cells reactive with melanocyte-specific antigens (Wańkowicz-Kalińska et
al., 2003). Because melanocyte-specific antigens are also targeted by T cells in
deadly melanoma skin cancers, patients with vitiligo may develop immune

responses that affect their odds of developing melanoma. Autoimmune vitiligo

patients develop immune responses mediated by T cells expressing high-affinity T
cell receptors (TCRs) that may be exploited for melanoma treatment (Oyarbide-

Valencia et al., 2006). Indeed, melanoma and other skin cancers appear to occur less
frequently in established vitiligo patients (Oyarbide-Valencia et al., 2006).

Moreover, increased numbers of CD11c+ dendritic cells (DCs) have been observed in
vitiligo perilesional skin, which may lend to an increased vitiligo/antimelanoma
response (Kroll et al., 2005).

Inducible heat shock protein 70 (HSP70i) has recently gained attention for its

role in precipitating vitiligo (Mosenson et al., 2012). In an initial screening of

potential stress protein involvement, HSP70i in nonlesional and lesional skin

biopsies provided the most apparent example of differential expression (Le Poole
and Luiten, 2008). Depigmentation in mice vaccinated with DNA encoding

melanocyte antigens was markedly enhanced in response to the presence of

HSP70i-encoding DNA, suggesting the immune-enhancing role of the stress protein
(Denman et al., 2008). In knockout mice, the absence of HSP70i greatly affected
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their ability to develop progressive depigmentation, which correlated with reduced
activation of a CD8+ T cell–mediated response to melanocytes (Mosenson et al.,

2012). In addition, the antigen-presenting cell (APC) profile is driven toward an
inflammatory repertoire in vitiligo-prone mice after vaccination with HSP70i
(Mosenson et al., 2012).

HSP70i can be secreted by live cells of neuronal ancestry (Asea, 2007).

Soluble HSP70i can activate DCs, leading to more efficient uptake, processing, and
presentation of antigens (Srivastava, 2002). Thus, the interaction between

extracellular, soluble HSP70i and recipient DCs will need to be compromised to

intervene with depigmentation. A strategy involving targeting of the DC surface is

limited by the existence of multiple different receptors for HSP70i on DCs (Asea et
al., 2002; Basu et al., 2001; Becker et al., 2002; Wang et al., 2005), and functionally
blocking all receptors will have consequences well beyond preventing HSP70i

activity. Blocking HSP70i itself at a site otherwise involved in binding DCs may be
more successful. Here, we identified an HSP70i variant that prevents the vitiligoassociated inflammatory DC phenotype and averts depigmentation in mice. We

conclude that mutant HSP70i is not only an inactive variant but also binds DCs and

alters their function to interfere with subsequent T cell activation. The implications
of this study are that HSP70iQ435A DNA delivery may be used for the treatment of

vitiligo patients.

RESULTS
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Vitiligo patients present with inflammatory DCs
DC subsets can be identified on the basis of surface expression of CD11b and

CD11c markers and by the cytokines they generate. Inflammatory DCs

(CD11b+CD11c+) produce interleukin-17 (IL-17) and are associated with

inflammation, whereas an anti-inflammatory CD11b+CD11c− population will

generate cytokines including IL-10 and transforming growth factor–β to support
regulatory T cell differentiation (Pulendran et al., 2008; Denning et al., 2007).
Conventional CD11b−CD11c+ DCs are particularly supportive of T helper 1

responses and secrete IL12p70 (Pulendran et al., 2008; Denning et al., 2007).

Differential expression of HSP70 in vitiligo skin is accompanied by DC infiltrates

(Kroll et al., 2005; Le Poole and Luiten, 2008). Exposure of mice to HSP70i results in

increased abundance of inflammatory (CD11b+CD11c+) DCs (Mosenson et al., 2012).
To establish whether the same elevated inflammatory DC content is also found in

vitiligo patients (see table 1 for patient information), we stained peripheral blood
mononuclear cells (PBMCs) from vitiligo and non-vitiligo controls for CD11b and
CD11c expression (after gating out T and B cells). A marked increase in

CD11b+CD11c+ cells (R2) was observed among PBMCs from the vitiligo patients (Fig.
19, A and B; P = 0.04). No differences were found between the two groups among
the percent of cells staining for CD11b+ or CD11c+ alone. To assess whether this

inflammatory DC subset is present in skin, we stained biopsies from non-vitiligo

controls and nonlesional and perilesional tissue from vitiligo patients for CD11b and
CD11c expression to identify different subsets of APCs. A significant increase was

observed in inflammatory

CD11b+CD11c+

cells in perilesional skin versus
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nonlesional (P = 0.0495) and non-vitiligo skin (P = 0.0495) (Fig. 19, C to F). The

inflammatory DC population was observed mainly in the dermis and toward the

dermo-epidermal junction (Fig. 19, C to E). These data reveal a markedly increased
abundance of inflammatory CD11b+CD11c+ DCs in human vitiligo.
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Table 1. Vitiligo patient information. A table showing relevant patient
information including treatment is shown. The tissue samples used for data
acquisition by fluorocytometry and immunohistochemistry shown in Fig. 19 are
indicated.

83

CD11c
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Figure 19. APCs in progressive human vitiligo reflect the phenotype observed
in response to HSP70i. (A) PBMCs from non-vitiligo (N.V.) control (left flow plot)
and vitiligo (right flow plot) patients were gated for expression of CD11b and
CD11c after excluding T and B cells. (B) Quantification of the percentage of cells
among R1 to R3 indicates an increase in R2 (CD11b+CD11c+) cells among the
vitiligo patient samples. (C to E) Non-vitiligo (N.V.) patient (C) and vitiligo patient
(D) nonlesional (N.L.) and (E) perilesional (P.L.) skin were stained for expression of
APC markers CD11b (red staining and arrows) and CD11c (blue staining and
arrows) with colocalization observed in purple (purple staining and arrows). (F)
Quantification of double positive–stained cells indicates a significant increase in
CD11b+CD11c+ cells within perilesional skin. Scale bars, 25 μm. Data are presented
as the mean ± SEM, n = 3. (A to B) analyzed by Student’s unpaired two-tailed t-test
and (C to F) analyzed by Wilcoxon’s rank sum test. Degrees of freedom were
calculated using Satterthwaite’s formula. *P < 0.05, **P < 0.01.

Autoimmune stimulatory activity resides in the C terminus of HSP70i
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HSP70i is necessary for autoimmune vitiligo in mice (Mosenson et al., 2012).

Therefore, we hypothesized that manipulating HSP70i could locally alter the APC

profile and affect the resulting immune response. Thus, it was important to identify
the DC-activating region in HSP70i. We cloned overlapping sequence fragments of

HSP70i encoding either the N-terminal (amino acids 1 to 377) or C-terminal (amino
acids 320 to 641) regions. Protein expression was confirmed by Western blot with

HSP70i-reactive antibodies (Fig. 20). C57BL/6 mice were then vaccinated with DNA
plasmids encoding human melanocyte antigen TRP-2 (hTRP-2), which is capable of
inducing temporary, minor depigmentation, combined with DNA encoding full-

length HSP70i, N- or C-terminal HSP70i fragments, or empty vector DNA (Fig. 21A).

Significant depigmentation was observed in mice vaccinated with full-length HSP70i,
which accounted for >14% depigmentation compared to ~2% in the empty vector–
vaccinated mice (P = 0.0088; Fig. 21A). The HSP70i C terminus alone achieved

markedly greater levels of depigmentation (>40%) than the full-length sequence
when compared to empty vector–vaccinated mice (P = 0.0139; Fig. 21A) and N

terminus–vaccinated mice (P = 0.0275; Fig. 21A). By contrast, the N terminus did
not induce depigmentation (<5%, similar to empty vector–vaccinated mice) (Fig.
21A). The overlapping N- and C-terminal regions are depicted in Fig. 21B.

The DnaK peptide QPSVQIQVYQGEREIAAHNK (DnaK407–426) was shown to

drive DC activation during inflammation in response to infection, inducing DCs to
produce tumor necrosis factor–α and IL-12 (Wang et al., 2005). However, the

corresponding DC-activating region within human HSP70i remains unidentified to
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date. To further define the region within the C terminus of human HSP70i required
for inducing depigmentation, we identified the peptide sequence QPGVLIQVYEGER

as maximally homologous with the proposed DC-activating region of microbial DnaK
(Wang et al., 2005). To assess this peptide’s actual contribution to autoimmune

activation, we generated mutant constructs using site-directed mutagenesis (Fig.
21B). Protein expression from mutant sequences was demonstrated by Western
blot with monoclonal antibody SPA-810, generated against a 67-mer partially

overlapping the peptide of interest, and polyclonal antibody SPA-811 recognizing a
C-terminal peptide downstream (Fig. 20).

We next determined the depigmenting effects of mutant HSP70i in vivo. Wild-

type C57BL/6 mice were vaccinated with plasmids encoding wild-type or mutant
HSP70i and melanosomal antigen hTRP-2, and depigmentation was assessed 5
weeks after the final vaccination (Fig. 21C). Depigmentation was significantly

decreased in the presence of variants HSP70iQ435A (P = 0.0055), HSP70iV438K, I440A (P =
0.0178), and HSP70iV442A, Y443V (P = 0.0015) compared to wild-type HSP70i. This

further confirms a peptide of interest consisting of amino acids QPGVLIQVYEG as

crucial to immune activation [and excludes amino acids ER (amino acids 446 to 447)
as being necessary for depigmentation].

Of interest, antibody SPA-810 demonstrated markedly reduced reactivity

toward mutants HSP70iV438K, I440A, HSP70iV442A, Y443V (>60% reduced reactivity), but
not HSP70iE446V, R447A compared to the wild-type sequence (Fig. 20, A and B). In

concordance with the immunizing peptide used to generate SPA-810, recognition of

HSP70iQ435A was not affected (Fig. 20, A and B). Together, the data indicate that SPA-
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810 recognizes an epitope that overlaps with our DC activation sequence of interest,
yet antibody binding is unaffected by the HSP70iQ435A mutation. Because SPA-810
can inhibit DC activation in vitro, these data provide further support for the

involvement of its target sequence in DC activation (Mosenson et al., 2012). Because
the HSP70iQ435A mutation does not affect binding of SPA-810, this mutation is well
suited for further studies. Further, a three-dimensional representation of HSP70i

demonstrates that the Q435A mutation is peripherally located, and thus suggests
that it is uniquely positioned to interact with DCs independent of its chaperone
function (Fig. 21D, arrow). Therefore, a single amino acid difference in the

QPGVLIQVYEG peptide is sufficient to inactivate the depigmentation accelerating
effects of HSP70i and supports the crucial involvement of the moiety in inducing
autoimmune depigmentation.

Mice vaccinated with HSP70i develop a humoral response to the protein

(Denman et al., 2008). The exact sequence with HSP70i bound by these circulating
antibodies may affect the ability of HSP70i to activate DCs. To determine whether
the N or C terminus of HSP70i was the target of humoral responses in mice, we
prepared protein homogenates from HSP70i-transfected COS7 cells and

electrophoresed them on an SDS-polyacrylamide gel. In serum from the empty
vector– and HSP70i1–377–vaccinated mice, antibodies toward HSP70i were not

detected, whereas mice vaccinated with either full-length HSP70i or the C terminal
(HSP70i320–642) developed antibodies toward the C terminal of HSP70i (Fig. 22A).

Further Western blotting revealed that humoral responses were directed toward

residues 494 to 641, rather than residues 262 to 551, recognizing C-terminal amino
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acids beyond amino acid 551 (Fig. 22B). The data are congruent with the proposed
location of the DC-activating region within HSP70i proposed above and explain why
endogenous antibodies to HSP70i may not affect DC binding and activation

mediated by HSP70i. The C terminus is thus required for inducing depigmentation
and is more immunogenic than the full-length HSP70i.
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Figure 20. SPA-810 antibody recognizes the DC activating region of HSP70i.
(A) A Western blot showing relative recognition by HSP70i reactive antibody.
HSP70i bands reacted with SPA-810 and SPA-811 are visible at 70 KDa, and actin
bands are observed at 55 KDa. (B) The mutant protein HSP70iQ435A is recognized
with equal efficiency as wild-type HSP70i (WT) whereas monoclonal antibody
SPA-810 shows 60-65% reduced reactivity towards mutant HSP70i plasmids
HSP70iV438K, I440A and HSP70iV442A, Y443V as calculated by comparing band
intensities t o W T observed using antibody SPA-811 which binds downstream of
the DC activating region. Thus the SPA-810 binding epitope includes the
sequence PGVLIQVYEG. Data are presented as the mean ± SEM, and were repeated
twice with similar results (n = 2). Student’s unpaired one-tailed t-test. * P < 0.05, ***
P < 0.001).
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B

Figure 21, Part I. A peptide within the C terminus of HSP70i is required for
inducing depigmentation. Continued on page 93.

C

D

Figure 21, Part II. A peptide within the C terminus of HSP70i is required for
inducing depigmentation. Continued on page 93.
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Figure 21. A peptide within the C terminus of HSP70i is required for inducing
depigmentation. Part I, (A) To identify the region of HSP70i critical for inducing
depigmentation, mice were vaccinated with DNA plasmids encoding wild-type (WT) N
terminus, C terminus, or full-length HSP70i. Mice vaccinated with HSP70i N terminus
(residues 1 to 377) expressed depigmentation similar to the empty vector control–
treated animals. Mice vaccinated with the HSP70i C terminus displayed far greater
levels of depigmentation than those exposed to full-length HSP70i plus hTRP-2
vaccination (n = 5). Representative images of C57BL/6 mice imaged 4 weeks after
vaccination with DNA-encoding melanosomal antigen hTRP-2 and either full-length
HSP70i, N-terminal (N-term) or C-terminal (C-term) HSP70i fragments, or empty
vector (EV) are shown. Mice were vaccinated five times, every 7 days, with 5.6 μg of
total DNA. (B) Schematic of the N-terminal ATP-binding domain (ABD) and C-terminal
substrate–binding domain (SBD) of HSP70i and fragments (HSP70i1–377 and
HSP70i320–641) and mutations introduced within the putative DC-activating region.
Part II, (C) No depigmentation was observed in mice receiving vaccinations with hTRP2 and several mutant versions of HSP70i compared to hTRP-2 and WT HSP70i,
supporting the crucial involvement of the 11-mer with the exceptions of amino acids
446 and 447. Representative images of mice 5 weeks after vaccination (n = 10) are
shown. Mice were vaccinated four times, every 7 days, with 4 μg of total DNA. (D)
Three-dimensional representation showing the peripheral location of the mutant
Q435A (magenta) residue (red arrow) ideally located at the interface of the ATP- and
substrate-binding domains. Data are presented as the mean ± SEM. Numeric data
were analyzed for statistical significance using two-tailed Wilcoxon’s rank sum test,
and degrees of freedom were calculated using Satterthwaite’s formula. *P < 0.05, **P
< 0.01.
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Figure 22. The C-terminus induces a humoral response to HSP70i in
vaccinated mice. (A) Serum was collected from mice vaccinated with full length
or fragmented HSP70i encoding DNA plasmids and used to probe proteins from
COS7 cells transfected with either N-terminus (N-term) or C- terminus (C-term) of
HSP70i DNA. Bands corresponding to the C-terminal peptide (36 kDa; amino acids
320-641) and full length HSP70i (70 kDa) were revealed only by sera from mice
vaccinated with the C-terminus or full length HSP70i. No bands corresponding to
the N-terminal peptide (41 kDa; amino acids 1-377) were revealed. (B) Likewise,
bands corresponding to the HSP70i C-terminal peptide 494-641 which is
downstream of the DC activation region were revealed only by sera from mice
vaccinated with the C-terminus or full length HSP70i. (EV: Empty vector). n= 5
mice, with serum pooled for each group.

Mutant HSP70i interferes with DC activation
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To determine the role of the QPGVLIQVYEG moiety in DC activation, we

vaccinated wild-type C57BL/6 mice and vitiligo-prone TCR transgenic Pmel-1 mice
(Overwijk et al., 2003) using plasmids encoding either wild-type HSP70i,

HSP70iQ435A, or empty vector DNA. The Q435A mutation was used because of its

position potentially affecting DC binding and activation (Fig. 21D). Splenocytes were
stained for expression of markers CD11b and CD11c after excluding T and B cells.
No additional gating for monocytes was performed. We observed marked

differences in the abundance of monocyte-derived subpopulations based on CD11b
and CD11c expression levels shown as R1 to R3 (Fig. 23, A and B). The R1

population is characterized by expression of CD11b+CD11c−, typical for regulatory
DCs (Denning et al., 2007). Compared to HSP70i-based vaccination, we observed

significant skewing toward a greater R1 population after HSP70iQ435A vaccination (P
= 0.022; Fig. 23B). There was also a trend toward increasing activation after

HSP70iQ435A vaccination compared to empty vector (P = 0.0618; Fig. 23B). By
contrast, the DC populations R2 (CD11b+CD11c+), representative of

proinflammatory DCs, and R3 (CD11b−CD11c+), representative of classic

inflammatory DCs (Denning et al., 2007), showed opposing changes (Fig. 23B; P =
0.028 and P = 0.0029, respectively). Overall, these data indicate that wild-type

HSP70i and HSP70iQ435A oppositely drive the relative abundance of immune cell
subpopulations associated with autoimmune depigmentation in mice.

Mutant HSP70i inhibits depigmentation in vitiligo-prone mice
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Six months after vaccination, Pmel-1 mice exhibited spontaneous

depigmentation, yet animals exposed to wild-type HSP70i displayed significantly
increased ventral and dorsal depigmentation compared to HSP70iQ435A or empty

vector (P = 0.0495; Fig. 23, C, D and E). As expected, in the absence of a targetable

antigen, no depigmentation was observed in vaccinated C57BL/6 mice (Fig. 23, C, D

and E). Depigmentation was significantly prevented in Pmel-1 mice vaccinated with
HSP70iQ435A DNA compared to mice vaccinated with empty vector (P = 0.0495; Fig.

23, C, D, and E). Thus, a single amino acid variation in the putative DC binding region
of HSP70i is sufficient to actively interfere with immune activation and subsequent
depigmentation in vivo.

On the basis of our observations that HSP70iQ435A can prevent

depigmentation in mice prone to delayed and slowly progressing depigmentation,

we next assessed whether HSP70iQ435A can be therapeutic in the context of existing

vitiligo. We treated the early and rapidly depigmenting mouse strain h3TA2, which

expresses T cells bearing a human tyrosinase-reactive TCR transgene and HLA-A2.1
(Mehrotra et al., 2012). Depigmentation initiates by about 4 weeks of age,

accompanied by a marked loss of melanocytes in 5-week-old animals (Fig. 24).

Treatment with HSP70iQ435A or empty vector DNA was initiated at 5 weeks of age.

Images of representative mice comparing pre- and postvaccination are shown in Fig.
24. Eight weeks later, the pelage of h3TA2 mice unvaccinated or vaccinated with
empty vector DNA was 86% depigmented (Fig. 23, F and G). By contrast, an

astonishing 76% of depigmentation in the pelage of mice was restored with mutant

HSP70iQ435A and the pelage returned almost fully pigmented (P = 0.0143; Fig. 23, F
and G, and Fig. 24).Thus, HSP70iQ435A can reverse the depigmenting phenotype,
critical for treatment of active disease.
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Figure 23, Part I. WT HSP70i accelerates and mutant HSP70i prevents
depigmentation in vitiligo-prone mice. Continued on page 100.

F

G

Figure 23, Part II. WT HSP70i accelerates and mutant HSP70i prevents
depigmentation in vitiligo-prone mice. Continued on page 100.
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Figure 23. WT HSP70i accelerates and mutant HSP70i prevents
depigmentation in vitiligo-prone mice. Part I, (A) Tolerogenic DCs are induced in
response to HSP70iQ435A. (B) Representative flow cytometry plots and cumulative
graphs of mice vaccinated three times in total, every 7 days, with 4 μg of WT,
HSP70iQ435A (Q435A), or empty vector (EV) control DNA. Splenocytes from Pmel-1
mice (n = 3) 6 months after vaccination were analyzed by flow cytometry. Gating for
CD11b and CD11c expression among nonlymphocytes, we observed three distinct
populations that vary in abundance in response to the treatments. Differential
expression of CD11b and CD11c was found after vaccination with WT or
HSP70iQ435A plasmids. In contrast to WT HSP70i, the anti-inflammatory population
(R1) displays increased, and the inflammatory population (R2) displays decreased,
abundance in response to mutant HSP70i-encoding DNA. (C) Ventral and (D) dorsal
Images were obtained 6 months after treatment. Pmel-1 mice depigmented within
and distal to the site of vaccination. (E) Cumulative graphs of mice in (C and D).
Pmel-1 mice receiving mutant HSP70i displayed significantly less depigmentation
compared to WT HSP70i or empty vector–exposed C57BL/6 mice, confirming
inhibition by mutant HSP70i. Part II, (F) To test the therapeutic effects of
HSP70iQ435A in rapidly depigmenting vitiligo-prone mice, tyrosinase-responsive
TCR transgenic h3TA2 mice were vaccinated five times, every 6 days, with 5.6 μg of
either empty vector– or HSP70iQ435A-encoding DNA plasmid. Mice were imaged 4
weeks after the final vaccination at just over 9 weeks of age. (G) Cumulative data
from (F) demonstrating that empty vector–vaccinated mice had significantly more
depigmentation than the HSP70iQ435A-vaccinated mice (n = 4). Data are presented as
the mean ± SEM, and were repeated twice with similar results. Numeric data were
analyzed for statistical significance using Wilcoxon’s rank sum test for
depigmentation, with degrees of freedom calculated using Satterthwaite’s formula,
and Student’s two-tailed t-tests allowing for unequal variance for fluorocytometry.
*P < 0.05, **P < 0.01.

100

Figure 24. Skin melanocytes are lost prior to treatment in h3TA2 mice. (A)
Dorsal images of 4-week-old C57BL/6 and h3TA2.Depigmentation is already
observed in the ears.(B) Skin biopsies from C57BL/6 reveal melanocytes (red
staining) in the hair follicles (arrows) not present within the h3TA2 mice. These
images reveal that melanocyte death (and subsequent depigmentation) was
already present in the skin of h3TA2 mice prior to treatment. (C) Representative
pre and post-vaccination images of h3TA2 mice with DNA encoding empty (EV) and
HSP70iQ435A. Bar indicates 50 µm.

Mutant HSP70i prevents accumulation of antigen-specific T cells in the skin
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T cell activity mediates the loss of melanocytes in patients with vitiligo (Le

Poole et al., 1996). To analyze the local immune-modulating effects of wild-type

HSP70i and HSP70iQ435A DNA exposure, we probed the skin of the Pmel-1, C57BL/6,

and h3TA2 mice for T cell infiltration. Skin from Pmel-1 mice contained significantly
more CD3+ T cells in response to wild-type HSP70i compared to either empty

vector– or HSP70iQ435A-vaccinated mice, and skin-infiltrating T cells were primarily
located in the dermis and hair follicles (P = 0.0495;Fig. 25, A and E). By contrast, a

trend toward decreased T cell infiltration was observed in response to HSP70iQ435A
vaccination (Fig. 25, B and E). Skin from the h3TA2 mice contained significantly

fewer CD3+ T cells in response to HSP70iQ435A (P = 0.03; Fig. 25, C, D, and F). We next
examined cytotoxic T lymphocyte infiltrates held responsible for melanocyte killing
by staining for CD8. HSP70iQ435A vaccination significantly decreased this population
in Pmel-1 mice compared to HSP70i (P = 0.0495; Fig. 25, G, H, and K) and showed a
decreasing trend compared to empty vector–exposed mice. The number of

melanocyte-reactive antigen-specific T cells was also significantly reduced in

HSP70iQ435A-treated h3TA2 skin (P = 0.03; Fig. 25, I, J, and L) corresponding to

pigment retention. Together, these data reveal a direct effect between skin exposure
to HSP70iQ435A and decreased T cell infiltration resulting in pigment retention.

To further demonstrate a role for T cells in mediating depigmentation, we

vaccinated CD4 and CD8 knockout mice using DNA plasmids encoding either wildtype HSP70i, HSP70iQ435A, or empty vector in combination with antigenic mouse
Tyrp1ee (optimized TRP-1) (Guevara-Patino et al., 2006). Wild-type HSP70i
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significantly supported depigmentation only in C57BL/6 control mice compared to
empty vector (P = 0.0088; Fig. 26) and HSP70iQ435A (P = 0.0493; Fig. 26). By contrast,
depigmentation was not observed in the CD4 or CD8 knockout mice, demonstrating
the requirement for both helper and cytotoxic T cells in depigmentation (Fig. 26).
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Figure 25. Decreased T cell infiltration is observed after HSP70iQ435A
vaccination. (A) Pmel-1 mice vaccinated with empty vector (EV) DNA showed
abundant skin infiltration by CD3+ T cells (arrows) localized mostly to hair follicles
(asterisks). (B) CD3+ T cell infiltrates seen in (A) were decreased after HSP70iQ435A
(Q435A) administration. (C and D) T cell infiltrates in skin of h3TA2 mice in
response to empty vector and (D) HSP70iQ435A. (E) Cumulative data showing
changes in skin-infiltrating T cells in treated mice. (F) Quantification of T cell
infiltrates in h3TA2 mice. (G) Most of the skin-infiltrating T cells were cytotoxic. (H)
In the Pmel-1 mice, CD8+ infiltrates in response to empty vector decreased after
HSP70iQ435A exposure. (I) Reduced number of melanocyte-reactive T cells was
observed in response to HSP70iQ435A. T cells were quantified on the basis of
expression of the tyrosinase transgene–reactive TCR Vβ12 subunit. (J) A decrease
in Vβ12+ cells was observed after vaccination with HSP70iQ435A. (K) Quantification
of cytotoxic T cell infiltrates in C57BL/6 and Pmel-1 mice, n =3 mice per group. (L)
Quantification of melanocyte-reactive T cells in h3TA2 mice, n =5 mice per group.
Data are presented as the mean ± SEM. Numeric data were analyzed for statistical
significance using Wilcoxon’s rank sum two-tailed test, with degrees of freedom
calculated using Satterthwaite’s formula. Scale bars, 50 μm. *P < 0.05.
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Figure 26. T cells are required for autoimmune depigmentation. (A)
Representative images of C57BL/6, CD4 knockout, and CD8 knockout mice four
weeks after vaccination with empty vector (EV), wild-type (WT), or HSP70iQ435A
(Q435A) plus mouse Tyrp1ee (optimized TRP-1) DNA. Mice were vaccinated five
times, every six days with 5.6 μg total DNA. C57BL/6 mice displayed significantly
more depigmentation with WT DNA compared to EV and Q435A. No depigmentation
was observed in the CD4 or CD8 knockout mice with any of the vaccinations. (B)
Cumulative graphs of mice in (A). n=5; Data are presented as the mean ± SEM.
Numeric data were analyzed for statistical significance using Wilcoxon’s rank sum
two-tailed test, and degrees of freedom were calculated using Satterthwaite’s
formula. * P < 0.05.

Mutant HSP70i interferes with T cell activation
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The relative expression of the transcription factors Eomes and T-bet has

been shown in T cells to define a quiescent versus effector status (Rao et al., 2010).
T cells from the HSP70iQ435A-treated Pmel-1 mice were analyzed for these

transcription factors. Although T-bet expression remained similar among the mouse
groups, Eomes expression was lower among CD8+ T cells from HSP70i-vaccinated
Pmel-1 mice (versus empty vector–vaccinated mice, P = 0.039; Fig. 27A) and

showed a decreasing trend compared to HSP70iQ435A vaccination (P = 0.05; Fig. 27A),
reflecting a more apparent effector phenotype. By contrast, treatment with HSP70i

induces an effector phenotype resulting in a significant depression of the Eomes to
T-bet ratio despite minimal changes in T-bet alone (P = 0.035 compared to
HSP70iQ435A, and P = 0.02 compared to empty vector; Fig. 27, B and C).

In the previous experiment, we demonstrated that the Eomes/T-bet ratio in

mice reflects an effector T cell status after vaccination with HSP70i. Because the

immune profiles in vitiligo patients appear to reflect HSP70i-induced changes, we

next examined T cell profiles in vitiligo patient tissues. T cells from non-vitiligo and
vitiligo patients were stained for Eomes and T-bet, and analyzed by flow cytometry
(Fig. 27, D and E). We observed a decreasing trend in the Eomes/T-bet ratio, again
indicating an effector response in the periphery of vitiligo patients (P = 0.06; Fig.

27F). Similarly, perilesional skin from vitiligo patients displays decreased Eomes

expression by CD8+ T cells (P = 0.0495; Fig. 27, G and H) as well as increased T-bet
expression (P = 0.0495; Fig. 27, I and J) compared to nonlesional and non-vitiligo

control skin. As with the HSP70i-vaccinated mice, reduced Eomes/T-bet ratios were
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observed in the skin of vitiligo patients (P = 0.0495; Fig. 27K). We also determined
that human vitiligo perilesional skin contains more cells expressing the homing

receptor CXCR3 cells than nonlesional skin (P = 0.02; Fig. 28), again correlating with
the role assigned to this gene product in a mouse model of vitiligo (Gregg et al.,
2010).
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Figure 27, Part I. HSP70i-treated mice display a similar effector T cell
phenotype as vitiligo patient tissue. Continued on page 111.

109

D
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Figure 27, Part II. HSP70i-treated mice display a similar effector T cell
phenotype as vitiligo patient tissue. Continued on page 111.
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Figure 27. HSP70i-treated mice display a similar effector T cell phenotype as
vitiligo patient tissue. Part I, (A) A decreased percentage of splenocytes from the
WT HSP70i-exposed Pmel-1 mice (Fig. 23) expresses the T cell transcription factor
Eomes, supporting an enhanced effector T cell phenotype. (B and C) Combined with
T-bet expression (C), the resulting Eomes/T-bet ratio further indicates increased
effector responses in mice exposed to HSP70i (n = 3). Part II, (D and E)
Representative histograms of human PBMCs from non-vitiligo (N.V.) control and
vitiligo patients similarly analyzed for Eomes and T-bet expression. (F) The
Eomes/T-bet ratio indicates an effector response in vitiligo peripheral blood
compared to non-vitiligo control patient samples. (G and H) Nonlesional (N.L.) (G)
and perilesional (P.L.) (H) vitiligo skin was stained for T-bet (red staining and
arrows) and CD8 (blue staining and arrows) expression, with the cytotoxic T cells
shown in purple (purple staining and arrows). A significantly larger number of
CD8+/T-bet+–expressing cells were observed in the dermis of perilesional skin. (I
and J) Nonlesional (I) and perilesional (J) skin stained for Eomes (red staining and
arrows) and CD8 (blue staining and arrows). Eomes-expressing CD8 cells were
significantly increased in non-vitiligo control and nonlesional skin from vitiligo
patients. (K) The ratio of Eomes/T-bet–expressing CD8 cells indicates an effector
response in perilesional vitiligo skin, similar to that seen in the periphery. n = 3.
Data are presented as the mean ± SEM. Numeric data were analyzed for statistical
significance using Wilcoxon’s rank sum two-tailed test for immunohistochemistry ,
with degrees of freedom calculated using Satterthwaite’s formula. Numeric data
were analyzed for statistical significance using Student’s two-tailed t-tests allowing
for unequal variance for fluorocytometry. *P < 0.05, **P < 0.01.
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Figure 28. The T cell homing antigen CXCR3 is overexpressed in actively
depigmenting vitiligo skin. Image of nonlesional (A) and perilesional (B) tissue
displaying CXCR3+ cells (arrows) in the dermis. (C) Image analysis indicates that
perilesional skin contains more CXCR3 expressing cells than nonlesional and
control skin. n=3; Data are presented as the mean ± SEM. Numeric data were
analyzed for statistical significance using Wilcoxon’s rank sum two-tailed test, with
degrees of freedom calculated using Satterthwaite’s formula. * P < 0.05.

Wild-type, but not mutant, HSP70i activates human DCs in vitro
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Next, we compared the DC-stimulatory effects of wild-type and mutant

HSP70i in vitro. Human PBMCs were magnetically sorted and driven toward

immature DCs by addition of granulocyte-macrophage colony-stimulating factor
(GM-CSF) and IL-4 cytokines (O’Neill and Bhardwaj, 2001). After 1 week, Hislabeled wild-type HSP70i or HSP70iQ435A full-length protein, or commercially

obtained wild-type HSP70i was added. Twenty-four hours later, the DCs were

analyzed for CD11c, CD80, CD83, CD86, and HLA-ABC expression by flow cytometry
(Fig. 29, A to E). Among the entire CD11c+ population, increases in expression of all
DC activation markers were observed in presence of HSP70i or lipopolysaccharide

(LPS) (Fig. 29, A to E). By contrast, addition of HSP70iQ435A decreased expression of
the activation markers (Fig. 29, A to E).

The previous findings show that HSP70iQ435A protein directly affects DC

activity. To determine whether HSP70iQ435A can bind DCs despite the mutation, we
used ImageStream analysis, allowing us to quantify expression of a marker by

fluorocytometry and localize its expression by confocal analysis within the same set
of cells. Antibodies toward HSP70i (SPA-820) and the His tag were used to

determine relative binding of wild-type and HSP70iQ435A to DCs (Fig. 29E). Indeed,
we detected labeling by both antibodies in the wild-type and also HSP70iQ435A-

treated samples, whereas media alone samples contained background levels of

fluorescence (Fig. 29, E and F). Together, these data confirm that HSP70iQ435A binds
to human DCs and actively interferes with activation marker expression.
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Figure 29. Mutant HSP70i suppresses human DC activation. (A) Representative
histogram displaying HLA-ABC expression from human PBMCs differentiated into
immature DCs via GM-CSF and IL-4 and exposed to His-tagged WT or HSP70iQ435A
(Q435A) protein (1 μg/ml). Commercially purchased HSP70i [WT(C)], LPS (1
μg/ml), and complete media served as controls. CD11c+ cells were analyzed for
expression of CD80, CD83, CD86, or HLA-ABC and analyzed by flow cytometry. (B to
E) Changes in mean fluorescence intensity (MFI) between treatments indicating
increased expression of activation markers after addition of His-tagged isolated WT
HSP70i and commercially purchased HSP70i [WT(C)] and reduced expression of all
activation markers after addition of HSP70iQ435A compared to control media. (F)
ImageStream images of DCs after the addition of His-tagged WT or HSP70iQ435A
(Q435A), or media alone. Cells were stained with antibodies (Ab) toward HSP70i
(SPA-820) or the His tag. Single and overlaid channel images are displayed. (G)
Similar MFIs using the anti-His antibody show that DCs bind both mutant and WT
HSP70i.

HSP70i activates transcriptional and homing factors in human skin
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To translate responses to HSP70iQ435A toward treatment of human disease,

we exposed human skin samples ex vivo and followed the profiles of collected

immune cells by fluorocytometry. Skin explants were treated with or without wildtype or mutant HSP70i protein added to the media. Skin T cells were analyzed by
flow cytometry 6 days later. Eomes expression was up-regulated in response to

HSP70iQ435A (P = 0.02; Fig. 30A) and wild-type HSP70i (P = 0.0027; Fig. 30A). By

contrast, a trend toward decreased T-bet expression was visible only in response to
HSP70iQ435A (Fig. 30B). As we have shown in treated mice (Fig. 27C), HSP70iQ435A
resulted in a shift of the Eomes/T-bet ratio from an effector to a quiescent

phenotype (P = 0.0154 compared to HSP70i, and P = 0.02 compared to media only;
Fig. 30C). In addition, the T cell skin-homing marker cutaneous lymphocyte-

associated antigen (CLA) was up-regulated in response to wild-type HSP70i (P =

0.0147 compared to HSP70iQ435A, and P = 0.0327 compared to media only; Fig. 30D),
congruent to observations in vitiligo donors (Wijngaard et al., 2000).

We also examined whether T cell activation can be abrogated by HSP70iQ435A

in human peripheral blood samples. To measure antigen-specific T cell responses,
we took advantage of preexisting cytomegalovirus (CMV)–reactive T cells from

CMV+ HLA-A2+ donors. PBMCs were pulsed with CMVpp65 peptide and cocultured
with wild-type or HSP70iQ435A. After 48 hours, the cells were analyzed by flow
cytometry. As in the skin explant model (Fig. 30C), Eomes expression was up-

regulated in response to HSP70iQ435A (P = 0.0041; Fig. 31A) and wild-type HSP70i (P
= 0.0244; Fig. 31A). By contrast, T-bet was significantly decreased in response to
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HSP70iQ435A (P = 0.0095; Fig. 31B) and increased in response to HSP70i (P = 0.0299
compared to media only, and P = 0.027 compared to HSP70iQ435A; Fig. 31B).

HSP70iQ435A resulted in a notable shift of the Eomes/T-bet ratio from an effector to a
quiescent status (P = 0.0262 compared to HSP70i, and P = 0.0216 compared to
media only; Fig. 31C). Likewise, expression of the homing receptor CLA was

significantly up-regulated in response to wild-type HSP70i (P = 0.0147 compared to
HSP70iQ435A, and P = 0.0327 compared to media only; Fig. 31D).

We also demonstrated that human skin cells express both wild-type and

mutant HSP70i proteins after biolistic transfection (Fig. 32), indicating that DNA
vaccination can affect human skin. This may be an important step in bringing

HSP70iQ435A to the clinic. Together, these data reflect that the immune response in

human tissues can be differentially driven by HSP70i, which may provide a crucial
step in treating vitiligo.
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Figure 30. WT and mutant HSP70i differentially activate human skin T cells.
Skin explants were maintained submerged in control media supplemented with or
without 4 μg of WT or HSP70iQ435A (Q435A) protein for 6 days, and T cell profiles
were analyzed after gating for CD3 expression. (A) Eomes expression was
significantly up-regulated in T cells from WT and mutant HSP70i-treated skin T
cells. (B) T-bet expression is reduced among T cells in response to HSP70iQ435A. (C)
Together, the Eomes/T-bet ratios reveal an effector versus memory phenotype in
response to WT and mutant HSP70i, respectively. (D) The T cell–homing receptor
CLA is highly expressed among T cells in response to WT HSP70i. n = 2. Data are
presented as the mean ± SEM. Numeric data were analyzed for statistical
significance using Student’s two-tailed t-tests allowing for unequal variance. *P <
0.05, **P < 0.01.
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Figure 31. Wild-type and mutant HSP70i differentially activate antigenchallenged human peripheral blood cells. PBMCs from healthy CMV IgG+ donors
were cultured in media only, or supplemented with 4 μg of wild-type (WT) or
mutant HSP70i (Q435A), with or without 1 μg of CMVpp65 peptide. After 48 hours,
PBMCS were gated for CD8 and analyzed for T cell marker expression. (A) Eomes
expression was significantly increased among wild-type HSP70i and HSP70iQ435A
treated PBMCs. (B) T-bet expression is significantly increased in response to HSP70i
and lowered in response to HSP70iQ435A. (C) Together, the Eomes/T-bet ratios
indicates an enhanced memory response in wild-type versus mutant HSP70i treated
PBMCs respectively. (D) HSP70i enhanced expansion of the T cell homing receptor
CLA is increased in response to wild-type HSP70i. n=2; Data are presented as the
mean ± SEM. Numeric data were analyzed for statistical significance using Student’s
two-tailed t-tests allowing for unequal variance. * P < 0.05, ** P < 0.01.
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Figure 32. Transfected human skin expresses HSP70i. Skin biopsies were
biolistically DNA-transfected with WT HSP70i (WT), HSP70iQ435A (Q435A), or
empty vector and analyzed by flow cytometry 4 days later for expression of HSP70i.
Histograms display the relative expression and MFI for each vaccination. Note
marked expression of HSP70i as well as its mutant variant among cells collected
from adult skin with the respective constructs. n = 3.

DISCUSSION
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Differential expression of HSP70i has been observed among nonlesional and

lesional human skin samples from vitiligo patients, which prompted us to

investigate the phenotype of infiltrating DCs in perilesional vitiligo patient skin. A

prevalence of CD11b+CD11c+ DCs as observed here is congruent with our hypothesis
that HSP70i secreted under stress will activate local DCs and induce an

inflammatory phenotype as previously observed in mice in response to the HSP70i
vaccine (Mosenson et al., 2012), and this inflammatory CD11b+CD11c+ DC subset
may provide a target for therapy. To better understand the role of HSP70i in

autoimmune activation, and identify a region that may be blocked from binding and
activating DCs, we generated DNA constructs containing either the N or the C

terminus of the molecule, in effect comprising the adenosine triphosphate (ATP)–
and substrate-binding domains. Indeed, there is discussion in the field as to the
region within stress proteins most important to immune activation. Although

protein fusion molecules have been generated that include only the substrate-

binding region, others have suggested that the ATP-binding domain is required and
sufficient for immune activation (Wang et al., 2002; Zhang et al., 2006). In part, this
will be defined by the necessity to include an antigenic moiety that provides
direction for the immune response to follow (Javid et al., 2007). Here, the C

terminus, including the substrate-binding domain and some residues from the ATPbinding region, had even more pronounced effects than the full-length molecule.
Subject to further analysis, it is possible that the compact size or folding of the

resulting molecule, optimally exposing its immune-activating region, positively

affects its DC binding ability.

120

The DC-activating peptide identified within HSP70i was derived by aligning

the molecule to DnaK, looking for a sequence with high homology (Wang et al.,

2005). Among mutant plasmids, some residues proved more critical than others,
ultimately supporting the importance of our 11-mer for DC activation. The

QPGVLIQVYEG sequence is shared among HSP70 isoforms and is highly conserved

among species from protists to mice to humans (Germot and Philippe, 1999; Adams
et al., 1993).

Among the HSP70i mutations that affected immune function, we initially

selected HSP70iQ435A to further examine using in vivo effects in vitiligo-prone mice.
Its position within the periphery of the molecule, strategically positioned to affect
DC binding independent of bound substrate, together with the change from a

charged, hydrophilic moiety (Q) to a smaller, hydrophobic one (A), suggests a

potential role for enhanced aggregation or preferential receptor binding in the
observed effects. This is important particularly as this moiety can affect the

preferred receptor for wild-type versus mutant HSP70i. It stands to reason that
engaging and disengaging DCs involves activation and possibly blocking of cell

surface receptors. DC activation has been related to the relative engagement of Ctype lectin receptors (CLRs) and Toll-like receptors (TLRs), with autoimmune

pathology resulting from simultaneous activation of both and tolerance resulting

from CLR activation in the absence of TLR engagement (Geijtenbeek et al., 2004).
Knowing that HSP70i can bind CLRs, including LOX1, as well as TLRs, including
TLR2 and TLR4 (Delneste et al., 2002), we can infer that the differential effects

observed for mutant and wild-type HSP70i in these studies may be explained at
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least in part by differential binding to these receptors, resulting in a different DC

phenotype and, in turn, in differential T cell activation and recruitment to the skin.
This implies that both wild-type and mutant HSP70i bind DCs, which we showed
here.

In Pmel-1 mice, T cells do not become spontaneously activated early on,

possibly partly due to differences between the human epitope used to generate the
model and the mouse epitope targeted in autoimmunity (Overwijk et al., 2003).
These animals are thus ideal to study depigmentation after activation of

melanocyte-reactive T cells, much as this occurs in humans. In this model, HSP70i is
sufficient to induce depigmentation (Mosenson et al., 2010). However, natural

depigmentation did not develop in animals vaccinated with HSP70iQ435A. Instead, we
observed persistent skewing of the DC phenotype toward the inflammatory subset

in response to wild-type HSP70i and encountered this subset among PBMCs and in
skin of human patients with progressive disease. Conversely, we observed

persistent skewing of the DC phenotype toward the tolerogenic subset in animals

vaccinated with HSP70iQ435A. Also, HSP70iQ435A exposure similarly affected human
DC activation in vitro. Our data support the concept that the direct effect of

HSP70iQ435A is on DCs. The Q435A mutation may affect the ability of the resulting
stress protein to bind and activate DCs based on differential engagement of
receptors described for HSP70i (Zitzler et al., 2008).

We postulate that the resulting DC phenotypes support different cytokine

profiles, necessary to activate or suppress relevant T and B cell subsets. Indeed

differential Eomes/T-bet ratios as observed are likely to affect the effector
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phenotype and quiescent potential of resulting cytotoxic T cells (Rao et al., 2010). It
has been shown that T-bet is the master regulator of type I effector differentiation,
whereas low T-bet expression (and high Eomes expression) promotes memory

formation (Rao et al., 2010). Exposure to wild-type HSP70i was accompanied by

enhanced cytotoxic T cell responses and suppressed responses after exposure to
HSP70iQ435A. The same shift toward increased Eomes/T-bet ratios found in mice

treated with HSP70iQ435A was also observed in human skin explants. Among cells

collected from HSP70iQ435A-treated human skin, Eomes/T-bet ratios were markedly
increased. In addition, wild-type HSP70i was shown to up-regulate expression of

both CXCR3 and the T cell surface marker CLA implicated in increased homing to
vitiligo patient skin observed in earlier studies (Wijngaard et al., 2000).

HSP70i vaccination stimulated humoral responses in mice, directed to the C

terminus, leaving the question why naturally occurring antibodies do not deplete
HSP70i and prevent the stress protein from inducing autoimmunity. Further

analysis of the targeted sequence within HSP70i revealed that circulating antibodies
bind downstream of our peptide of interest, offering an explanation for the

coexistence of HSP70i overexpression and vitiligo development. Elevated serum
levels of HSP70i have, in fact, been reported in coronary artery disease patients,
where it was likewise determined that such antibodies do not affect disease
expression (Kocsis et al., 2002).

Another vitiligo model included in our studies expresses a transgenic TCR to

tyrosinase (Mehrotra et al., 2012). The advantage of including this model is that

spontaneous depigmentation initiates even before animals become available for
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vaccination. The ears and tail are then fully depigmented, and hair depigmentation
initiates by 4 weeks of age. When DNA vaccination was initiated at 5 weeks of age,

the pelage remained black yet melanocytes were lost from the hair follicles. Animals
untreated or vaccinated with empty vector DNA at that age show a completely

depigmented pelage after the hair has regrown. However, in animals treated with

HSP70Q435A, the pelage returned pigmented; thus, melanocyte precursors must have
migrated from the hair bulge to the follicle and differentiated to express tyrosinase,
which is both the antigen recognized by the transgenic TCR as well as the enzyme
responsible for pigmentation (Watabe et al., 2004).

Using knockout mouse models, we demonstrated that both helper and

cytotoxic T cells are required for depigmentation. Moreover, in both sets of vitiligoprone mice, depigmentation was accompanied by relevant T cell infiltration to the
skin. In the Pmel-1 model, CD8+ T cells were observed infiltrating the hair follicles

where depigmentation takes place. In the h3TA2 model, we observed infiltration by
transgenic TCR-expressing T cells that can react with remaining melanocytes

(Mehrotra et al., 2012). In both models, responses were muted by HSP70iQ435A,

attesting to its amazing ability to deactivate an ongoing autoimmune response.

Several lines of evidence support a particular function for stress proteins in DC

activation. Similarly, an immature phenotype among DCs supports a regulatory
function (Diao et al., 2012). Several recent studies suggest that immunizing

autoimmune patients with tolerogenic DCs as a means of interfering with immune

responses to self-antigens can be successful, and CD11b-expressing myeloid-derived

suppressor cells have been widely implicated in tumor immune suppression
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(Ioanno et al., 2012; Rezzonico et al., 2000).

Last but not the least, we were able to induce elevated HSP70i expression,

both wild-type and mutant, among lymphocytes collected from gene gun–vaccinated
human skin. This provides a platform to translate our findings to a human setting;

however, this is also a limitation of the study. Whereas this study suggests that gene
gun vaccination may be effective in humans as well, current DNA applications in

humans do not make use of a gene gun. We have yet to find whether other means of
introducing DNA that are more readily supported by the U.S. Food and Drug

Administration will show similar results in human skin, for example, tattooing or
electroporation (Bolhassani et al., 2011). Also, we do not yet know whether

dampening immune responses by skin application of mutant HSP70i will have

consequences for other, more desirable immune responses and perhaps affect

systemic immunity as well. It is also possible that additional peptides within HSP70i
affect DC activation and currently remain undetected, although this will not

necessarily affect our proposed use of HSP70iQ435A in a therapeutic setting. Before

performing an actual clinical trial, we cannot be certain that the impact observed on
immunocyte profiles in human skin will likewise lead to improved skin

pigmentation in treated human patients. Such studies can, however, be further

designed following the results presented in our current article. Here, we provide

evidence for the positive impact of HSP70iQ435A on DC and T cell profiles and show in
vivo data demonstrating that HSP70iQ435A can affect depigmentation and

repigmentation in mice, strongly suggesting that the same HSP70i variant will

support repigmentation of lesional skin in human patients.
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In summary, the current study gives rise to a potential treatment opportunity

for vitiligo by introducing HSP70i with a single amino acid modification. Preclinical
data obtained in mouse models reflecting the effector phase of the autoimmune
depigmentation response support the use of HSP70iQ435A in patients. We have

demonstrated that HSP70iQ435A DNA can be transfected in human skin and can alter
the immune profile toward an anti-inflammatory phenotype similar to results

observed in preclinical mouse models. The in vitro and in situ data support the

potential significance for human vitiligo; however, it remains to be determined

whether the same construct will be effective when treating patients with active

disease. DNA vaccination has shown limited overall efficacy when applied to human
subjects, yet when applied toward dermatologic conditions, the use of

electroporation, for example, enables the next move to a clinical trial in perilesional

vitiligo skin using existing constructs (Murakami and Sunada, 2011). Should protein
or peptide-based constructs ultimately prove more effective than DNA-based

applications, the next step will be to define the minimal sequence to exert an effect
upon topical application. With the current strategy, the therapeutic value of
HSP70iQ435A can offer a potential treatment for vitiligo.

SUMMARY

CHAPTER VI: GENERAL DISCUSSION

Vitiligo is disabling to millions of patients around the world, yet the cause

still eludes researchers and clinicians. There is ample evidence that supports vitiligo
as an autoimmune disorder, but the mechanism leading to melanocyte reactive T

cells has not been defined. The impetus of my dissertation was to firmly establish

HSP70i as a critical component in mediating this autoimmune response, and identify
a means to block HSP70i. In chapter 3, I determined that HSP70i is located within
the melanosome, and is in close proximity to melanosomal antigens. In addition,
vitiliginous melanocytes secrete more HSP70i in response to chemical-induced
stress. These data suggest a mechanism whereby HSP70i binds melanosomal
antigens and is secreted from the cell. Once in the extracellular matrix the

HSP70i/melanosomal-antigen complexes activate DCs, which initiates an immune

response resulting in targeted killing of melanocytes. In chapter 4, I determined that
HSP70i is important for vitiligo development after my results demonstrated that
Hsp70-1 knockout mice were resistant to melanocyte-antigen induced

depigmentation. By contrast, wild-type mice developed robust vitiligo mediated by
cytotoxic T cells. We also showed that vaccination with HSP70i alone accelerates
depigmentation in vitiligo-prone mice. I also established that HSP70i activates

dendritic cells, which can be abrogated with addition of HSP70i-specific antibodies.
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In chapter 5, I determined that the immune activating region of HSP70i resides in
the C-terminus, specifically in the sequence QPGVLIQVYEG. Importantly, we

generated a mutant isoform (HSP70iQ435A) that prevents and reverses vitiligo.

Mechanistically, we determined that wild-type HSP70i activates and drives an
inflammatory subset of antigen presenting cells, and induces an effector T cell

phenotype. By contrast, treatment with HSP70iQ435A induces an opposite, anti-

inflammatory phenotype. We also provided evidence that human cells respond to

treatment similarly. Ultimately, the data in this dissertation strongly supports a role
for HSP70i in mediating an immune response directed towards melanocytes, and
identified HSP70iQ435A as a novel agent for treating autoimmune vitiligo.

Key Findings
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Chapter III: Preferential secretion of inducible HSP70 by vitiligo
melanocytes under stress
•
•

HSP70i is overexpressed in lesional skin from vitiligo patients

•

response to MBEH or 4-TBP

•

determined by density gradient centrifugation and Western blot

Cell viability is similar between vitiliginous and control melanocytes in
HSP70i is in the same cell fractions as melanosomal antigens as

HSP70i resides in melanosomes as determined by electron and confocal

•

microscopy

•

augmented by MBEH

Vitiliginous melanosomes contains greater levels of HSP70i, which can be
Vitiliginous melanocytes secrete more HSP70i in response to chemical
(MBEH, 4-TBP) induced stress

Table 2. Summary of key findings
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Key Findings
Chapter IV: HSP70i is a critical component of the immune response leading
to vitiligo
•

DNA vaccination with HSP70i and the melanocyte antigen opt-TRP-1

•

induces depigmentation in wild-type mice

•

demonstrating a systemic response

Depigmentation occurs locally and distal to the vaccination site
Hsp70-1, but not Hsp70-2 knockout mice are resistant to developing
vitiligo after HSP70i/opt-TRP-1ee/ng vaccination, thus indicating the

•

requirement for HSP70i in vitiligo development

Vitiligo is mediated by cytotoxic T lymphocytes as determined by IHC and

•

in vivo CTL assays

•

responses towards the vaccinated antigen

•

Hsp70-1 knockout mice have reduced T cell skin infiltrates and CTL
Vaccination with HSP70i alone accelerates depigmentation in vitiligoprone mice

HSP70i activates and drives inflammatory CD11b+CD11c+ dendritic cells
in vivo

•

HSP70i protein activates mouse dendritic cells in vitro which can be
blocked with antibodies (SPA-810) to HSP70i

Table 2. Summary of key findings
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Key Findings
Chapter V: Mutant HSP70 reverses autoimmune depigmentation in vitiligo
•

•

Inflammatory CD11b+CD11c+ antigen presenting cells are more abundant
in Vitiligo patient perilesional skin and peripheral blood

The C-terminus, but not N-terminus of HSP70i is required for inducing

•

mouse vitiligo

•

depigmentation response than the full length construct

•

mice.

•

crucial for depigmentation

•

inducing depigmentation

Vaccination with the C-terminus of HSP70i induces a greater
The C-terminus induces a humoral response to HSP70i in vaccinated
The dendritic cell activating sequence (QPGVLIQVYEG) of HSP70i is
Mutating the dendritic cell activating sequence prevents HSP70i from
The commercially available SPA-810 recognizes the HSP70i sequence

•

including the peptide PGVLIQVYEG

•

from knockout mice

CD4 and CD8 T cells are required for autoimmune vitiligo as determined
HSP70iQ435A provides both a prophylactic and therapeutic vaccine against
vitiligo development

Table 2. Summary of key findings

Key findings
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Chapter V continued
•

Vaccination with wild-type HSP70i drives an inflammatory response

•

mediated by activated antigen presenting cells and effector T cells.

•

P-mel1 mice

Effects of vaccination with HSP70iQ435 are measurable for > 6 months in
Vaccination with HSP70iQ435 drives an anti-inflammatory response

associated with a greater tolerogenic APC compartment, and a decreased

•

inflammatory APC compartment

•

skin-infiltrating T cells

Wild-type HSP70i increases and HSP70iQ435 decreases the number of

Wild-type and mutant HSP70i drive effector versus quiescent T cells

respectively in vaccinated mice, and human tissues as determined by
•

expression of the T cell transcription factors Eomes and T-bet

•

abundance of effector T cells as determined by Eomes/T-bet staining

Vitiligo patient perilesional skin and peripheral blood have greater

•

HSP70i protein increases CLA expression in human tissues

•

activation and inhibition respectively

•

Wild-type and HSP70iQ435 bind human dendritic cells, resulting in
Vitiligo patient skin presents with more CXCR3 expressing T cells

Wild-type and HSP70iQ435 encoding DNA can be expressed in human skin

Table 2. Summary of key findings

FINAL CONSIDERATIONS AND FUTURE DIRECTIONS
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HSP70i and vitiligo etiology
Several theories have emerged discussing the root cause of vitiligo. Part of

this discrepancy is due to the observation of symmetrical lesions in non-segmental

vitiligo. This has leant credibility to the neural theory in which melanocytes (which
are neural crest derived) are sensitive to neural peptides, catecholamines, or the
sympathetic nervous system (Le Poole and Boissy, 1997; Gauthier et al., 2003).
Melanocytes arise from the neural crest and migrate along dermatomes during
development; thus it is thought that symmetrical loss may be attributed to
inadequate sympathetic innervation. There is also the defective adhesion

hypothesis, which theorizes that melanocytes fail to attach to the epidermal

basement membrane (Gauthier et al., 2003). It has been suggested that increased
levels of tenascin, an extracellular matrix glycoprotein in the basal membrane

prevents melanocytes from adhering to fibronectin (Le Poole et al., 1997). Failure of
melanocytes to adhere may result in their loss or inability to repopulate lesional

sites(Le Poole et al., 1997). Similar to the neural theory, defective adhesion could
induce symmetrical lesions as a result of the Koebner phenomenon, in which

exposed areas of the body (e.g., hands and face) are more sensitive to trauma

resulting in greater melanocyte death. Although the adhesion and neural theories

are interesting, there has been little supporting evidence. For one, tenascin is known
to be upregulated in response to inflammation in several tissues including the skin
(Ogawa et al., 2005). Thus, rather than a direct cause of vitiligo, increased tenascin

may result from autoimmunity or inflammation which accelerates vitiligo
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pathogenesis. In addition, the concentration of neural peptides and catecholamines
in the skin is not sufficient to induce melanocyte death (Gauthier et al., 2003).

Moreover, these theories fail to address the etiology of segmental (unilateral) or

occupational (exposure to bleaching agents) vitiligo which can induce lesions distal
to the affected areas. Interestingly, occupational vitiligo often leads to symmetrical
(generalized) vitiligo (Boissy and Manga, 2004).

Currently, impaired redox status and autoimmunity are the leading theories

for the cause of vitiligo. As I will discuss, these theories may not be independent of
each other. With the impaired redox theory, melanocytes are thought to die from
increased levels of intracellular oxidative stress, most likely produced during

melanogenesis (Gauthier et al., 2003). The increased sensitivity to stress may be

linked to genetic and cell abnormalities observed in vitiliginous melanocytes. Low

catalase activity leading to increased hydrogen peroxide (H2O2) production has been

observed in lesional skin and cultured melanocytes (Goth et al., 2004; Hasse et al.,

2004). It has also been shown that vitiliginous melanocytes have impaired calcium

uptake which is important for maintaining antioxidant activity (Schallreuter-Wood

et al., 1996). From these observations, medications such as pseudocatalyase have
been developed to inhibit H2O2 and/or ROS (reactive oxygen species) activity.

However, treatment efficacy with pseudocatalyase is minimal, with the majority of
studies showing no therapeutic effects (Naini et al., 2012). Moreover, in blinded

studies where patients receive a combination of narrowband UVB (NBUVB) and

pseudocatylase, researchers suggest it is the NBUVB rather than pseudocatylase
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that is having a (minimal) treatment effect (Gawkrodger, 2009).

Support for vitiligo as an autoimmune disease is provided by infiltrates of T

cells and macrophages described for the skin of actively depigmenting patients (Le
Poole et al., 1996; Ongenae et al., 2003). In addition, the detection of circulating

autoantibodies towards melanocyte antigens was amongst the first evidence linking
vitiligo to autoimmunity (Bor et al., 1969). It has been shown that antibodies to

melanocyte antigens are detected in a large proportion of vitiligo, but not healthy

individuals (Xie et al., 1999; Laberge et al., 2005). However, it is controversial which
melanocyte antigens these antibodies detect, and is suggested that their production
is a result of vitiligo pathogenesis (melanocyte death), rather than a direct cause

(Xie et al., 1999). This is supported by the fact that many of these antibodies detect

intracellular antigens, rendering these antibodies ineffective in eliciting cytotoxicity
(Xie et al., 1999). Interestingly, the melanosomal transmembrane protein MelanA

(aka, MART-1; melanocyte antigen recognized by T-cells) only induces CTL, but not
humoral responses (Waterman et al., 2002). This suggests that autoimmune

destruction of melanocytes is mediated by cytotoxic T cells, rather than antibodies.
Family studies have identified mutations in genes associated with

autoimmunity such as HLA which defines antigen presentation; moreover, vitiligo
melanocytes often contain abnormal gene expression of proteins essential for

antigen processing and protein folding (Stromberg et al., 2008; Lerner, 1959). In

addition, vitiligo patients often develop other autoimmune disorders such as thyroid
disease, pernicious anemia, Addison's disease, and type 1 diabetes mellitus (Picardi
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et al., 2003). These and several other autoimmune disorders have been linked with
HLA molecules (Alkhateeb et al., 2003) Patients with HLA molecules susceptible to
binding autoantigens have higher frequencies of autoreactive T cells in their

circulation (Law et al., 2012). Recently, it was shown that vitiligo patients have

increased MHCI (HLA-A*33:01, HLA-B*44:03) and MHCII (HLA-DRB1*07:01) allele
expression (Singh et al., 2012). These authors suggest that vitiligo is a type 1

immune response orchestrated by CD4+ T cells which drive CTL autoimmune

targeting of melanocytes. Interestingly, vitiligo melanocytes express MHCII (Le

Poole et al., 1993c) which is typically restricted to APCs. Thus vitiligo melanocytes

may aberrantly display self-antigens on MHCII to CD4+ T cells, which subsequently

drive a type I immune response.

We believe that vitiligo is due to autoimmune destruction of melanocytes.

This is evident from accumulations of infiltrating melanocyte-reactive T cells in

patient skin (Le Poole et al., 1993b). These observations are similar to what we have
seen in our animal models where skin taken from vitiligo-prone P-mel1 and h3TA2

mice show an abundance of effector T cell infiltrates (chapters 4 and 5). Moreover, I
showed that vaccinations with HSP70i increase the abundance of skin infiltrating
CTLs resulting in depigmentation.

Genetic studies provide further support for vitiligo as an autoimmune

disorder. A genomewide association study found 10 independent susceptibility loci
for generalized vitiligo (Jin et al., 2010). In the MHC encoding region, differential
genome expression was observed in both the class I (between HLA-A and HLA-

HGC9) and class II (between HLA-DRB1 and HLA-DQA1) genes. Outside the MHC
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region, differential expression was identified in several genes linked to autoimmune
diseases, many of which are associated with vitiligo (Jin et al., 2010). In addition, a
high percentage of vitiligo patients have a single amino acid mutation ( Leu155>His) in the NLRP1 (NLR family, pyrin domain containing 1) gene which may

contribute to pathogenesis (Jin et al., 2007). NLRP1 encodes for caspases 1 and 7
that activate interleukin-1β, which is overexpressed in vitiligo patients

(Levandowski et al., 2013). In addition, a polymorphism is associated with the TYR

gene (which encodes tyrosinase) in vitiligo patients (Jin et al., 2010). Interestingly, a
TYRQ402R mutation was identified in vitiligo, whereas TYRR402Q is closely associated

with melanoma (Jin et al., 2010). These authors postulate that peptides containing
the TYRQ402R mutation are more efficiently displayed on MHCI, whereas peptides

with the TYRR402Q mutation may fail to be identified by the immune system (Jin et al.,
2010). Both NALP-1 and TYR suggest that a single amino acid mutation can have
different effects on immune activation, similar to our HSP70iQ435A variant.

Because vitiligo is initiated and accelerated under stress, HSP70i may be the

link to mediating downstream autoimmune responses. We have shown that

vitiliginous melanocytes are more sensitive to stress (chapter 3) with higher

production and secretion of HSP70i. Because of the similarities in this response with
the proposed redox theory, it is likely that these mechanisms work in sync. Thus, it

is likely that vitiliginous melanocytes are inherently sensitive to stress. Exposure to
stressors (mechanical damage, UV, chemicals, emotional stress) likely imparts a

cellular response, inducing an overproduction of ROS and HSPs. Our results indicate
that vitiliginous melanocytes respond to ROS by producing and secreting higher
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levels of HSP70i (chapter 3), rather than undergoing apoptosis as proposed by the
impaired redox theory. This is similar to previously published results showing that
H2O2 treatment upregulates production of HSP70i (Jornot et al., 1991).

A pilot study indicated that HSP70 is aberrantly expressed in vitiligo skin (Le Poole
et al., 2004). This is in concordance with recently published data that detected

greater expression of HSP70 in vitiligo perilesional and lesional skin (Abdou et al.,
2013). In that study, antibodies were directed towards both the constitutive and
inducible isoforms (Abdou et al., 2013). Here, I showed that inducible HSP70

specifically is overexpressed in perilesional and lesional tissue (chapter 3). We
propose that HSP70i is secreted by melanocytes which initiates autoimmune
targeting as discussed in HSP70i functions as a chaperone and adjuvant.
Future directions for HSP70i and vitiligo etiology:
My results have strengthened the autoimmune theory, and have shown that HSP70i
is a critical component in mediating this response. It may be argued that our animal
models do not replicate the environment in naturally occurring vitiligo. We have

relied on artificial systems, including vaccinating mice with melanocyte antigens, or
utilizing genetically modified mice which express melanocyte reactive TCRs.

Fortunately, there are other animal models which display naturally occurring

vitiligo, with symptoms closely mimicking human vitiligo. The Smyth Line chicken
develops spontaneous vitiligo, and mirrors many of the disease traits in human

vitiligo including the development of autoimmune linked diseases such as alopecia
and thyroid disease, which are commonly associated with human vitiligo (Smyth,

1989). Depigmentation is observed in the feathers, and is caused by melanocyte-
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antigen reactive T cells. This T cell response is highly aggressive, leaving Smyth Line
chickens prone to uveitis and ultimately blindness. Interestingly, genomic studies in
Smyth Line chickens have pointed to abnormal expression of HSP70 (Picardo et al.,

2010; Shi et al., 2012), and autoantibodies against HSP70i and melanocyte antigens

have been detected (Wang and Erf, 2003). In addition to the Smyth Line chicken, the
Sinclair miniature swine displays spontaneous regression of melanoma, often

followed by vitiligo development (Picardo et al., 2010). Because pigs have similar

physiology to humans, they are often used in pre-clinical studies. Thus the Sinclair
swine may be an important next step for testing the treatment potential of

HSP70iQ435A. In addition, it would be interesting to study the effects of HSP70i in

these spontaneous animal models using techniques we have already established in
mice. For instance, vitiligo development can be observed following overexpression
or silencing (knock-out) of HSP70i. Furthermore, the interactions between redox

production, HSP70i expression, and autoimmunity can be explored in more detail.

Data from these proposed studies may finally unify several vitiligo etiology theories.
HSP70i functions as a chaperone and adjuvant
HSPs are a class of intracellular chaperones shown to be upregulated in

response to stress (Lindquist and Craig, 1988; Mehlen et al., 1996). HSPs are

involved in protein folding which maintains cellular integrity, and inhibits apoptosis
(Lindquist and Craig, 1988; Mehlen et al., 1996). They also have important immune
functions such as their ability to process and cross-present antigens via HLA class I
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and II pathways, which may invoke both the innate and adaptive immune systems
(Javid, 2007; Srivatava, 2002). There is accumulating evidence that HSPs are

involved in cross-presentation at several points along the antigen presentation

pathway (Srivastava, 2002). The induction of CD8+ T cells by HSPs has important
implications as a protective mechanism; however, this function of binding and
presenting antigens to APCs could lead to the generation of antigen specific Tlymphocytes, thus providing the basis for an autoimmune response.

Indeed, there are functional redundancies amongst HSPs. For example, gp96

has also been shown to activate DCs directly and via its chaperoned peptides

(kuppner et al., 2001). This lends the argument that HSP70i may not be exclusively
responsible for activating the immune response. It should be noted however that
many of these studies were carried out under artificial settings, such as removing

the ER retention sequence KDEL in order to induce secretion and capitalize on the

adjuvant properties of HSPs (Strbo and Podack, 2008). HSP70i on the other hand is
special in that it is secreted by living cells, thus its actions occur naturally in vivo

(Mambula et al., 2007). In addition, HSP70i is more effective at eliciting immune

responses as compared to other HSPs. For instance, the chemoattraction of DCs to
Murine Lewis Lung carcinoma cells (3LL) was impaired after RNA silencing of

HSP70, but not HSP60, HSP90, or gp96 of the 3LL cells (Chen et al., 2009). I further
demonstrated the unique role of HSP70i in vivo, where I examined the exclusive,

causative role of HSP70i in inducing autoimmune depigmentation in mice. Using
constitutive and inducible HSP70 knockout mouse models, we showed that the
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inducible, but not constitutive isoform of HSP70 is solely responsible for inducing
and perpetuating an autoimmune response (chapter 4).

HSP70 is the best understood protein of the HSP family, due in part to the

resolution of the crystal and solution structures of its substrate binding domain
(Zhu et al., 1996; Stevens et al., 2003). These findings have shown that HSP70

preferentially interacts with unfolded peptides, such as NRLLLTG which was used in
a crystallography study (Zhu et al., 1996, Javid, 2007). Interestingly, there is

evidence that the peptide side-chains may dictate which HSP70 isoforms (BiP, DnaK,
HSP70, HSC70, etc.) bind, due in part to subtle differences in the substrate binding

domain (Marcinowski et al., 2013). Moreover, recent studies suggest that HSP70 has
an affinity for hydrophobic residues located within β-sheet regions of proteins

(Marcinowski et al., 2013). This is congruent with the finding that HSP70 binds the
hydrophobic tyrosinase peptide b-GSGHWDFAWPWGSGYMNGTMSQV, which is

processed by APCs to YMNGTMSQV and displayed on HLA-A2 (Pandya et al., 2009;
Noessner et al., 2002), Not surprisingly, MHCI molecules preferentially display
hydrophobic peptides (Huang et al., 2011), and provide further evidence that
MHCI/II evolved from HSP70 (Hughes and Nei, 1993).

Although it is not well understood how HSP70 exerts its function in vivo, it

has been shown that HSP70 secreted from tumors confer anti-tumor responses via
the peptides they chaperone (Srivastava, 2002). Thus, HSP70 can be thought to act

as both a chaperone, enhancing the immunogenicity towards its bound peptide, and
as a chemokine activating APCs directly. Whereas intracellular HSPs serve a

cytoprotective function, upon secretion, the inducible isoform of HSP70 functions as

a chaperokine, eliciting innate and adaptive immune responses (Mambula et al.,
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2007; Asea, 2006; Johnson and Fleshner, 2006)

The mechanism of HSP70i secretion is not understood, but is thought to be

induced by the sympathetic nervous system (Johnson and Fleshner, 2006). Many

studies suggest that HSP70i secretion involves a non-canonical pathway similar to

the cytokine IL-1b, including entering lysosomes where it may be released in to the
cytosol, or through exosomal evagination (Calderwood and Murshid, 2012).

Although there is no secretory signal, there is a correlation with production of

Lysosomal-associated membrane protein 1 (LAMP1), further supporting HSP70i
secretion by an endolysosomal pathway (Mambula et al., 2007). It has also been

suggested that HSP70 is transported to the cell membrane by lipid rafts, which may
also form budding vesicles (Broquet et al., 2003). Within melanocytes, HSP70i may
be secreted along with melanin/melanosomes that are routed to keratinocytes.

As discussed in chapter 3, there is substantial evidence that melanosomes

evolved from lysosomes (Orlow, 1995; Le Poole et al., 1993a; Raposo et al., 2002).
There is genetic evidence, similarities in structure and physiology (e.g., pH), and
shared enzymes such as LAMP-1 that indicate melanosomes are specialized

lysosomes (Orlow, 1995). Intriguingly, similar to lysosomes, melanosomes contain
the machinery for antigen processing and presentation (MHCI/II) in addition to

several unique and highly antigenic proteins (TRP-1/2, Tyrosinase, gp100, MART-1)
(Wang et al., 1999). This may address why melanocytes are specifically targeted in
vitiligo.
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We have demonstrated that vitiliginous melanocytes secrete higher levels of

HSP70i in response to stress (chapter 3). This suggests that in vivo, vitiligo

melanocytes are more prone to eliciting immune activation, subsequently resulting
in their destruction. Under stressful conditions, melanocytes may secrete HSP70i

which then activates DCs directly through specific receptor binding, leading to the
production of various cytokines such as IL-12, and IFN-γ. In addition, secreted

HSP70i may serve as a chaperone, binding melanocytic antigens to be processed by
APCs and eliciting autoimmune responses to melanocytes in active disease. DCs

activated by HSP70i/melanocyte antigen complexes could lead to the activation and
recruitment of effector cells from draining lymph nodes (Srivastava, 2002).

In chapter 3, we showed that HSP70i is in close proximity to melanocyte

antigens, as demonstrated by microscopy and Western blotting. It has been

demonstrated that HSP70i isolated from melanoma is bound to melanocyte

antigens. This is likely to occur in vitiliginous melanocytes, especially considering
there are mutations in melanocyte proteins, and abnormalities in the ER

(endoplasmic reticulum) and melanosomes (Jin et al., 2010; Le Poole et al., 2000; Li

et al., 2009; Boissy et al., 1991). Moreover, we showed that vitiliginous melanocytes

have greater colocalization of HSP70i and melanocyte-antigens which is augmented

after exposure to MBEH. As mentioned, melanosomes contain MHCII; thus HSP70i is
in a position to cross-present peptides. Together, our findings (chapter 3) have
determined that HSP70i colocalizes with melanocyte antigens which may be

secreted in response to stress. Because of the adjuvant properties of HSP70i, this

may establish a mechanism for autoimmune targeting of melanocytes in vitiligo
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patients.

Future directions for HSP70i functions as a chaperone and adjuvant:
My hypothesis is that HSP70i specifically is required for vitiligo development,

due in part to its unique secretion properties. We have shown that HSP70i is

secreted by vitiliginous melanocytes, and that it is critical for inducing autoimmune
vitiligo. However, it has been shown that HSP70i (and other HSPs) are released by
necrosis, but not apoptosis (excluding HSP70i), gaining access to the extracellular
matrix (Basu et al., 2000). This suggests that after necrosis, additional HSPs may
contribute to immune activation. We demonstrated that knocking out HSP70i in

mice prevents the development of vitiligo, yet we did not test whether additional

HSPs released by necrotic melanocytes can trigger depigmentation. To test this, we
can expose Hsp70-1 knockout mice to 4-TBP (which induces necrosis) or MBEH
(which induces apoptosis) to determine if other HSPs can induce immune

activation/depigmentation once they have access to APCs. In addition, we can
vaccinate C57BL/6 and hsp70-1 knockout mice with melanocyte antigens in

combination with alternative HSP isoforms (BiP, DnaK, HSP60/90/110, etc.).

Because of the adjuvant/chaperone properties of these HSPs, I would predict

depigmentation to occur. However, we have shown that HSP70i is required for
depigmentation in naturally developing vitiligo. Determining the adjuvant

properties of additional HSPs may be important for developing vaccines towards
vitiligo and melanoma.

In addition, we determined that HSP70i is over-secreted by vitiliginous
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melanocytes, yet did not test whether this secreted HSP70i can activate DCs in vitro.
It is possible that HSP70i secreted by vitiliginous melanocytes is more antigenic, as

may be attributed to having greater access to melanosomal compartments. As such,
I have shown that HSP70i is located within melanosomes, yet I did not test whether
it is bound to melanocyte antigens; however, others have confirmed this in

melanoma (Noessner et al., 2002). This is an important part of our mechanism as it

explains the targeted response towards melanocytes. In order to elucidate whether
HSP70i is bound to melanocytes antigens, we can use immunoprecipitate assays,

and/or fluorescence energy transfer (FRET). Likewise, due to the stress-sensitive
nature of vitiliginous melanocytes, proteins are commonly misfolded and/or

degraded, which may allow HSP70i to bind peptides not normally accessible in

healthy melanocytes. These additional studies will be important for defining HSP70i
as a critical adjuvant in vitiligo development.
HSP70i and immune activation
Dendritic cells are recognized as one of the most important APC in inducing

an immune response. Various HSPs including HSP60, HSP70, and gp96 have been
shown to upregulate DC surface expression of MHCII and B7 (CD80/83/86)

molecules (Kuppner et al., 2001; Basu et al., 2000). As mentioned, HSP70i is the

most abundantly expressed HSP, and is unique in that it can be secreted by live cells
of neuronal origin (Georgopoulos and Welch, 1993; Asea, 2007). However, various
HSPs with immune activation properties can gain access to APCs after cellular
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necrosis. Yet it was shown that silencing HSP70, but not HSP60, HSP90, or gp96 can
impair the chemoattraction of DCs to tumor cells (Chen et al., 2009). Thus HSP70i
may play a larger role in immune activation. This same study also suggests that

HSP70 activates DCs through TLR4 (Toll-like receptor 4), although other reports
have suggested the involvement of additional receptors such as TLR2, CD40, and
CD14 (Chen et al., 2009, Asea et al., 2002, Asea et al., 2000).

The immune activating region of HSP70i is controversial, with studies

suggesting that the N-terminal ATP binding domain as a critical component

(Nicchitta, 2003). However, other studies have shown that the C-terminal portion of
HSP70 (residues 359-610) activates DCs and other innate cells to produce TNF-α,

IL-12, nitric oxide (NO), and drive TH1 responses (Wang et al., 2005; Lehner et al.,
2004; Manucha and Valles, 2008; Lehner et al., 2000). In these studies, we have

shown that vaccinating mice with the N-terminus of HSP70i has no effect, whereas

the C-terminus was critical for inducing depigmentation (chapter 5). In fact,

vaccination with the C-terminus gave a stronger response than full length HSP70i.
Working with microbial HSP70 (DnaK), a region that binds and activates DCs was
identified (Wang et al., 2005). From this work, and studies that identified crossrecognition between mammalian and microbial HSP leading to autoimmune

disorders (Kaufman, 1990), we hypothesized that intrinsic human HSP70i will
similarly activate DCs, and that the binding region in human HSP70i can be

predicted by aligning human and microbial HSP70. We thus identified the peptide

sequence QPGVLIQVYEGER (HSP70435-447) as a potential target for blocking entities
to prevent DC activation (patent application PCT/US2008/076266).
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Because vaccinations with peptides have proven an effective means to induce

immune responses and generate antibodies towards the full length proteins

(Berzovsky, 1995), we predicted the peptide sequence QPGVLIQVYEGER as a novel
target in preventing an autoimmune response. The importance of the DC activating
peptide lies in opportunities to bind and prevent its association with specific

receptors. Because of the promiscuity of HSP70 in binding inflammatory receptors,
finding blocking agents against HSP70i will be a more achievable task in inhibiting
APC activation. In addition, it will avoid non-specific activation by these receptors.
Our findings suggest that blocking this peptide with antibodies (e.g., SPA-810) can

prevent DC activation (chapter 4). These results may prove useful as a treatment

against autoimmune disorders, or alleviate inflammation. Unfortunately, SPA-810

did give some unwanted DC activation, most likely attributed to Fc receptor binding.
Developing a Fab version of SPA-810 may alleviate these unwanted responses.

As mentioned, residues 407-426 in DnaK were identified to enhance DC

maturation, and induce the production of IL-12 (Wang et al., 2005). BLAST analysis

of this peptide region recognizes the sequence QPGVLIQVYEGERAMTKDNN to be

critical for human DC activation, of which we identified QPGVLIQVYEGER as being
homologous to DnaK. However, it should be noted that this group identified an

additional peptide, IVHVTAKDKGTGKENTIRIQEGSGLSKEDIDRMIKDAEAH, located
downstream of the peptide binding groove which may have immune inhibitory
properties. A BLAST search identifies

ILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKY, with 54% homology in
mammalian HSP70i. This is interesting as there has been controversy regarding

HSP70i in immune activation. Some studies suggest that HSP70 is important for
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inhibiting inflammation, and has tolerating effects toward self antigens mediated by
DCs in other disease models, although the mechanism was not defined (Millar et al.,

2003). It is also suggested that endotoxin contamination of HSP70 contributes to DC
activation in vitro (Stocki et al., 2012). It should be noted that we achieved DC

activation with endotoxin-free HSP70i protein, as well as gene-gun vaccination with
DNA-encoding plasmids.

It may be that HSP70i has activating or inhibitory functions depending on the

peptide it is bound to, or the TLRs it binds. Having both activating and inhibitory
sequences could allow HSP70i to have “on” and “off” properties which may be

dictated by early and late stages of inflammation or infection. As mentioned, HSP70i
may bind several TLRs including CD91, TLR-2, CD14/TLR4, CCR5, and several

scavenger receptors (Thėriault et al., 2006; Aneja et al., 2006; Floto et al., 2006; Qazi
et al., 2007; Fischer et al., 2010). Depending on the receptor(s) HSP70i binds, cell
signaling is thought to occur through mNF-κB, and/or the MAP-kinase family

(ERK1/2, p38, and SAPK/JNK) (Aliprantis et al., 2002; Oppermann et al., 2004). In

fact, DCs express different cytokines depending on which TLR(s) are agonized,

including the production of inhibitory cytokine IL-10 (Mayer et al., 2009). Thus,
HSP70i may induce DC inhibition or activation depending on the TLR it binds.

Studies also indicate that binding to surface CLRs (C-type lectin receptors) results in
DC inhibition (Meyer-Wentrup et al., 2008). Moreover, DCs can be induced to

provide inhibitory signals to T cells directly (e.g., signaling through CTLA-4 and PD1) or secrete IL-10 to upregulate production of Tregs (Lau et al., 2008). This may
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provide a mechanism whereby wild-type and HSP70iQ435A bind a different repertoire
of TLRs/CLRs, resulting in opposite responses attributed to these proteins.

We have further shown the importance of immune activation by HSP70i in

vivo. The vitiligo prone mouse strain Pmel-1 faithfully mimic human vitiligo in which
melanocyte-reactive T cells escape clonal deletion, and stress is shown to augment
the T cell response (Overwijk et al., 2003). We chose to vaccinate these mice with

mutant HSP70iQ435A to test whether a mutation at residue 435 would have an effect
on depigmentation, since this mutation prevented SPA-810 Ab from binding. Here,

we showed that depigmentation is accelerated after vaccination with wild-type
HSP70i, whereas mutant HSP70iQ435A slowed down the rate of depigmentation

(chapter 5). This may indicate that HSP70iQ435A induces an antagonistic effect when

binding to DCs. Alternatively, autoantibodies may be generated against HSP70i

through molecular mimicry as has been previously observed with bacterial infection
(Kaufmann, 1990). My results demonstrated that wild-type and HSP70iQ435A have

opposite effects on DC activation. As a result of this, downstream T cell activation is
likely affected. We showed that splenocytes and skin from wild-type and

HSP70iQ435A vaccinated mice display effector versus quiescent phenotypes as

determined by EOMES and T-bet ratios. Thus, it is possible that HSP70iQ435A is acting
as a dominant-negative, or is binding a different repertoire of TLRs leading to
suppressed immunity.

Future directions for HSP70i and immune activation:
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Although the studies with wild-type and HSP70iQ435A have shown astounding

results, the mechanism of action is still not fully understood. The response elicited
by APCs depends on which TLRs are agonized, or whether HSPs are taken up

through a non-receptor route (Calderwood et al., 2012). In addition, the peptides
that are bound by HSPs may induce immune activation, such as anti-tumor

stimulation through antigen-cross presentation. It is possible that peptide binding
may be affected in HSP70iQ435A, although this is not likely as the mutation lies

outside the substrate binding cleft. As mentioned, HSP70iQ435A may bind a different
subset of TLRs leading to inhibition. Alternatively, HSP70iQ435A may bind the same

TLRs as wild-type HSP70i without causing activation. In this regard, HSP70iQ435A

may be acting as an antagonist, or dominant negative. In either case, determining
receptor binding and resulting cell signaling of HSP70iQ435A will be crucial for

understanding its immune effects. Interestingly, HSPs can be taken up by non-APCs

as well. It was shown that HSP90 can be taken up by Chinese Hamster Ovary cells by
scavenger receptor binding, where it is transported to proteasomes and interacts
with antigens (Calderwood et al., 2012). It would be interesting to test whether
melanocytes can take up wild-type and/or mutant HSP70i.

From studies using DnaK we hypothesized that the DC activating region

would be homologous to human HSP70i. Through a database search, we identified

and patented the peptide sequence QPGVLIQVYEGER (HSP70435-447). Here, we show
that as little as one residue change in this region is sufficient to decrease

depigmentation in mice when vaccinated in combination with TRP-2. Because our

goal is to bring HSP70i vaccinations to the clinic, DnaK may provide an even
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stronger immune response as compared to mammalian HSP70i. Likewise, studies

have identified cross-recognition between mammalian and microbial HSP leading to
autoimmune disorders (Kauffman, 1990). Thus, vaccination with DnaK may induce
mimicry in which the immune system targets and neutralizes HSP70i from
activating an immune response.

HSP70i and autoimmunity/tumor immunity
Observations that HSPs can serve as adjuvants in anti-tumor vaccines first

suggested to us a link between these proteins and vitiligo. Melanocytic antigens in
combination with HSP70 have been shown to elicit immune responses towards

cancerous and healthy melanocytes (Das et al., 2001; Castelli et al., 2004). As with
the anti-tumor vaccines, secreted HSP70i can be thought of as a chaperokine,

binding melanocytic antigens which can be processed by APCs (Javid et al., 2007;

Srivastava, 2002). The relationship between HSPs and melanocytic killing suggest a
role for HSP70i in mediating stress induced events that elicit auto-immune
responses in vitiligo.

Targeting tumors with self-antigens has been en vogue for several years

(Castelli et al., 2004). Importantly, it was shown that injecting mice with a

combination of HSP70 and melanocyte antigen encoding plasmids is sufficient for

inducing vitiligo, and this response is mediated by CD8+ T cells (Sanchez-Perez et al.,
2006; Mosenson et al., 2012). This study demonstrates the shared relationship

between vitiligo and melanoma in the targeting of specific cells mediated by HSPs.
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Here, we showed that depigmentation in C57BL/6 mice occurred within and distal
to the site of the gene gun vaccinations (chapters 4 and 5). As with the findings by

Denman (2008), cytotoxicity towards melanocytes was associated with an antigenspecific and systemic immune response to melanocyte antigen. Here, Hsp70-1

knockout mice displayed reduced killing of melanocyte antigen pulsed splenocytes,
indicating a role for HSP70i in the immunogenicity towards these cells. These

results mirror the melanoma studies in which a CTL response was only elicited after
inclusion of HSP70 (Sanchez-Perez et al., 2006). In the case of tumor immunity,

HSP70i is thought to efficiently present self-antigens, or directly activate the innate

immune system (Nicchitta, 2003). In the latter, APCs will be activated leading to the

recruitment of effector cells, and the eventual killing of target cells (Nicchitta, 2003).
Previous vaccination studies using HSP70i in combination with melanocyte

antigens at suboptimal levels have shown that immune responses can be elicited

towards these target antigens (Denman et al., 2008). Depigmentation preferentially
occurred after inclusion of HSP70i in the vaccine, for the first time demonstrating

the importance of this protein in mediating autoimmune responses to melanocytes
(Denman et al., 2008). Tumor studies have shown that directing HSP70 towards

melanocytes can enhance anti-melanoma responses (Sanchez-Perez et al., 2006),
demonstrating the shared relationship between vitiligo and melanoma in the

targeting of specific cells mediated by HSPs. In the current studies, reduced killing of
melanocyte antigen-pulsed splenocytes was observed in hsp70-1 knockout mice,

providing further support for a role of HSP70 in the immunogenicity towards these
cells.

In addition to vitiligo, HSPs have been implicated in several other
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autoimmune disorders including psoriasis, autoimmune intestinal inflammation,

autoimmune encephalomyelitis, and Kawasaki disease (Seung et al., 2007; Steinhoff

et al., 1999; Mor and Cohen, 1992; Jin et al., 2007). Although the mechanisms for the
etiology of these diseases remains elusive, HSPs are thought to initiate an

inflammatory response which may cause damage to susceptible tissues, such as the
bowel. Innate cells activated by HSPs are known to secrete several inflammatory

cytokines including IL-6, IL-12, and TNFα contributing to tissue damage (Asea et al.,
2007). In addition to systemic inflammation, peptides bound to these HSPs may
induce cell targeting after processing by APCs.

By contrast, other studies have shown that HSPs may in fact play a protective

role in preventing autoimmunity. HSP65 for instance has been shown to treat

autoimmune arthritis in Lewis rats (Rajaiah and Moudgil, 2009). It is thought that

HSP65 (as well as other HSPs including HSP70) activates Tregs which suppress the
autoimmune response (Rajaiah and Moudgil, 2009; Borges et al., 2012). Moreover,
several autoimmune disorders including arthritis, atherosclerosis, and diabetes

have been associated with antibody targeting of HSPs (Rajaiah and Moudgil, 2009).
It is thought that infections such as Mycobacterium tuberculosis induce the

production of antibodies towards bacterial antigens including HSPs. Because of the
evolutionally conserved nature of these proteins, mimicry may occur in which the
antibodies target mammalian HSPs. It is thought that these antibodies bind and
damage cells expressing surface HSPs, such as endothelial cells (Rajaiah and

Moudgil, 2009). Together, the role of HSPs in autoimmunity remains controversial,

with evidence for both a protective and pathogenic role. This dichotomy may
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explain my results in which wild-type HSP70i is important for initiating

autoimmune vitiligo, whereas HSP70iQ435A inhibits this response. Whether the

effects are due to differential processing, receptor binding, or antibody production
remains to be determined.

In conclusion, we have shown that HSP70i is necessary and sufficient to

precipitate vitiligo. Importantly, mutant HSP70iQ435A-encoding DNA was able to

reverse the inflammatory phenotype of DCs, prevent infiltration of melanocyte
reactive T cells to the skin, and avert depigmentation. The general strategy is

outlined in Figure 33. This leaves several important and interesting questions to be
addressed. Can human patients be treated with a DNA vaccine introduced to the

skin? Will it affect the development of other autoimmune diseases, or cancer? The

responses HSP70i will ignite are directed towards the antigens chaperoned by the

stress protein. Thus, muted responses may likewise depend on the peptides bound
to the (mutant) stress protein, and may be less dependent on the stress protein (if
any) engaged in disease precipitation. When stimulating anti-tumor responses or

interfering with responses to self, such substrate specificity or the source of the heat
shock protein can help selectively support therapeutic effects. Another selective

approach makes use of the exclusive surface expression of HSP70 family members
by tumors. This renders the extracellular portion amenable to targeting by

antibodies, and antibodies to HSP70 can be therapeutic in cancer (Stangl et al.,
2011).

Taken together, targeting HSP70i is a promising approach towards the
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treatment of vitiligo. Mutant HSP70iQ435A prevented the depigmentation process in
different mouse models prone to vitiligo development. Moreover, HSP70iQ435A

reversed vitiligo as was seen in h3TA2 mice, where active depigmentation was
occurring. We believe that HSP70iQ435A dampens the autoimmune response,

allowing melanocyte stem cells to repopulate affected areas. Future studies will

show how best to translate findings to a clinical trial to determine the safety and
efficacy of mutant HSP70 treatment in vitiligo patients.

Future directions for HSP70i and autoimmunity/tumor immunity:
Bringing HSP70iQ435A to the clinic will be the ultimate goal. Because of the

contradictory results regarding HSPs and the immune system (pathogenic versus

protective) understanding how wild-type and mutant HSP70i function will need to
be addressed. This will include understanding whether there is uptake and

presentation by APCs, identifying the TLRs and CLRs each of these proteins bind,
and the role that HSP70i antibodies play in mediating inflammatory versus antiinflammatory immune responses.

We have shown that blocking HSP70i and vaccination with HSP70iQ435A are

viable methods for treating vitiligo. It will be important to test these therapies in

other autoimmune disorders. HSPs are implicated in several autoimmune disorders,
of which animals models have been developed. We have chosen administration of

DNA in the skin by gene gun vaccination as this allows the protein to be expressed
locally in the affected sites. It may be necessary to modify the route of
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administration depending on the disease. This may include intramuscular or oral
administration. Moreover, because gene gun vaccinations are not fully approved for
the clinic, we will need to test alternate methods. This may include DNA

electroporation, or even tattooing, both of which are FDA approved in other

settings. Also, it may be necessary to use RNA or protein instead of DNA. Modifying

the vector to include shorter peptides (such as the DC activating region) may prove
more effective than full length protein, similar to our finding in chapter 5. In

addition, it may be beneficial to treat patients with lenti/retrovirus carrying the

HSP70iQ435A gene. These viruses can be modified to allow for stable infection, thus
eliminating the need for booster vaccinations. In addition, the viruses can encode

ligands/receptors to bind specific cell types (e.g., DCs, melanocytes, etc), and may
allow for a local (skin) versus systemic response.

In addition to treating vitiligo, HSP70iQ435A may provide a treatment for

melanoma. These diseases are considered “mirror images” in that vitiligo leads to

autoimmune targeting of melanocytes, whereas melanoma is an overproliferation of
these cells that often avoid immune detection. Although vitiligo and melanoma

develop by different mechanisms, there may be shared therapeutic targets (Stangl et
al, 2010). Thus, vaccination with HSP70iQ435A may be the first treatment to achieve
anti-tumor responses without the induction of autoimmunity.
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Figure 33. Translating stress to the skin into an autoimmune response to
melanocytes. [1] Melanocytes, when exposed to stressors [2] compromise their
physiology and lead to generation of ROS. [3] Melanocytes secrete/release HSP70
(in part chaperoning melanocyte-specific antigens) which [4] activates dendritic cell
(DC) that migrate to skin-draining lymph nodes to [5] recruit CD4 and, particularly,
CD8 T cells, which [6] kill remaining melanocytes by the perforin/granzyme
pathway. We propose to [7] apply mutant HSP70iQ435A to block HSP70 from
activating and perpetuating autoimmunity and associated depigmentation, allowing
[8] melanocyte stem cells to differentiate and migrate to depigmented areas of the
skin during repigmentation.

CHAPTER VII: GENERAL METHODS
Mice
C57BL/6, B6.129S2-Cd4tm1Mak/J (CD4 knockout), B6.129S2-Cd8atm1Mak/J (CD8

knockout), and the vitiligo-prone 78B6.Cg-Thy1a/CyTg(TcraTcrb)8Rest/J (Pmel-1)
gp100-reactive TCR transgenic mice were purchased from Jackson Laboratories.

Inducible hsp70 (Hsp70-1) knockout mice (B6;129S7-Hspa1a ⁄ Hspa1btm1Dix ⁄

Mmcd) were purchased from Mutant Mouse Resource Center (UC Davis, CA, USA).

Constitutive hsp70 (Hsp70-2) knockout mice were contributed by Dr. E.M. Eddy and
maintained as heterozygotes; male Hsp70-2 knockout mice are infertile, whereas

females are not (Eddy, 1998). A neomycin insert precedes the Hsp70-2 gene; DNA

was isolated from mice tail snips, followed by PCR with the appropriate primers to
determine homozygosity of the offspring with Hsp70-2 knockout mice displaying
the presence of neomycin gene insert that obliterates Hsp70-2 expression and

complete absence of Hsp70-2-encoding DNA. Wild-type mice were also selected and
used in the Hsp70-2 knockout experiments. Vitiligo-prone h3TA2 tyrosinase-

reactive TCR transgenic mice were generated in the laboratory of S.M. In Pmel-1
mice, the melanocyte-reactive, transgenic TCR is CD8-dependent and is thus

expressed on most of the CD8+ T cells. In these mice, relevant T cells are followed by
virtue of CD8 expression. In h3TA2 mice, however, the major histocompatibility
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complex class I–restricted, transgenic TCR was originally isolated from human CD4+

tumor-infiltrating lymphocytes and functions independent of CD8 co-receptor

expression. Most of the transgenic T cells are CD4−CD8− in this model (Mehrotra et
al., 2012). In these mice, transgenic T cells were followed by CD3 expression and
detection of the TCR transgene. Mice were 5 to 8 weeks old when included in

experiments, excluding the Hsp70-2 knockouts and associated control animals that
were 18–24 months of age. Animals were gender-matched to wild-type controls

where relevant. Experiments included 10 mice per group and are repeated twice
unless stated otherwise in the figure legends. Mice were maintained in facilities
approved by Loyola University Institutional Animal Care and Use Committee

regulations and adhered to guidelines provided by the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.

Human tissues
Blood samples (30 ml) were obtained from patients with active vitiligo, defined as
noticeable progression over the past 3 months. PBMCs were purified over a Ficoll

density gradient, washed in phosphate-buffered saline, and stored in 10% dimethyl
sulfoxide under liquid nitrogen until further use. Four-millimeter punch biopsies

were obtained from the border of actively progressing vitiligo lesions in volunteer
patients attending the Loyola Dermatology outpatient clinic or from patients

undergoing unrelated surgeries at Rush University Medical Center. Tissues and

blood samples were obtained from three or more patients per group, and staining

was performed on 10,000 cells per fluorocytometry sample. Immunohistochemical

analysis was performed at least in triplicate for each staining and on each tissue
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sample, on at least three sections for each staining. Actual sample sizes are listed in
the figure legends. Informed consent was obtained from patients, and all samples
were obtained with approval from the Institutional Review Board at Loyola

University and at Rush University Medical Center, adopting the principles described
in the Declaration of Helsinki.

Preparation of bleaching agents
4-tertiary butyl phenol 4-TBP (Sigma, St. Louis, Missouri, USA) was prepared as a
stock solution of 250 millimol in 70% ethanol and diluted to a working

concentration of 250 μmol. Monobenzyl ether of hydroquinone MBEH (Sigma) was
dissolved in 20% dimethyl sulfoxide (Sigma) and mixed with 70% ethanol for a

stock concentration of 250 millimol. 4-TBP and MBEH were diluted with media to
the listed working concentrations.
Cell Culture
For all experiments using melanocytes, cells were harvested from skin incubated
overnight in (0.1 mg/ml trypsin (Mediatech, Manassas, VA, USA), 100 IU/ml

penicillin,100 mg/ml streptomycin, 100 mg/ml amphotericin (Mediatech) prepared
in Dulbecco’s Phosphate Buffered Solution (DPBS; Mediatech). Melanocytes were

maintained in melanocyte media: Ham’s F-12 medium (Mediatech) with 2 mmol/l

glutamine (Mediatech), 100 IU/ml penicillin,100 mg/ml streptomycin,100 mg/ml
amphotericin (Mediatech), 0.1 mmol/l isobutylmethylxanthine (Sigma, St. Louis,
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Missouri, USA), 10 ng/ml 12-O-tetradecanoyl phorbol-13-acetate (Sigma), and 1%

Ultroser G serum substitute (PALL Life Sciences, Port Washington, NY, USA).

Informed consent was obtained from patients and all samples were obtained with
approval from the Institutional Review Board at Loyola University, adopting the
principles described in the Declaration of Helsinki.
Melanocyte Fractions
HM162P7 melanocytes were dounced with a tight pestle (pestle 'A'; Pierce,

Rockford, IL, USA) on ice in hypotonic buffer presence of antipain, leupeptin,

phosphoramidon, pefabloc and aprotinin before underlayering a 5-30% iodixanol

gradient then spun for 18 hrs at 29,000 rpm. Resulting fractions were collected from
the top.

Western Blotting
Cell lysates were obtained from healthy melanocytes (HM162, p7) and protein

content was measured using Bio-Rad Protein Assay reagent (Bio-Rad, Hercules, CA,
USA), for equal loading at 20 μl for cellular proteins, or 5 μg of purified HSP70 per

slot onto a 10% polyacrylamide minigel. After electrophoresis, separated proteins

were transferred on to Immobilon-P membrane (Millipore, Billerica, MA, USA). The
blots were incubated with SPA-820 to constitutive and inducible HSP70 (mouse
monoclonal IgG1; Enzo Life Sciences). In a separate experiment blots were

incubated with SPA-811 to inducible HSP70 (polyclonal rabbit; Enzo Life Sciences),
and HMB45 to gp100 (monoclonal mouse IgG1; Dako, Carpinteria, CA, USA). After
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washing, blots were reacted with horseradish peroxidase labeled goat anti-mouse
antiserum; Dako) or alkaline phosphatase labeled goat anti-rabbit antiserum Dako)
conjugated secondary Abs. Blots were developed with amino ethyl carbazole
(Sigma) as the substrate.
Electron Microscopy
After cell fractionation, HM162P7 fractions (7-9 and 20-22) were pooled then

centrifuged at 10,000rpm for 10 minutes to pellet the cellular material. Gradient

material was aspirated off and the cellular material re-suspended in 500ul of half-

strength Karnovski’s fixative for 30 minutes at room temperature. Material was recentrifuged, fixative aspirated, 1 ml of 1% Agar in sodium cacodylate buffer added
(Agar, low melting, SIGMA cat#A-5030) and refrigerated overnight. The Agar
gelatin cast containing the pellet was processed in EPON 812 (Ted Pella, Inc.,

Redding, CA) by routine procedure (Boissy et al., 1991). For immunocytochemistry,
melanocytes were cultured in Tissue-Tek chamber slides and treated with 4-TBP as
previously described. Cells were then washed, fixed with half-strength Karnovski’s

fixative, and processed in EPON 812 (Ted Pella, Inc.) by routine procedure. Sections
were obtained using a RMC-MT6000XL ultramicrotome and stained with uranyl

acetate and lead citrate. For immunocytochemistry, sections were washed, treated
with mouse anti-HSP70i at 1:5, wash, treated with goat anti-mouse antibody

conjugated to 5 nm gold particles (Ted Pella, Inc.) at 1:10, and counterfixed and

stained by routine procedures. All sections were viewed, and selected images were
digitally photographed using a JEOL JEM-1230 transmission electron microscope.

Cytoxicity assay
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Cell viability was measured by 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assays (Bioassay system, Hayward, California, USA) according to the

manufacturer’s instructions. Briefly, 20,000 cells/well were plated in triplicate wells
of a 96-well plate to attach overnight. Cells were either treated with vehicle alone or
with 125, 250, or 500 μM 4-TBP or MBEH for 72 h. MTT reagent (tetrazole) was

added to the cells and incubated in a 37ºC humidified chamber for 4 h. Tetrazole is
converted to formazan in the mitochondria of living cells. The formazan crystals

formed were solubilized in buffer (PBS) and the wavelength was read in a reader at
562 nm (BMG Labtech, Inc., Durham, North Carolina, USA). Cell viability was

calculated as absorbance in % of the vehicle-treated control. Primary melanocytes:
healthy neonatal (Mf0887P2; Mf0627P6; Mf0644P1; Mf0865P4; Mf0862P2;

Mf1005P5; Mf0880P2), healthy adult (Mu09236P3), and adult vitiligo (Mc10103P4;
Mc1054P2; Mc1043P2; Mu08114P7; Mc1044 P4).
HSP70i ELISA
Melanocytes from vitiligo and non-vitiligo donors were plated in triplicate at 20,000

cells per well, and the immortalized cell lines PIG1 and PIG3V were plated in

triplicate at 10,000 cells per well in a 96 well flat-bottom plate (Falcon). Cells were

treated for 24 hours with either 125 μmol MBEH (prepared as above), vehicle (20%
dimethyl sulfoxide diluted in 70% EtOH, and diluted to 1:1000 in melanocyte

media), or media alone. All cells were maintained in a total volume of 150 μl. After

24 hours, cells were imaged, and 100 μl of supernatant was added to an HSP70i high

sensitivity ELISA kit (Enzo Life Sciences) and HSP70i was detected according to
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manufactures instructions. Primary melanocytes: healthy adult melanocytes from

Invitrogen (HEMa-LP C024-5C; lot# 5C061P6; lot# 1183797P3; Life Technologies,
Carlsbad, CA, USA), healthy neonatal (Mf12385P5; Mf12387P5) and adult vitiligo

(Mc1044P6; Ma13090P1; Mp12134P4). Immortalized cell lines: healthy PIG1 P96
and vitiligo PIG3VP54.
Confocal microscopy
Melanocytes isolated from healthy neonatal foreskin, or adult vitiligo skin were
plated at 10,000 cells per well on 8 well gelatin coated Lab-Tek chamber slides

(Thermo Fisher Scientific, Rochester, NY, USA). Cells were maintained in melanocyte
media as described above. Cells were treated for 24 hours with 250 μM of either 4TBP, MBEH, or untreated. The cells were fixed with with 3.7% formaldehyde

(Polysciences) in 0.1 M PIPES, pH 6.8 [piperazine-N, N'-bis (2-ethanesulfonic acid)]
(Sigma). Polyclonal rabbit anti-HSP72 (SPA-811; Enzo Life Sciences) and

monoclonal mouse anti-gp100 (HMB45; Dako) were incubated in 0.3% saponin
(Sigma) in PBS. After washing, fluorescent staining was performed with FITC

conjugated goat anti-rabbit, and PE/Cy7 goat anti-mouse secondary antibodies

(Southern Biotech). Confocal images were captured using a Zeiss LSM 510 scanning
electron microscope (Zeiss, Maple Grove, MN, USA). Image analysis was performed

using Adobe Photoshop (Adobe Systems Inc.) and ImageJ (U.S. National Institutes of
Health, Bethesda, MD, USA) software. For visualizing colocalization, the following

channels were used: FITC as green, and PE/Cy7 as red. Colocalization was quantified

with the ImageJ plug-in JACoP (Just Another Co-localization Plugin; Bolte and
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Cordelières, 2006). Primary melanocytes: healthy neonatal (Mf0887P7; Mf0627P4;
Mf11234P1) and adult vitiligo (Mu0885P11; Mc1044P11; Mu0885 P4).
Immunohistology
Mouse tissue: After euthanasia, mouse skin biopsies from vaccinated sites were

snap-frozen in OCT compound (Sakura Finetek). Cryostat sections (8 μm) were fixed
in cold acetone, and indirect immunoperoxidase staining procedures were

performed essentially as described previously (Le Poole et al., 1993b). Tissue

sections were treated with Super Block (ScyTek) to prevent nonspecific antibody

binding. Primary antibodies Ta99 to mouse TRP-1 (mouse monoclonal; Covance),

biotinylated 145-2C11 to CD3ε (Armenian hamster monoclonal; BD Pharmingen),
biotinylated 53-6.7 to CD8α (mouse monoclonal; BioLegend), and 511 to Vβ12
(mouse monoclonal; Thermo Scientific) followed by horseradish peroxidase–

conjugated secondary antibodies [streptavidin, goat anti-mouse immunoglobulin 2a
(IgG2a), or goat anti-rat; Santa Cruz Biotechnology Inc.] were used. Enzymatic

detection was finalized with aminoethylcarbazole as a substrate (Sigma). Staining
was quantified as the number of cells per square millimeter of skin observed by
light microscopy (Nikon) and Adobe Photoshop software (Adobe Systems Inc.).

Fluorescent staining was performed with APC⁄Cy7-conjugated 145-2C11 to mouse
CD3e (Biolegend), fluorescein isothiocyanate (FITC)-conjugated 536.7 to mouse
CD8a (BD Pharmingen), and V450-conjugated RM4-5 to mouse CD4 (BD

Pharmingen). Confocal images were captured using a Zeiss LSM 510 scanning
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electron microscope (Zeiss, Maple Grove, MN, USA). Image analysis was performed
using Adobe Photoshop (Adobe Systems Inc.) and ImageJ (U.S. National Institutes of
Health, Bethesda, MD, USA) software. For visualizing colocalization, the following

channels were used: APC ⁄ Cy7 visualized as red, FITC as green, and V450 as blue.
Human tissue: Human skin sections were prepared as above. Four-millimeter punch
biopsies were obtained from non-vitiligo control patients, or non-lesional and

lesional areas of actively progressing vitiligo in volunteer patients attending the

Loyola Dermatology outpatient clinic. Primary antibodies EP1345Y to human CD11b
(rabbit monoclonal; Novus Biologicals), B-ly6 to CD11c (mouse monoclonal; BD

Pharmingen), 16H4L5 to T-bet (rabbit monoclonal; Invitrogen), rabbit serum to
Eomes452–618 (rabbit polyclonal; Novus Biologicals), 49801 to CXCR3 (mouse

monoclonal; R&D Systems), and SPA-810 to HSP70i (mouse monoclonal; Enzo Life
Sciences formerly Stressgen), followed by horseradish peroxidase–conjugated

secondary antibodies (streptavidin, goat anti-mouse IgG2a, or goat anti-rabbit;
Santa Cruz Biotechnology Inc.). Enzymatic detection and quantification was

performed as described above. Immunohistochemical analysis was performed at
least in triplicate for each staining and on each tissue sample, on at least three
sections for each staining. Actual sample sizes are listed in the figure legends.

Informed consent was obtained from patients, and all samples were obtained with
approval from the Institutional Review Board at Loyola University, adopting the
principles described in the Declaration of Helsinki.

Activating immature DCs and in vitro cell cultures
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Human DCs: Generation of DCs from human PBMCs was prepared from a modified

protocol (27). Briefly, PBMCs were isolated on different occasions from whole blood
of healthy volunteers by Ficoll-Paque (GE Healthcare) density gradient

centrifugation. The experiment was performed three times with samples from

different donors. Subsequently, monocytes were enriched with the EasySep Human
Monocyte Enrichment Kit (Stemcell Technologies) according to the manufacturer’s

instructions. Data from a representative experiment are shown. To generate DCs, we
maintained the cells in Teflon containers (Savillex) to prevent adherence in RPMI
medium (Mediatech Inc.) supplemented with 10% fetal bovine serum, penicillin

(100 U/ml), streptomycin (100 mg/ml), recombinant human GM-CSF (100 ng/ml)

(Leukine, Berlex), and recombinant human IL-4 (25 ng/ml) (R&D Systems). On day
7, either LPS (Sigma) or HSP70i (1 μg/ml) (BioVision) was added. To assess the
wild-type and HSP70iQ435A isoforms, we isolated His-tagged protein from

transfected COS7 cells with His-Select Spin Columns (Sigma) and added it at a final
concentration of 1 μg/ml to the DCs. After 24 hours, expression of activation
markers was assessed as described under flow cytometry.

Mouse DCs: Bone marrow-derived monocytes were prepared by culturing murine

bone marrow cells using a modified protocol (Boudreau et al., 2008). Briefly, bone
marrow cells were flushed aseptically from the femurs and the tibia of mice.

Monocytes were enriched using the EasySep Mouse Monocyte Enrichment Kit

(Stemcell Technologies, Vancouver, BC, Canada) according to the manufacturer’s

instructions. To generate dendritic cells, non-adherent cells were maintained in
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Teflon containers (Savillex, Minnetonka, MN, USA), in Roswell Park Memorial

Institute medium (RPMI) (Mediatech Inc., Manassas, VA, USA) supplemented with

10% fetal bovine serum,100 U ⁄ ml penicillin, 100 mg ⁄ ml streptomycin, 50 ng ⁄ ml
murine GM-CSF (Peprotech, Rocky Hill, NJ, USA), and 12.5 ng ⁄ ml murine

interleukin-4 (IL-4) (Peprotech). On day 7, 1 lg ⁄ ml of either lipopolysaccharide

(Sigma) or HSP70i (Biovision, San Francisco, CA, USA) was added. To block HSP70i,
the cells were first incubated with 2ll ⁄ ml of Fc-receptor block (rat anti-mouse

CD16 ⁄ CD32; BD Pharmigen) followed by the addition of HSP70i (Biovision) and
SPA-810 to HSP70i (mouse monoclonal; Enzo Life Sciences Inc., Farmingdale, NY,

USA). After 24 h, the expression of activation markers was assessed as descri bed
under flow cytometry.

Site-directed mutagenesis
Human HSP70i and microbial DnaK were aligned in a BLAST search to identify a 13–
amino acid stretch as the putative DC-activating peptide region within human
HSP70. To test this, we next created vectors with single- or double-nucleotide

mutations in the putative DC-binding region of human HSP70i (HSP70i435–447) using
appropriate primers to induce mutations in the sequence QPGVLIQVYEGER. As a

template for the site-directed mutagenesis, our expression vector encoding HSP70i

was used as described (12). In vitro mutagenesis of HSP70 residues was performed
on a double-stranded template with polymerase chain reaction as previously

described (45). Mutant sequences were verified by DNA sequencing (Sequenase

version 2.0, U.S. Biochemical Corp.). To verify protein expression, we transfected
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COS7 cells (Invitrogen) with individual plasmids encoding human HSP70i or mutant
HSP70i plasmids using Lipofectamine (Invitrogen), and we verified protein

expression by Western blotting. Blots were probed with anti-HSP70 antibody

(rabbit polyclonal antibody SPA-811 or mouse monoclonal antibody SPA-810; Assay
Designs) and horseradish peroxidase–conjugated secondary antibodies (goat antirabbit or goat anti-mouse; Santa Cruz Biotechnology Inc.). Blots were developed
with aminoethylcarbazole as a substrate (Sigma).
Gene gun vaccinations
Vaccinations for all experiments were prepared as described previously (12) unless
stated otherwise. Briefly, bullets were prepared by precipitating endotoxin-free

plasmid DNA onto spermidine-coated gold beads (Fluka BioChemika and Sigma-

Aldrich) and used to coat silicone tubing (Bio-Rad). All bullets were used within 14

days of preparation and maintained under vacuum before use. Mice were prepared
for vaccination by biweekly abdominal hair removal with Nair (Church and Dwight
Co.) and vaccinated with a Helios Gene Gun (Bio-Rad) under isoflurane anesthesia

(E-Z Euthanex gas chamber, E-Z Systems Corp.). Unless otherwise stated, mice were
ventrally vaccinated weekly for four consecutive weeks with a 4.8-μg dose of total
DNA. Where combinations of plasmids were used, such DNA was mixed 1:1 to the
same total dose of DNA and combined to prepare bullets.

Evaluating depigmentation
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Depigmentation was quantified by flatbed scanning of the ventral and dorsal sides
of mice under anesthesia immediately before the initial vaccination and 4 weeks
after final vaccination (6 months after the final vaccination in Pmel-1 mice), and

subsequent image analysis was performed with Adobe Photoshop software (Adobe
Systems Inc.). The percent depigmentation was calculated from the largest

evaluable area as the percentage of pixels among >150,000 evaluated with a

luminosity above the cutoff level set to include 95% of pixels for untreated mice
(12). Mice were also photographed with a DSC-S950 SteadyShot digital camera
(Sony) as indicated.

Assessment of CTL activation
In vivo cytotoxicity assays were performed as described (Denman et al., 2008).

Briefly, 4 weeks after evaluating depigmentation, mice received two booster gene

gun vaccinations 3 days apart. Separate batches of splenocytes were pulsed from the
respective knockout mice with TRP-1-derived, K(b)-restricted peptide 455–463
TAPDNLGYM, TRP-2-derived, K(b)-restricted peptide 180–188 SVYDFFVWL or

control HPV16E7-derived, D(b)-restricted peptide 49–57 RAHYNIVTF (Pi

Proteomics, Huntsville, AL, USA). Then, cells were loaded with 1, 3, and 9 lM
carboxyfluorescein succimidyl ester (CFSE) (Invitrogen, Carlsbad, CA, USA),

respectively. One and 9 lM concentrations were used where only two peptides were
analyzed in the assay. Labeled cells were periorbitally injected 4 days after the final
booster gene gun vaccination, and splenocytes were harvested after 18 h. Samples
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representing 1000 irrelevantly pulsed splenocytes were acquired using FACS Canto
equipment (BD Biosciences, Sparks, MD, USA) comparing the ratio of TRP-1 or TRP2 peptide-pulsed splenocytes between vaccinated and naive mice from shifts in the
area under the curves.

Skin explant transfections and culture
For ex vivo skin explant gene transfections, skin from two volunteer patients was
biopsied and 1 mm × 2 mm skin pieces (three) were placed on each Statamatrix

matrix (Cytomatrix Pty Ltd.; a gift from the laboratory of R. A. Clark, Brigham and
Women’s Hospital, MA). In one experiment, on day 10, the skin/matrix was

transfected (4.8-μg dose of total DNA) with wild-type or mutant (Q435A) HSP70i.

On day 14, media were collected and cells were stained for HSP70i expression. For
another experiment (as indicated), the skin/matrix was cultured in media only or
with wild-type or mutant (Q435A) HSP70i protein (4 μg/ml). Half of the skin T

media were refreshed every 2 to 3 days. On day 6, media were collected and cells
were stained for transcription factors and homing markers.
Flow cytometry
For experiments including the Pmel-1 mice, splenocytes were recovered 25 weeks

after the final vaccination and stained for the following surface markers: CD3, CD8,
CD11b, CD11c, CLA, CXCR3, F4/80, and IgM-Thy1.2 (BD Biosciences). Initial gating
was performed on live nondebris singlets, with subsequent gating toward CD11c+

versus CD11b+ cells using FACS LSR-II equipment (BD Biosciences). IgM+, Thy1.2+,

and

CD3+

cells were excluded from the final gating. For intracellular profiles,
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antibodies to CD62L, T-bet, Eomes, FoxP3, CD44, and CD25 (eBioscience) were used.
For experiments using in vitro–generated human DCs from PBMCs, the cells were
gently spun and stained with mouse anti-human CD11c, CD80, CD83, CD86, and

HLA-ABC antibodies labeled with allophycocyanin, phycoerythrin, phycoerythrincyan, fluorescein isothiocyanate, and V450 fluorochromes, respectively (BD
Biosciences). Initial gating was performed on live nondebris singlets, with

subsequent gating toward CD11c+ cells using FACSCanto II and FACS LSR-II

equipment (BD Biosciences). For ImageStream X (Amnis) analysis, cells were

incubated with primary antibodies SPA-820 toward HSP70i (Assay Designs) and

3D5 toward 6× His (histidine tag; Invitrogen) followed by phycoerythrin goat antimouse IgG1 (BD Biosciences) and allophycocyanin goat anti-mouse IgG2b (BD
Biosciences) secondary antibodies, respectively.
Statistical analyses
All data are presented as means ± SEM, unless otherwise indicated. Distributions of
data and means were compared with Wilcoxon’s rank sum test for depigmentation
and immunohistochemistry data throughout, and t tests allowing for unequal

variance for fluorocytometry, and Western blot data, except when skewness of the
data suggested that the rank test would be more appropriate. Degrees of freedom

for two-sample t tests were calculated with Satterthwaite’s formula. Two-sided tests
were performed except for two data sets where we are confirming a previously
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reported increase or decrease only (Western blot probed with SPA-810 and CXCR3
immunostaining of skin). Wilcoxon’s rank sum and t tests were calculated with Stata
version 11 (StataCorp). Graphs were made with Prism software (GraphPad). P
values less than 0.05 were considered statistically significant.
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